%PDF-1.3%‚„œ”
1 0 obj<< /CreationDate (D:191001026152334)/Producer (Acrobat Distiller 3.0 for Windows)/Subject (07)/Keywords ()/Author (ariel)/Creator (Adobe PageMaker 6.5)/Title (07)/ModDate (D:20001026153816-04'00')>> endobj2 0 obj<< /Type /Page /Parent 11 0 R /Resources 4 0 R /Contents 3 0 R /CropBox [ 28.8 55.44 566.2 801.67999 ] >> endobj3 0 obj<< /Length 7730 >> stream
BT
/F4 1 Tf
10 0 0 10 493.49 85.31 Tm
0 0 0 rg
/GS2 gs
0.006 Tc
(451)Tj
ET
0 0 0 RG
0 J 0 j 0.48 w 10 M []0 d
/GS1 gs
1 i 
28.61 53.87 m
28.61 -1.33 l
567.17 53.87 m
567.17 -1.93 l
-2.83 53.63 m
28.37 53.63 l
566.93 53.63 m
596.69 53.63 l
567.17 841.91 m
567.17 802.19 l
28.61 843.23 m
28.61 802.19 l
566.93 801.95 m
598.13 801.95 l
-2.23 801.95 m
28.37 801.95 l
S
BT
7 0 0 7 85.01 759.71 Tm
/GS2 gs
0.009 Tc
0.056 Tw
[(Re)26(vista da Sociedade Br)9(asileir)-8(a de Medicina )43(T)123(ropical)]TJ
0 -1.594 TD
0.054 Tw
(33\(5\):451-464, set-out, 2000.)Tj
/F6 1 Tf
8 0 0 8 425.69 758.99 Tm
0.006 Tc
0.032 Tw
(ARTIGO DE REVIS\303O)Tj
ET
0.24 w 
/GS1 gs
85.25 195.35 m
142.01 195.35 l
S
BT
/F8 1 Tf
15 0 0 15 263.33 689.51 Tm
/GS2 gs
-0.035 Tc
(Gonorr\351ia)Tj
/F10 1 Tf
13 0 0 13 270.17 660.11 Tm
-0.053 Tc
(Gonorrhea)Tj
/F6 1 Tf
9 0 0 9 131.21 631.19 Tm
0.005 Tc
0.034 Tw
[(Ger)18(son Oliveira P)18(enna)]TJ
5.2 0 0 5.2 229.01 634.19 Tm
(1)Tj
9 0 0 9 232.01 631.19 Tm
[(,)44( Ludhmila Abrah\343o Hajjar)]TJ
5.2 0 0 5.2 345.29 634.19 Tm
(2)Tj
9 0 0 9 348.29 631.19 Tm
0.036 Tw
[( e )99(T)84(atiana Ma)6(galh\343es Braz)]TJ
5.2 0 0 5.2 461.33 634.19 Tm
(3)Tj
10 0 2.126 10 85.01 599.39 Tm
-0.001 Tc
(Resumo )Tj
/F4 1 Tf
4.164 0 TD
0 Tc
-0.069 Tw
[( A gonorr\351ia \351 uma inf)24(ec\347\343o bacter)-12(iana freq\374ente)12(, causada pela )]TJ
10 0 0 10 406.85 599.39 Tm
[(Neisser)-24(ia gonorrhoeae)]TJ
10 0 2.126 10 507.53 599.39 Tm
(,)Tj
-42.04 -0.996 TD
0.003 Tc
0.003 Tw
(um diplococo Gram-negativo de transmiss\343o quase que exclusiva atrav\351s de contato sexual ou)Tj
0.214 -1.008 TD
0.033 Tw
[(per)-22(inatal.)62( Pr)-10(imar)-22(iamente af)26(eta membranas m)14(ucosas do trato genital inf)26(er)-10(ior)38(,)1( e mais rar)14(amente,)]TJ
0.212 -0.996 TD
0.109 Tw
[(as mucosas do reto)27(, orof)27(ar)-21(inge e conjuntiv)27(a.)63( A inf)27(ec\347\343o genital ascendente na mulher le)27(v)35(a)3( a)]TJ
0.212 -0.996 TD
-0.008 Tw
(uma complica\347\343o s\351ria, a salpingite aguda, uma das principais causas de infertilidade feminina.)Tj
0.214 -1.008 TD
0.076 Tw
(A partir dos anos 90, deu-se in\355cio a um novo tempo no que se refere a descobertas sobre a)Tj
0.212 -0.996 TD
0.001 Tc
-0.069 Tw
(patogenia da gonorr\351ia e seu agente etiol\363gico. O controle da gonorr\351ia tem sido dif\355cil na maioria)Tj
0.212 -0.996 TD
0.04 Tc
0.138 Tw
[(das popula\347\365es, e essa permanece um exemplo da influ\352ncia que os fatores sociais,)]TJ
0.214 -1.008 TD
-0.003 Tc
-0.068 Tw
(comportamentais e demogr\341ficos exercem na epidemiologia de uma doen\347a infecciosa. O manejo)Tj
0.212 -0.996 TD
0.005 Tc
0.137 Tw
(da gonorr\351ia e de outras doen\347as sexualmente transmiss\355veis requer tanto o tratamento do)Tj
0.212 -0.996 TD
-0.003 Tc
-0.068 Tw
(paciente e de seu parceiro sexual como medidas de sa\372de p\372blica para interromper a transmiss\343o)Tj
0.214 -1.008 TD
0.003 Tc
0.016 Tw
(da infec\347\343o e evitar complica\347\365es a longo prazo.)Tj
/F6 1 Tf
0.273 -1.284 TD
(Palavras-chaves: )Tj
/F4 1 Tf
8.544 0 TD
(Gonorr\351ia. )Tj
10 0 0 10 221.09 476.51 Tm
0.035 Tw
(Neisseria gonorrhoeae.)Tj
/F6 1 Tf
10 0 2.126 10 85.01 450.83 Tm
(Abstract )Tj
/F4 1 Tf
4.32 0 TD
-0.045 Tw
[( Gonorrhea is a common bacterial infection caused by )]TJ
10 0 0 10 367.37 450.83 Tm
(Neisseria gonorrhoeae,)Tj
10 0 2.126 10 471.53 450.83 Tm
0.001 Tc
[( a Gram-)]TJ
-38.44 -0.996 TD
0.002 Tc
0.137 Tw
[(negativ)14(e diplococcus that is tr)14(ansmitted almost e)26(xclusiv)14(ely b)14(y)-1( se)26(xual contact or per)-22(inatally)98(.)64( It)]TJ
0.214 -1.008 TD
-0.054 Tw
(primarily affects the mucous membranes of the lower genital tract and less frequently those of the)Tj
0.212 -0.996 TD
0.023 Tc
0.137 Tw
[(rectum, orophar)-37(ynx, and conjunctiv)23(a)-5(e)23(.)61( Ascending genital inf)23(ection in w)11(omen leads to the)]TJ
0.212 -0.996 TD
0.003 Tc
-0.012 Tw
(predominant complication, acute salpingitis, one of the most common causes of female infertility)Tj
0.212 -0.996 TD
-0.008 Tc
-0.069 Tw
[(in the world. Since the 1990s, a remarkable surge of information ensued regarding the pathogenesis)]TJ
0.214 -1.008 TD
0.003 Tc
0.06 Tw
(of gonorrhea and its agent. Gonorrohea has proven difficult to control in most populations and)Tj
0.212 -0.996 TD
0.044 Tw
(remains a prime example of the influence that social, behavioral, and demographic factors can)Tj
0.212 -0.996 TD
0.099 Tw
(have on the epidemiology of an infectious disease. The management of gonorrhea and other)Tj
0.214 -1.008 TD
-0.048 Tw
(sexually transmitted infections requires both treatment of the patient as an individual and of his or)Tj
0.212 -0.996 TD
0.008 Tw
(her sexual partner\(s\) as a public health measure to interrupt the onward spread of infection and)Tj
0.212 -0.996 TD
0.037 Tw
(prevent long-term complications.)Tj
/F6 1 Tf
0.275 -1.296 TD
(Key-words: )Tj
/F4 1 Tf
5.784 0 TD
(Gonorrhea. )Tj
10 0 0 10 196.85 327.95 Tm
0.03 Tw
(Neisseria gonorhoeae.)Tj
7 0 0 7 85.13 185.99 Tm
0.009 Tc
0.037 Tw
[(1.)43( M\351dico Der)-8(matologista do Hospital Univ)9(ersit\341r)-25(io de Br)9(as\355lia e Doutor)-8(ando em Medicina )61(T)106(ropical do N\372cleo de Medicina )43(T)123(r)-1(opical)]TJ
59.309 0 TD
[( da)]TJ
-59.309 -1.2 TD
-0.033 Tw
(Faculdade de Medicina/UnB; 2. Interna do 6\272 ano da Faculdade de Medicina da Universidade de Bras\355lia; 3. Residente de Dermatolo)Tj
59.385 0 TD
(gia)Tj
-59.385 -1.2 TD
0.028 Tw
(do Hospital Universit\341rio da Faculdade de Medicina da Universidade de Bras\355lia.)Tj
7 0 1.488 7 85.13 160.79 Tm
0.01 Tc
0.138 Tw
[(Endere\347o par)10(a correspond\352ncia:)]TJ
7 0 0 7 190.61 160.79 Tm
0.139 Tw
[( Dr)62(.)48( Gerson Oliv)27(eir)10(a P)44(enna.)61( N\372cleo de Medicina )44(T)124(ropical, F)27(aculdade de Medicina/Univ)27(ersidade de)]TJ
-15.069 -1.2 TD
0.009 Tc
0.031 Tw
[(Br)9(as\355lia, Campus Univ)9(ersit\341r)-42(i)15(o)43(, Asa Nor)-59(te)9(, 70919-970 Br)9(as\355lia, DF)146(, Br)-8(asil.)]TJ
T*
0.026 Tw
(Fax: 55 61 340-1670)Tj
T*
0.038 Tw
(Recebido para publica\347\343o em 24/3/2000.)Tj
9.5 0 0 9.5 99.17 290.51 Tm
0.027 Tc
0.139 Tw
(A gonorr\351ia \351 doen\347a infecciosa do trato)Tj
-1.491 -1.124 TD
0.017 Tc
(urogenital, bacteriana, transmitida quase que)Tj
T*
0.004 Tc
0.004 Tw
(exclusivamente por contato sexual ou perinatal.)Tj
0 -1.137 TD
-0.004 Tc
-0.07 Tw
(Acomete primariamente as membranas mucosas)Tj
0 -1.124 TD
0.004 Tc
-0.032 Tw
(do trato genital inferior e menos freq\374entemente)Tj
T*
0.112 Tw
[(aquelas do reto)42(, orof)17(a)9(r)-21(inge e conjuntiv)29(a.)55( )53(T)122(r)9(ata-)]TJ
T*
0.071 Tc
0.14 Tw
(se de afec\347\343o de manifesta\347\365es cl\355nicas)Tj
0 -1.112 TD
0 Tc
-0.069 Tw
(pleom\363rficas, variando desde a aus\352ncia total de)Tj
23.419 7.907 TD
0.004 Tc
0.079 Tw
(sintomas at\351 a ocorr\352ncia de salpingite aguda,)Tj
0 -1.074 TD
0.006 Tc
0.14 Tw
(uma das causas mais comuns de infertilidade)Tj
T*
-0.024 Tc
-0.069 Tw
[(f)27(eminina no mundo)39(.)52( Al\351m disso)39(, s\343o conseq\374\352ncias)]TJ
T*
-0.018 Tc
(adicionais importantes as infec\347\365es bacteri\352micas,)Tj
T*
0.004 Tc
0.015 Tw
(a conjuntivite neonatal e a epididimite aguda)Tj
5.5 0 0 5.5 497.57 253.19 Tm
0.001 Tc
(23)Tj
9.5 0 0 9.5 503.69 250.07 Tm
(.)Tj
-19.162 -1.377 TD
-0.006 Tc
-0.069 Tw
(A gonorr\351ia encontra-se entre as mais antigas)Tj
-1.491 -1.099 TD
0.107 Tc
(doen\347as humanas conhecidas, havendo)Tj
T*
0.057 Tc
(refer\352ncias da uretrite ven\351rea nos escritos)Tj
ET
endstreamendobj4 0 obj<< /ProcSet [ /PDF /Text ] /Font << /F4 5 0 R /F6 6 0 R /F8 7 0 R /F10 8 0 R >> /ExtGState << /GS1 9 0 R /GS2 10 0 R >> >> endobj5 0 obj<< /Type /Font /Subtype /Type1 /Name /F4 /Encoding 58 0 R /BaseFont /Helvetica >> endobj6 0 obj<< /Type /Font /Subtype /Type1 /Name /F6 /Encoding 58 0 R /BaseFont /Helvetica-Bold >> endobj7 0 obj<< /Type /Font /Subtype /Type1 /Name /F8 /FirstChar 0 /LastChar 255 /Widths [ 400 400 500 520 520 480 300 440 320 320 420 340 500 320 280 280 280 280 280 280 280 280 280 280 280 280 280 280 280 280 280 280 280 280 400 560 560 880 760 220 400 400 340 560 280 300 280 440 560 560 560 560 560 560 560 560 560 560 280 280 560 560 560 420 720 660 640 660 760 600 560 720 780 360 400 740 540 860 720 760 600 760 660 520 600 700 640 940 700 680 620 280 540 280 560 500 400 520 600 500 600 520 360 540 660 320 300 600 320 940 660 600 640 600 460 460 340 600 540 820 620 560 480 280 560 280 560 620 620 620 260 560 440 1000 540 540 500 1260 520 200 1000 620 620 620 620 260 260 440 440 620 500 1000 520 860 460 200 920 620 620 680 280 280 560 560 560 560 560 400 440 760 360 340 560 300 760 520 400 560 336 336 400 600 660 280 320 336 360 340 840 840 840 420 660 660 660 660 660 660 960 660 600 600 600 600 360 360 360 360 760 720 760 760 760 760 760 560 760 700 700 700 700 680 600 640 520 520 520 520 520 520 800 500 520 520 520 520 320 320 320 320 600 660 600 600 600 600 600 560 600 600 600 600 600 560 640 560 ] /Encoding 58 0 R /BaseFont /Garamond-Bold /FontDescriptor 56 0 R >> endobj8 0 obj<< /Type /Font /Subtype /Type1 /Name /F10 /FirstChar 0 /LastChar 255 /Widths [ 360 360 420 420 380 400 220 400 280 320 380 300 420 260 320 320 320 320 320 320 320 320 320 320 320 320 320 320 320 320 320 320 320 220 340 500 500 760 700 200 360 360 340 560 260 320 260 400 500 500 500 500 500 500 500 500 500 500 260 260 560 560 560 300 740 640 640 620 740 560 520 740 740 320 320 660 480 800 700 780 560 780 580 480 580 700 640 920 640 660 600 240 520 240 560 500 360 480 560 460 560 500 300 520 560 260 220 540 260 820 560 560 580 560 340 400 280 560 500 780 520 500 460 260 560 260 560 620 620 620 220 500 360 1000 400 400 420 1080 480 160 1000 620 620 620 620 220 220 380 380 620 500 1000 420 860 400 160 880 620 620 660 320 220 500 500 500 500 560 360 400 760 340 260 560 320 760 380 400 560 300 300 360 560 620 260 320 300 340 260 750 750 750 300 640 640 640 640 640 640 940 620 560 560 560 560 320 320 320 320 740 700 780 780 780 780 780 560 780 700 700 700 700 660 560 560 480 480 480 480 480 480 740 460 500 500 500 500 260 260 260 260 560 560 560 560 560 560 560 560 560 560 560 560 560 500 580 500 ] /Encoding 58 0 R /BaseFont /Garamond-Light /FontDescriptor 57 0 R >> endobj9 0 obj<< /Type /ExtGState /SA false /OP false /HT /Default >> endobj10 0 obj<< /Type /ExtGState /SA false /OP true /HT /Default >> endobj11 0 obj<< /Type /Pages /Kids [ 2 0 R 12 0 R 15 0 R 18 0 R 23 0 R 26 0 R 29 0 R 32 0 R 35 0 R 38 0 R ] /Count 10 /Parent 44 0 R >> endobj12 0 obj<< /Type /Page /Parent 11 0 R /Resources 14 0 R /Contents 13 0 R /CropBox [ 28.8 55.44 566.2 801.67999 ] >> endobj13 0 obj<< /Length 10381 >> stream
BT
/F4 1 Tf
10 0 0 10 85.01 83.87 Tm
0 0 0 rg
/GS2 gs
0.006 Tc
(452)Tj
ET
0 0 0 RG
0 J 0 j 0.48 w 10 M []0 d
/GS1 gs
1 i 
28.61 53.87 m
28.61 -1.33 l
567.17 53.87 m
567.17 -0.01 l
-4.27 53.63 m
28.37 53.63 l
566.93 53.63 m
598.13 53.63 l
567.17 841.91 m
567.17 802.19 l
28.61 843.83 m
28.61 802.19 l
566.93 801.95 m
598.13 801.95 l
-2.23 801.95 m
28.37 801.95 l
S
BT
7 0 0 7 85.01 759.71 Tm
/GS2 gs
0.01 Tc
0.012 Tw
[(Penna GO  et al)]TJ
9.5 0 0 9.5 85.01 693.11 Tm
0.059 Tc
-0.069 Tw
[(chineses)8(, no )47(V)82(elho )59(T)127(estamento b\355b)21(lico e em)]TJ
0 -1.099 TD
0.056 Tc
0.14 Tw
(outras literaturas da antiguidade. O nome)Tj
0 -1.112 TD
0.004 Tc
-0.035 Tw
(gonorr\351ia origina-se do grego e foi Galeno \(130-)Tj
0 -1.099 TD
0.119 Tw
(200 d.C.\) que assim a denominou \226 gonorr\351ia)Tj
0 -1.112 TD
0.002 Tw
(\(gonos = espermatoz\363ide + rhoia = corrimento\),)Tj
0 -1.099 TD
0.082 Tc
-0.069 Tw
(pela confus\343o do exsudato purulento com)Tj
0 -1.112 TD
0.004 Tc
(s\352men)Tj
5.5 0 0 5.5 113.81 633.35 Tm
0.001 Tc
(22)Tj
9.5 0 0 9.5 120.05 630.11 Tm
(.)Tj
-2.198 -1.402 TD
0.004 Tc
0.106 Tw
(Neisser em 1879 descreveu o organismo e)Tj
-1.491 -1.099 TD
0.076 Tc
-0.069 Tw
[(Leistik)13(o)13(w)-1( e Loeffler o cultiv)26(ar)13(am em 1982,)]TJ
0 -1.112 TD
0.011 Tc
0.14 Tw
(quando recebeu a denomina\347\343o )Tj
9.5 0 2.019 9.5 232.37 595.79 Tm
0.142 Tw
(de Neisseria)Tj
-15.278 -1.099 TD
0.004 Tc
(gonorrhoea)Tj
5.5 0 0 5.5 134.21 588.47 Tm
0.001 Tc
(22)Tj
9.5 0 0 9.5 140.33 585.35 Tm
(.)Tj
-4.333 -1.415 TD
0.014 Tc
0.14 Tw
(Embora se observasse que infec\347\365es n\343o)Tj
-1.491 -1.099 TD
0.004 Tc
-0.001 Tw
(tratadas curavam-se espontaneamente em dias)Tj
0 -1.112 TD
-0.016 Tc
-0.07 Tw
(ou em algumas semanas, reinfec\347\365es mostravam-)Tj
0 -1.099 TD
0.049 Tc
0.139 Tw
[(s)19(e)-1( comuns, embora n\343o se dispusesse de)]TJ
0 -1.112 TD
0.004 Tc
-0.016 Tw
(m\351todos capazes de diferenciar entre gonorr\351ia)Tj
0 -1.099 TD
0.015 Tc
0.139 Tw
(recorrente e uretrite n\343o-gonoc\363ccica. Muitas)Tj
0 -1.112 TD
0.011 Tc
(terapias foram tentadas, mas somente com o)Tj
0 -1.099 TD
0.004 Tc
-0.051 Tw
(advento das sulfonamidas na d\351cada de 30 e da)Tj
0 -1.112 TD
-0.004 Tw
(penicilina em 1943, houve a disponibiliza\347\343o de)Tj
0 -1.099 TD
0.005 Tc
0.026 Tw
(terap\352utica eficaz.)Tj
1.491 -1.402 TD
0.004 Tc
0.001 Tw
(Durante 80 anos, o conhecimento a respeito)Tj
-1.491 -1.099 TD
0.109 Tw
(do agente causal e da patogenia da gonorr\351ia)Tj
0 -1.086 TD
-0.012 Tw
(permaneceu escasso, por\351m no in\355cio dos anos)Tj
0 -1.099 TD
0.017 Tc
0.14 Tw
(70 tem in\355cio uma nova era na informa\347\343o a)Tj
T*
-0.006 Tc
-0.07 Tw
(respeito da doen\347a, e nos anos 90 uma revolu\347\343o)Tj
0 -1.086 TD
-0.001 Tc
(consider\341vel ocorre no conhecimento da biologia)Tj
0 -1.099 TD
0.004 Tc
-0.011 Tw
(molecular do )Tj
9.5 0 2.019 9.5 142.37 401.75 Tm
(gonococcus)Tj
9.5 0 0 9.5 193.37 401.75 Tm
(, que nos permite com)Tj
-11.406 -1.099 TD
0.043 Tc
0.14 Tw
(mais detalhes entender os mecanismos de)Tj
0 -1.086 TD
0.004 Tc
0.012 Tw
(intera\347\343o entre este agente e o homem.)Tj
1.491 -1.402 TD
0.015 Tc
0.14 Tw
(A gonorr\351ia tem-se demonstrado de dif\355cil)Tj
-1.491 -1.086 TD
-0.003 Tc
-0.07 Tw
(controle na maioria das popula\347\365es e permanece)Tj
0 -1.099 TD
0 Tc
(um exemplo prim\341rio da influ\352ncia que os fatores)Tj
T*
0.066 Tc
0.141 Tw
(demogr\341ficos, sociais e comportamentais)Tj
0 -1.086 TD
0.048 Tc
0.14 Tw
(exercem na epidemiologia de uma doen\347a)Tj
0 -1.099 TD
0.016 Tc
(infecciosa, apesar da disponibilidade de uma)Tj
T*
0.004 Tc
0.032 Tw
(terap\352utica antimicrobiana eficaz.)Tj
1.491 -1.389 TD
0.003 Tc
-0.032 Tw
(Considerando a mudan\347a de conhecimentos)Tj
-1.491 -1.099 TD
0.004 Tc
0.099 Tw
(a respeito da gonorr\351ia, ocorrida nos anos 90,)Tj
0 -1.086 TD
0.045 Tw
(podemos dividir essa doen\347a em duas fases: a)Tj
0 -1.099 TD
0.09 Tw
(gonorr\351ia antes dos anos 90 e a dos anos 90,)Tj
T*
0.007 Tc
0.14 Tw
(essa \372ltima caracterizada pelo desvendar das)Tj
0 -1.086 TD
-0.019 Tc
-0.07 Tw
(intera\347\365es pat\363geno-hospedeiro, dos mecanismos)Tj
0 -1.099 TD
-0.004 Tc
(de doen\347a pr\363prios do gonococcus, de seus tipos)Tj
T*
0.004 Tc
0.069 Tw
(de resist\352ncia e da associa\347\343o entre gonorr\351ia)Tj
0 -1.086 TD
-0.04 Tw
[(e inf)29(ec\347\343o pelo HIV)118(, sendo essa \372ltima capaz de)]TJ
0 -1.099 TD
0.009 Tc
0.139 Tw
(provocar uma mudan\347a na hist\363ria natural da)Tj
T*
0.004 Tc
0.012 Tw
(gonorr\351ia e de tornar a terap\352utica mais dif\355cil.)Tj
1.491 -1.402 TD
0.059 Tc
0.14 Tw
(Os autores registram a import\342ncia da)Tj
9.5 0 2.019 9.5 85.01 164.15 Tm
-0.018 Tc
-0.07 Tw
(abordagem sindr\364mica das Doen\347as Sexualmente)Tj
0.234 -1.099 TD
0.004 Tc
0.047 Tw
[(T)122(r)9(ansmiss\355v)29(eis \(DST\))]TJ
9.5 0 0 9.5 176.09 153.71 Tm
0.052 Tw
(, pois se de um lado essa)Tj
-9.587 -1.112 TD
0.011 Tw
(abordagem perde um pouco em especificidade,)Tj
0 -1.099 TD
0.017 Tc
0.139 Tw
(de outro, ganha enormemente em termos do)Tj
23.432 58.989 TD
0.005 Tc
(aumento da sensibilidade no diagn\363stico e na)Tj
0 -1.099 TD
0.004 Tc
-0.031 Tw
[(abordagem terap\352utica dos pacientes com DST)118(,)]TJ
0 -1.112 TD
0.006 Tc
0.14 Tw
(e dentre essas, das doen\347as com corrimento,)Tj
0 -1.099 TD
0.004 Tc
0.031 Tw
(destacadamente a gonorr\351ia.)Tj
1.491 -1.402 TD
0.065 Tw
(Do ponto de vista do ensino m\351dico imp\365e-)Tj
-1.491 -1.112 TD
0.028 Tw
(se que os profissionais de sa\372de em forma\347\343o,)Tj
0 -1.099 TD
0.001 Tc
-0.07 Tw
(pelo menos os alunos de gradua\347\343o de medicina)Tj
0 -1.112 TD
-0.025 Tc
(e enfermagem e os m\351dicos residentes de doen\347as)Tj
0 -1.099 TD
0.004 Tc
0.005 Tw
(infecciosas e da dermatologia tenham acesso e)Tj
0 -1.112 TD
-0.06 Tw
(sejam treinados tanto na abordagem cl\341ssica do)Tj
0 -1.099 TD
0.019 Tc
0.14 Tw
(paciente com gonorr\351ia como na abordagem)Tj
0 -1.112 TD
0.007 Tc
(sindr\364mica.)Tj
1.491 -1.402 TD
0.048 Tc
(Diante da transi\347\343o epidemiol\363gica que)Tj
-1.491 -1.112 TD
-0.024 Tc
-0.07 Tw
(vivemos, da situa\347\343o de sa\372de de nossa popula\347\343o)Tj
0 -1.099 TD
0.004 Tc
-0.052 Tw
(e da assist\352ncia m\351dica ofertada em nossa rede)Tj
0 -1.112 TD
0.13 Tw
(de servi\347os de sa\372de, o fator mais importante)Tj
0 -1.099 TD
-0.038 Tw
(da abordagem das DST encontra-se no controle)Tj
0 -1.112 TD
0.005 Tc
0.069 Tw
(das fontes de infec\347\343o, o que s\363 ser\341 poss\355vel)Tj
0 -1.099 TD
0.066 Tc
-0.069 Tw
(aumentando a cobertura com a abordagem)Tj
0 -1.112 TD
0.044 Tc
(sindr\364mica, incluindo, o manejo e orienta\347\343o)Tj
0 -1.099 TD
0.004 Tc
0.018 Tw
(corretos dos parceiros\(as\) dos\(as\) pacientes.)Tj
6.808 -2.147 TD
0.002 Tc
0.063 Tw
(AGENTE ETIOL\323GICO)Tj
-5.318 -1.768 TD
0.03 Tc
(A )Tj
9.5 0 2.019 9.5 332.57 440.27 Tm
0.029 Tc
0.139 Tw
(Neisseria gonorrhoeae )Tj
9.5 0 0 9.5 440.09 440.27 Tm
0.142 Tw
(\351 um diplococo)Tj
-13.945 -1.124 TD
0.004 Tc
0.02 Tw
(Gram-negativo, n\343o flagelado, n\343o formador de)Tj
0 -1.112 TD
-0.008 Tc
-0.07 Tw
[(esporos, encapsulado, anaer\363bio facultativo, )-8(c)14(o)14(m)]TJ
T*
0.01 Tc
0.139 Tw
(di\342metro entre 0,6 a 1,0)Tj
5.5 0 0 5.5 415.97 411.59 Tm
(6)Tj
9.5 0 0 9.5 419.09 408.47 Tm
[(\265)-15(.)0( Na bacterioscopia)]TJ
-11.735 -1.112 TD
0.032 Tc
(corada pelo m\351todo de Gram, apresenta-se)Tj
0 -1.124 TD
0.013 Tc
(como duas estruturas reniformes justapostas,)Tj
0 -1.112 TD
0.019 Tc
(espelhadas pela concavidade e aproximadas)Tj
T*
0.004 Tc
-0.011 Tw
(pela extremidade, quase sempre agrupadas em)Tj
0 -1.124 TD
-0.004 Tc
-0.07 Tw
(massa no espa\347o extracelular e/ou no citoplasma)Tj
0 -1.112 TD
0.004 Tc
0.039 Tw
(dos polimorfonucleares abundantes)Tj
5.5 0 0 5.5 460.01 347.99 Tm
0.001 Tc
(54)Tj
9.5 0 0 9.5 466.13 344.87 Tm
(.)Tj
-15.196 -1.415 TD
0.003 Tc
0.139 Tw
(O g\352nero )Tj
9.5 0 2.019 9.5 366.89 331.43 Tm
(Neisseria)Tj
9.5 0 0 9.5 406.85 331.43 Tm
0.005 Tc
[( apresenta cerca de 10)]TJ
-10.446 -1.124 TD
0.004 Tc
0.052 Tw
(esp\351cies sapr\363fitas ou patog\352nicas ao homem,)Tj
0 -1.112 TD
-0.037 Tw
(sendo a )Tj
9.5 0 2.019 9.5 343.61 310.19 Tm
-0.039 Tw
(Neisseria gonorrhoeae, N. meningitidis)Tj
9.5 0 0 9.5 507.65 310.19 Tm
(,)Tj
9.5 0 2.019 9.5 307.61 299.63 Tm
-0.022 Tc
-0.068 Tw
(N. pharyngis )Tj
9.5 0 0 9.5 359.69 299.63 Tm
-0.023 Tc
(e a)Tj
9.5 0 2.019 9.5 371.69 299.63 Tm
-0.02 Tc
-0.069 Tw
[( N. catarrhalis)]TJ
9.5 0 0 9.5 426.05 299.63 Tm
-0.021 Tc
[( as mais importantes.)]TJ
-12.467 -1.124 TD
-0.022 Tc
(A diferencia\347\343o das esp\351cies pode ser feita atrav\351s)Tj
0 -1.112 TD
0.014 Tc
0.139 Tw
[(da o)27(xida\347\343o dos a\347\372cares)14(.)65( A )]TJ
9.5 0 2.019 9.5 441.77 278.39 Tm
0.142 Tw
[(N.)65( gonorroheae)]TJ
9.5 0 0 9.5 307.61 267.83 Tm
0.004 Tc
0.045 Tw
(oxida a glicose mas n\343o a maltose, sucrose ou)Tj
0 -1.124 TD
0.005 Tc
(lactose)Tj
5.5 0 0 5.5 338.09 260.39 Tm
0.001 Tc
(17)Tj
9.5 0 0 9.5 344.21 257.15 Tm
(.)Tj
-2.362 -1.415 TD
0.004 Tc
0.031 Tw
(O gonococo n\343o tolera redu\347\343o da umidade)Tj
-1.491 -1.137 TD
-0.029 Tc
-0.069 Tw
(e as amostras devem ser inoculadas imediatamente)Tj
0 -1.124 TD
0.033 Tc
0.139 Tw
(em meio apropriado. Obt\351m-se crescimento)Tj
T*
0.003 Tc
-0.013 Tw
(melhor em temperaturas de 35 a 37)Tj
5.5 0 0 5.5 459.05 214.67 Tm
(o)Tj
9.5 0 0 9.5 462.05 211.55 Tm
(C, e muitas)Tj
-16.257 -1.124 TD
0.016 Tc
0.14 Tw
(amostras requerem uma certa quantidade de)Tj
T*
0.004 Tc
-0.004 Tw
(di\363xido de carbono ou de bicarbonato. Col\364nias)Tj
T*
0.009 Tc
0.14 Tw
(t\355picas surgem em 24 a 48 horas, por\351m sua)Tj
0 -1.137 TD
0.007 Tc
(viabilidade no meio perde-se rapidamente por)Tj
0 -1.124 TD
0.004 Tc
(aut\363lise)Tj
5.5 0 0 5.5 340.61 161.15 Tm
0.036 Tw
(34 40)Tj
9.5 0 0 9.5 354.65 158.03 Tm
(.)Tj
-3.461 -1.415 TD
0.01 Tc
0.14 Tw
(O \341gar-chocolate constitui meio de cultura)Tj
-1.491 -1.112 TD
0.008 Tc
(satisfat\363rio quando enriquecido com glicose e)Tj
ET
endstreamendobj14 0 obj<< /ProcSet [ /PDF /Text ] /Font << /F4 5 0 R >> /ExtGState << /GS1 9 0 R /GS2 10 0 R >> >> endobj15 0 obj<< /Type /Page /Parent 11 0 R /Resources 17 0 R /Contents 16 0 R /CropBox [ 28.8 55.44 566.2 801.67999 ] >> endobj16 0 obj<< /Length 11612 >> stream
BT
/F4 1 Tf
10 0 0 10 493.49 85.31 Tm
0 0 0 rg
/GS2 gs
0.006 Tc
(453)Tj
ET
0 0 0 RG
0 J 0 j 0.48 w 10 M []0 d
/GS1 gs
1 i 
28.61 53.87 m
28.61 -1.33 l
567.17 53.87 m
567.17 -1.93 l
-2.83 53.63 m
28.37 53.63 l
566.93 53.63 m
596.69 53.63 l
567.17 841.91 m
567.17 802.19 l
28.61 843.23 m
28.61 802.19 l
566.93 801.95 m
598.13 801.95 l
-2.23 801.95 m
28.37 801.95 l
S
BT
7 0 0 7 255.65 759.71 Tm
/GS2 gs
0.009 Tc
0.049 Tw
[(Re)26(vista da Sociedade Br)-8(asileir)9(a de Medicina )44(T)106(ropical 33:451-464, set-out, 2000)]TJ
9.5 0 0 9.5 85.01 693.11 Tm
0.004 Tc
-0.003 Tw
(outros suplementos. O isolamento do gonococo)Tj
0 -1.099 TD
0.107 Tc
-0.07 Tw
(de s\355tios que normalmente cont\352m altas)Tj
0 -1.112 TD
0.012 Tc
0.141 Tw
(concentra\347\365es de microorganismos sapr\363fitas)Tj
0 -1.099 TD
0.005 Tc
-0.031 Tw
(\(faringe, reto e c\351rvix\) pode ser dif\355cil, devido ao)Tj
0 -1.112 TD
-0.015 Tc
-0.07 Tw
(super-crescimento da flora normal. Esse problema)Tj
0 -1.099 TD
0.004 Tc
0.109 Tw
(pode ser vencido pelo uso de meios contendo)Tj
0 -1.112 TD
0.003 Tc
-0.07 Tw
(agentes antimicrobianos que inibem as esp\351cies)Tj
0 -1.099 TD
0.004 Tc
-0.037 Tw
(n\343o-patog\352nicas da )Tj
9.5 0 2.019 9.5 171.17 619.67 Tm
0.003 Tc
(Neisseria)Tj
9.5 0 0 9.5 211.01 619.67 Tm
0.005 Tc
-0.041 Tw
[( e outras esp\351cies)]TJ
-13.263 -1.112 TD
0.019 Tc
0.14 Tw
(e que permitem o crescimento do gonococo.)Tj
0 -1.099 TD
-0.015 Tc
-0.07 Tw
(Utiliza-se o \341gar-chocolate contendo vancomicina,)Tj
0 -1.112 TD
0.051 Tc
-0.068 Tw
[(colistina e nistatina \(meio de )40(Tha)26(y)20(er-Mar)-50(tin\))]TJ
0 -1.099 TD
0.004 Tc
0.089 Tw
[(com esse prop\363sito)29(.)55( Ao meio de )54(Tha)29(y)24(er-Mar)-47(tin)]TJ
0 -1.112 TD
0.107 Tw
(modificado adiciona-se trimetoprima para inibir)Tj
0 -1.099 TD
0.022 Tc
-0.069 Tw
(as esp\351cies de Proteus, sendo universalmente)Tj
0 -1.112 TD
0.033 Tc
-0.018 Tw
(empregado no cultivo da )Tj
9.5 0 2.019 9.5 198.65 546.11 Tm
-0.016 Tw
(N. gonorrohoeae)Tj
9.5 0 0 9.5 274.61 546.11 Tm
0.038 Tc
-0.021 Tw
(. O)Tj
-19.958 -1.099 TD
0.011 Tc
0.14 Tw
(material obtido de s\355tios que n\343o apresentam)Tj
0 -1.112 TD
0.074 Tc
0.085 Tw
(flora end\363gena \(sangue, fluido sinovial e)Tj
0 -1.099 TD
0.044 Tc
-0.056 Tw
(l\355quor\) deve ser cultivado em meios livres de)Tj
0 -1.112 TD
0.005 Tc
(antibi\363ticos)Tj
5.5 0 0 5.5 133.13 507.35 Tm
0.002 Tc
0.016 Tw
(17 22 34 42 54)Tj
9.5 0 0 9.5 170.45 504.11 Tm
(.)Tj
-7.503 -1.402 TD
0.004 Tc
0.024 Tw
(Como todas as bact\351rias Gram-negativas, o)Tj
-1.491 -1.099 TD
0.048 Tc
-0.069 Tw
(gonococo possui envelope celular composto)Tj
0 -1.112 TD
0.073 Tc
(de tr\352s camadas distintas: uma membrana)Tj
0 -1.099 TD
0.044 Tc
0.14 Tw
(citoplasm\341tica interna, a parede celular de)Tj
0 -1.112 TD
-0.007 Tc
-0.069 Tw
[(peptideoglicanas e membr)6(ana e)31(xter)-32(na.)56( A camada)]TJ
0 -1.099 TD
0.041 Tc
(de peptideoglicanas da )Tj
9.5 0 2.019 9.5 192.41 438.35 Tm
-0.068 Tw
(N. gonorroheae)Tj
9.5 0 0 9.5 263.21 438.35 Tm
-0.073 Tw
[( pode)]TJ
-18.758 -1.112 TD
0.004 Tc
0.039 Tw
(tamb\351m contribuir para a resposta inflamat\363ria,)Tj
0 -1.099 TD
0.07 Tc
-0.07 Tw
(porque os fragmentos de peptideoglicanas)Tj
0 -1.112 TD
0.004 Tc
0.007 Tw
(gonoc\363cicos mostram-se t\363xicos \340s trompas de)Tj
0 -1.099 TD
-0.006 Tc
-0.005 Tw
(Fal\363pio e causam consumo de complemento)Tj
5.5 0 0 5.5 271.49 399.47 Tm
-0.007 Tc
-0.009 Tw
(24 39)Tj
9.5 0 0 9.5 285.05 396.35 Tm
(.)Tj
-19.566 -1.415 TD
0.004 Tc
0.104 Tw
(Estudos da patog\352nese e da epidemiologia)Tj
-1.491 -1.099 TD
-0.002 Tc
-0.07 Tw
(da gonorr\351ia t\352m sido grandemente enriquecidos)Tj
0 -1.112 TD
0.004 Tc
(pelo desenvolvimento de m\351todos reproduz\355veis)Tj
0 -1.099 TD
-0.049 Tw
(de tipagem da )Tj
9.5 0 2.019 9.5 147.05 351.47 Tm
-0.053 Tw
[(N)6(.)55( gonorroheae)]TJ
9.5 0 0 9.5 212.45 351.47 Tm
-0.049 Tw
[(.)55( A car)17(acter)-21(iza\347\343o)]TJ
-13.415 -1.112 TD
-0.034 Tw
(das c\352pas dos gonococos tem sido baseada em)Tj
0 -1.099 TD
0.055 Tw
(auxotipagem e fenotipagem, que t\352m permitido)Tj
0 -1.112 TD
0.11 Tw
(mapear a ocorr\352ncia temporal e geogr\341fica da)Tj
0 -1.099 TD
-0.046 Tw
(gonorr\351ia em comunidades, analisar os padr\365es)Tj
0 -1.112 TD
0.084 Tc
-0.05 Tw
(de resist\352ncia antimicrobiana e estudar a)Tj
0 -1.099 TD
0.004 Tc
0.013 Tw
(transmiss\343o da doen\347a)Tj
5.5 0 0 5.5 184.25 291.59 Tm
0.002 Tc
0.018 Tw
(7 24 45)Tj
9.5 0 0 9.5 202.97 288.47 Tm
(.)Tj
-10.926 -1.427 TD
0.026 Tc
0.14 Tw
(Muitos gonococos possuem plasm\355dio de)Tj
-1.491 -1.124 TD
0.004 Tc
0.015 Tw
(conjuga\347\343o e, portanto, podem transferir outros)Tj
T*
-0.047 Tw
(plasm\355dios n\343o-pr\363prios com alta efici\352ncia)Tj
5.5 0 0 5.5 267.05 256.67 Tm
0.002 Tc
-0.05 Tw
(4 40 47)Tj
9.5 0 0 9.5 285.05 253.55 Tm
(.)Tj
-21.057 -1.124 TD
-0.009 Tc
-0.068 Tw
(Muitos outros possuem plasm\355dio Pc)Tj
5.5 0 0 5.5 234.89 245.99 Tm
(r)Tj
9.5 0 0 9.5 236.69 242.87 Tm
-0.071 Tw
[( que codifica)]TJ
-15.966 -1.124 TD
-0.003 Tc
-0.069 Tw
[(a produ\347\343o de um tipo )36(TEM-1 de beta-lactamase)22(.)]TJ
T*
0.004 Tc
-0.028 Tw
(Os dois tipos mais comuns desse plasm\355dio s\343o)Tj
0 -1.137 TD
0.077 Tc
0.139 Tw
(semelhantes aos encontrados em certos)Tj
9.5 0 2.019 9.5 85.01 200.03 Tm
-0.014 Tc
(Haemophilus)Tj
9.5 0 0 9.5 139.13 200.03 Tm
( )Tj
9.5 0 2.019 9.5 141.05 200.03 Tm
-0.01 Tc
(spp)Tj
9.5 0 0 9.5 156.05 200.03 Tm
-0.012 Tc
-0.069 Tw
(, incluindo )Tj
9.5 0 2.019 9.5 198.77 200.03 Tm
-0.068 Tw
(o H. ducreyi)Tj
9.5 0 0 9.5 246.77 200.03 Tm
-0.013 Tc
(. H\341 ainda)Tj
-17.027 -1.124 TD
0.004 Tc
0.025 Tw
(o determinante tetM, que ocorre em gonococos)Tj
T*
0.005 Tc
0.03 Tw
(com alto \355ndice de resist\352ncia \340s tetraciclinas e)Tj
T*
0.054 Tc
-0.055 Tw
(que confere resist\352ncia a uma variedade de)Tj
T*
0.026 Tc
0.141 Tw
(outras bact\351rias, incluindo )Tj
9.5 0 2.019 9.5 209.09 157.31 Tm
0.025 Tc
0.142 Tw
(Mycoplasma spp,)Tj
-12.819 -1.137 TD
0.043 Tc
0.14 Tw
(Streptococcus spp, Gardnerella vaginalis)Tj
9.5 0 0 9.5 277.97 146.51 Tm
0.189 Tc
0 Tw
( e)Tj
9.5 0 2.019 9.5 85.01 135.83 Tm
0.003 Tc
0.037 Tw
(Ureaplasma urealyticum)Tj
5.5 0 0 5.5 188.57 138.95 Tm
0.004 Tc
(50 51)Tj
9.5 0 0 9.5 202.61 135.83 Tm
(.)Tj
12.543 58.661 TD
-0.02 Tc
-0.068 Tw
(A resist\352ncia cromoss\364mica da )Tj
9.5 0 2.019 9.5 447.53 693.11 Tm
-0.022 Tc
-0.073 Tw
(N. gonorroheae)Tj
9.5 0 0 9.5 307.61 682.67 Tm
0.005 Tc
0.054 Tw
(a antibi\363ticos beta-lact\342micos e \340s tetraciclinas)Tj
0 -1.112 TD
-0.014 Tc
-0.07 Tw
(resulta de intera\347\365es entre uma s\351rie de muta\347\365es)Tj
0 -1.099 TD
0.004 Tc
-0.024 Tw
(individuais, algumas das quais \(por exemplo, os)Tj
0 -1.112 TD
-0.019 Tc
-0.07 Tw
(determinantes mtr e env\) alteram a permeabilidade)Tj
0 -1.099 TD
0.059 Tc
-0.068 Tw
(da membrana externa do organismo)Tj
5.5 0 0 5.5 476.09 643.79 Tm
0.044 Tc
(45)Tj
9.5 0 0 9.5 482.81 640.67 Tm
0.06 Tc
-0.074 Tw
(. Para)Tj
-18.442 -1.112 TD
0.004 Tc
0.141 Tw
(prop\363sitos epidemiol\363gicos consideram-se tais)Tj
0 -1.099 TD
-0.009 Tc
-0.069 Tw
(c\352pas resistentes apenas quando a concentra\347\343o)Tj
0 -1.112 TD
0.004 Tc
-0.04 Tw
(m\355nima inibit\363ria \(CMI\) mostram-se de tal monta)Tj
0 -1.099 TD
0.014 Tc
0.14 Tw
(que fal\352ncias cl\355nicas ocorrem com as doses)Tj
0 -1.112 TD
-0.006 Tc
-0.033 Tw
(terap\352uticas m\341ximas \(penicilina G CMI > 1mg/dl)Tj
0 -1.099 TD
0.004 Tc
0.01 Tw
[(ou tetraciclina CMI > 2mg/dl\).)67( A )]TJ
9.5 0 2.019 9.5 444.29 577.67 Tm
[(N)6(.)55( gonorroheae)]TJ
9.5 0 0 9.5 307.61 567.11 Tm
-0.021 Tw
(tamb\351m usa transfer\352ncia de DNA entre c\351lulas)Tj
T*
0.028 Tc
0.141 Tw
(\(transforma\347\343o\) para promover variabilidade)Tj
0 -1.112 TD
0.003 Tc
(gen\351tica)Tj
5.5 0 0 5.5 343.85 549.35 Tm
0.004 Tc
0.036 Tw
(21 22)Tj
9.5 0 0 9.5 357.89 546.11 Tm
(.)Tj
1.364 -2.135 TD
0.006 Tc
(EPIDEMIOLOGIA)Tj
-5.166 -1.768 TD
0.113 Tc
-0.07 Tw
(Poucos pa\355ses possuem sistemas de)Tj
-1.491 -1.112 TD
0.004 Tc
-0.009 Tw
(notifica\347\343o que permitem estimativas confi\341veis)Tj
0 -1.099 TD
0.002 Tc
-0.07 Tw
(da incid\352ncia da gonorr\351ia. No Brasil, os estudos)Tj
0 -1.112 TD
0.004 Tc
0.082 Tw
(revelam-se escassos, tanto no que se refere a)Tj
0 -1.099 TD
0.05 Tc
0.14 Tw
(dados epidemiol\363gicos quanto a dados de)Tj
0 -1.112 TD
0.004 Tc
0.04 Tw
(efic\341cia terap\352utica e de resist\352ncia. O n\372mero)Tj
0 -1.099 TD
-0.033 Tw
(de casos relatados nos Estados Unidos cresceu)Tj
0 -1.112 TD
0.024 Tc
-0.013 Tw
(de 250.000 na d\351cada de 60 para 1 milh\343o de)Tj
0 -1.099 TD
0.04 Tc
-0.068 Tw
(casos em 1978)Tj
5.5 0 0 5.5 375.65 428.15 Tm
0.044 Tc
(22)Tj
9.5 0 0 9.5 382.25 425.03 Tm
0.04 Tc
-0.07 Tw
(. Nesse per\355odo, a gonorr\351ia)Tj
-7.857 -1.112 TD
0.073 Tc
(transformou-se na doen\347a infecciosa mais)Tj
0 -1.099 TD
0.003 Tc
-0.06 Tw
[(pre)41(v)10(alente ap\363s o resfr)-10(iado comum.)54( A incid\352ncia)]TJ
0 -1.112 TD
-0.07 Tw
(estabilizou ou lentamente declinou na d\351cada de)Tj
0 -1.099 TD
0.004 Tc
0.051 Tw
(80 e, a partir de 1992, rapidamente decresceu.)Tj
0 -1.112 TD
0.092 Tw
(As maiores taxas de incid\352ncia de gonorr\351ia e)Tj
0 -1.099 TD
0.101 Tw
(de suas complica\347\365es ocorrem nos pa\355ses em)Tj
0 -1.112 TD
0.006 Tc
0.14 Tw
(desenvolvimento. Por exemplo, estima-se que)Tj
0 -1.099 TD
0.004 Tc
0.079 Tw
(em 1987, 10% de todos os rec\351m-nascidos no)Tj
0 -1.112 TD
0.061 Tc
0.14 Tw
(Qu\352nia foram adversamente afetados por)Tj
0 -1.099 TD
0.035 Tc
-0.07 Tw
(doen\347as sexualmente transmiss\355veis e houve)Tj
0 -1.112 TD
0.004 Tc
0.118 Tw
(50.000 casos de oftalmia gonoc\363cica neonatal)Tj
0 -1.099 TD
0.046 Tw
[(\(4% de todos os nascidos viv)17(os\).)67( A pre)29(v)24(al\352ncia)]TJ
0 -1.112 TD
0.116 Tc
-0.069 Tw
(m\351dia de gonorr\351ia em popula\347\365es n\343o)Tj
0 -1.099 TD
-0.002 Tc
(selecionadas de mulheres gr\341vidas gira em torno)Tj
0 -1.112 TD
0.004 Tc
0.069 Tw
[(de 10% na \301fr)-9(ica, 5% na Am\351r)-21(ica Latina e 4%)]TJ
0 -1.099 TD
0.005 Tc
0.01 Tw
(na \301sia)Tj
5.5 0 0 5.5 339.65 260.15 Tm
0.003 Tc
0.018 Tw
(22 24)Tj
9.5 0 0 9.5 353.57 257.03 Tm
(.)Tj
-3.347 -1.402 TD
0.004 Tc
0.013 Tw
(No Brasil, o Programa Nacional de Doen\347as)Tj
-1.491 -1.112 TD
-0.011 Tc
-0.068 Tw
[(S)12(e)27(xualmente )40(T)133(r)6(ansmiss\355v)14(eis e AIDS  )-16(do )6(Minist\351r)-24(i)9(o)]TJ
0 -1.099 TD
0.004 Tc
-0.018 Tw
(da Sa\372de estimou para 1994, 860.265 casos de)Tj
0 -1.112 TD
0.058 Tc
0.14 Tw
(gonorr\351ia, equivalendo a 56% do total de)Tj
0 -1.099 TD
0 Tc
-0.071 Tw
(doen\347as sexualmente transmiss\355veis registradas)Tj
0 -1.112 TD
0.004 Tc
0.004 Tw
(e 1.315 casos de oftalmia gonoc\363cica neonatal.)Tj
0 -1.099 TD
0.049 Tc
0.14 Tw
(Por\351m, oficialmente notificaram-se apenas)Tj
0 -1.112 TD
0.004 Tc
-0.003 Tw
(119.470 casos de 1987 a 1995)Tj
5.5 0 0 5.5 438.89 173.27 Tm
0.001 Tc
(37)Tj
9.5 0 0 9.5 445.13 170.15 Tm
(.)Tj
-12.985 -1.402 TD
0.084 Tc
-0.07 Tw
(At\351 a d\351cada de 70, a sensibilidade do)Tj
-1.491 -1.112 TD
0.032 Tc
0.14 Tw
(gonococo \340 penicilina mantinha-se elevada,)Tj
0 -1.099 TD
0.004 Tc
0.041 Tw
(entretanto em 1976, surgiram simultaneamente)Tj
ET
endstreamendobj17 0 obj<< /ProcSet [ /PDF /Text ] /Font << /F4 5 0 R >> /ExtGState << /GS1 9 0 R /GS2 10 0 R >> >> endobj18 0 obj<< /Type /Page /Parent 11 0 R /Resources 20 0 R /Contents 19 0 R /CropBox [ 28.8 55.44 566.2 801.67999 ] >> endobj19 0 obj<< /Length 10750 >> stream
BT
/F4 1 Tf
10 0 0 10 85.01 83.87 Tm
0 0 0 rg
/GS2 gs
0.006 Tc
(454)Tj
ET
0 0 0 RG
0 J 0 j 0.48 w 10 M []0 d
/GS1 gs
1 i 
28.61 53.87 m
28.61 -1.33 l
567.17 53.87 m
567.17 -0.01 l
-4.27 53.63 m
28.37 53.63 l
566.93 53.63 m
598.13 53.63 l
567.17 841.91 m
567.17 802.19 l
28.61 843.83 m
28.61 802.19 l
566.93 801.95 m
598.13 801.95 l
-2.23 801.95 m
28.37 801.95 l
S
BT
9.5 0 0 9.5 85.01 693.11 Tm
/GS2 gs
-0.01 Tc
-0.07 Tw
(nos Estados Unidos e Inglaterra cepas produtoras)Tj
0 -1.099 TD
0.007 Tc
0.139 Tw
(de penicilinase. No in\355cio dos anos 80, houve)Tj
0 -1.112 TD
0.028 Tc
(aumento significativo das cepas resistentes,)Tj
0 -1.099 TD
0.003 Tc
-0.07 Tw
(sendo considerada end\352mica em algumas \341reas)Tj
0 -1.112 TD
0.004 Tc
0.108 Tw
(norte-americanas e epid\352mica nos continentes)Tj
0 -1.099 TD
0.005 Tc
0.013 Tw
(africano e asi\341tico.)Tj
1.491 -1.402 TD
-0.003 Tc
-0.07 Tw
(No Brasil, identificaram-se as primeiras cepas)Tj
-1.491 -1.112 TD
0.004 Tc
0.029 Tw
(resistentes \340 penicilina a partir de 1984, e mais)Tj
0 -1.099 TD
-0.03 Tc
-0.069 Tw
(recentemente observou-se resist\352ncia \340 tetraciclina,)Tj
0 -1.112 TD
0.004 Tc
-0.021 Tw
(com 39,7% de resist\352ncia cromossomial e 1,7%)Tj
0 -1.099 TD
-0.005 Tc
-0.07 Tw
(de resist\352ncia plasmidial. Permanecem escassos)Tj
0 -1.112 TD
-0.008 Tc
(os estudos referentes \340 gonorr\351ia no Brasil e )Tj
19.314 0 TD
-0.03 Tc
(seus)Tj
-19.314 -1.099 TD
0.014 Tc
(padr\365es de resist\352ncia, n\343o causando surpresa)Tj
0 -1.112 TD
0.066 Tc
(se estes n\372meros na realidade alcan\347arem)Tj
0 -1.099 TD
0.006 Tc
0.14 Tw
(propor\347\365es ainda maiores. Os dados relativos)Tj
0 -1.112 TD
0.004 Tc
-0.045 Tw
(aos padr\365es de transmiss\343o e \340 sua distribui\347\343o)Tj
0 -1.099 TD
-0.024 Tw
(na popula\347\343o, que utilizamos no Brasil, refletem)Tj
0 -1.112 TD
-0.016 Tc
0.111 Tw
(as realidades de outros pa\355ses onde realizaram-)Tj
0 -1.099 TD
0.004 Tc
0.024 Tw
[(s)21(e)21( estudos epidemiol\363gicos.)]TJ
1.491 -1.415 TD
0.013 Tc
0.14 Tw
(A faixa et\341ria mais comprometida situa-se)Tj
-1.491 -1.099 TD
-0.007 Tc
-0.069 Tw
(entre 15 e 30 anos, com o maior n\372mero de casos)Tj
0 -1.112 TD
0.004 Tc
0.105 Tw
(entre 20 e 24 anos)Tj
5.5 0 0 5.5 169.01 470.15 Tm
0.002 Tc
0.109 Tw
(11 13)Tj
9.5 0 0 9.5 183.41 466.91 Tm
0.004 Tc
0.106 Tw
[(.)55( A maior)-21(ia dos casos \351)]TJ
-10.358 -1.099 TD
-0.008 Tc
-0.069 Tw
(encontrada em homens, provavelmente por )Tj
18.96 0 TD
-0.031 Tc
(maior)Tj
-18.96 -1.112 TD
-0.016 Tc
0.111 Tw
(facilidade diagn\363stica, j\341 que 70% das mulheres)Tj
0 -1.099 TD
0.058 Tc
0.14 Tw
[(inf)33(ectadas per)-30(manecem assintom\341ticas)20(.)45( )6(A)]TJ
0 -1.112 TD
0.003 Tc
0.068 Tw
(propor\347\343o homem:mulher caiu de 1,5 em 1981)Tj
0 -1.099 TD
0.004 Tc
0.081 Tw
[(para 1,3 em 1992.)55( A gonorr\351ia mostr)17(a-se mais)]TJ
0 -1.112 TD
0.028 Tc
0.14 Tw
(freq\374ente em n\343o brancos que em brancos,)Tj
0 -1.099 TD
0.004 Tc
0.034 Tw
(alcan\347ando propor\347\365es de at\351 40:1)Tj
5.5 0 0 5.5 236.45 396.59 Tm
0.036 Tw
(15 22)Tj
9.5 0 0 9.5 250.61 393.47 Tm
0.005 Tc
0.028 Tw
[(.)68( F)43(atores)]TJ
-17.432 -1.112 TD
0.004 Tc
0.087 Tw
(associadas com risco aumentado de gonorr\351ia)Tj
0 -1.099 TD
0.045 Tc
0.139 Tw
(incluem baixo n\355vel s\363cio-econ\364mico, n\355vel)Tj
0 -1.112 TD
0.004 Tc
0.016 Tw
(inferior de educa\347\343o e resid\352ncia urbana)Tj
5.5 0 0 5.5 259.49 365.15 Tm
0.003 Tc
0.018 Tw
(27 42)Tj
9.5 0 0 9.5 273.41 361.91 Tm
(.)Tj
-18.341 -1.402 TD
0.074 Tc
0.158 Tw
(A infec\347\343o gonoc\363cica apresenta alta)Tj
-1.491 -1.099 TD
0.004 Tc
0.064 Tw
(contagiosidade, sendo o homem o reservat\363rio)Tj
0 -1.112 TD
-0.022 Tw
(natural do gonococo. O homem doente constitui)Tj
0 -1.099 TD
-0.068 Tw
(a fonte de infec\347\343o, tendo essa, papel de grande)Tj
0 -1.112 TD
-0.049 Tw
[(v)24(e\355culo disseminador)29(.)55( Atualmente)17(, v)29(em se juntar)]TJ
0 -1.099 TD
-0.013 Tc
-0.069 Tw
(\340 prostitui\347\343o feminina, e \340 prostitui\347\343o masculina,)Tj
0 -1.112 TD
0.08 Tc
[(o homosse)17(xualismo e o bisse)30(xualismo)42(.)55( As)]TJ
0 -1.099 TD
0.004 Tc
0.037 Tw
(mucosas genital e anal representam a porta de)Tj
0 -1.112 TD
0.014 Tw
(entrada e sa\355da do agente etiol\363gico)Tj
5.5 0 0 5.5 240.77 267.71 Tm
0.001 Tc
(15)Tj
9.5 0 0 9.5 247.01 264.59 Tm
(.)Tj
-15.562 -1.402 TD
0.015 Tc
0.14 Tw
(O risco de aquisi\347\343o da gonorr\351ia em um)Tj
-1.491 -1.112 TD
0 Tc
-0.07 Tw
(\372nico intercurso na mulher gira em torno de 50%,)Tj
0 -1.099 TD
-0.015 Tc
(em duas exposi\347\365es de 87,5%, e em mais de duas)Tj
0 -1.112 TD
0.004 Tc
0.033 Tw
(exposi\347\365es de 100%. No homem, em um \372nico)Tj
0 -1.099 TD
0.019 Tw
(intercurso, aproxima-se de 80%)Tj
5.5 0 0 5.5 220.85 212.39 Tm
0.001 Tc
(22)Tj
9.5 0 0 9.5 226.97 209.27 Tm
(.)Tj
-13.453 -1.402 TD
0.004 Tc
0.125 Tw
(A gonorr\351ia e outras doen\347as sexualmente)Tj
-1.491 -1.112 TD
0.062 Tw
(transmiss\355veis geralmente s\343o transmitidas por)Tj
0 -1.099 TD
-0.018 Tc
-0.069 Tw
(pessoas com infec\347\365es assintom\341ticas ou que t\352m)Tj
0 -1.112 TD
-0.015 Tc
[(sintomas ignorados ou n\343o percebidos)23(.)48( A resposta)]TJ
0 -1.099 TD
0.074 Tc
0.068 Tw
(comportamental aos sintomas parece ser)Tj
0 -1.112 TD
0.004 Tc
-0.004 Tw
(determinada pela educa\347\343o e por v\341rios fatores)Tj
0 -1.099 TD
0 Tc
-0.069 Tw
(demogr\341ficos e s\363cio-culturais, mas exceto onde)Tj
23.432 58.964 TD
0.004 Tc
0.053 Tw
(a atividade sexual se mant\351m por necessidade)Tj
0 -1.099 TD
-0.024 Tc
-0.07 Tw
(econ\364mica ou outros fatores como o uso de drogas,)Tj
0 -1.112 TD
-0.008 Tc
(a maioria das pessoas com sintomatologia genital)Tj
0 -1.099 TD
0.005 Tc
0.085 Tw
(cessa a atividade sexual e procura assist\352ncia)Tj
0 -1.112 TD
0.093 Tc
-0.07 Tw
(m\351dica. Muitos transmissores da doen\347a)Tj
0 -1.099 TD
-0.003 Tc
(pertencem a um subgrupo de pessoas infectadas)Tj
0 -1.112 TD
0.004 Tc
0.031 Tw
(que n\343o possuem ou n\343o valorizam sintomas e)Tj
0 -1.099 TD
0.076 Tc
-0.069 Tw
(n\343o cessam espontaneamente a atividade)Tj
0 -1.112 TD
0.004 Tc
-0.044 Tw
(sexual. Esse conceito sustenta a import\342ncia da)Tj
0 -1.099 TD
0.047 Tc
0.14 Tw
(busca ativa para promover tratamento aos)Tj
0 -1.112 TD
0.004 Tc
0.016 Tw
(parceiros sexuais das pessoas infectadas.)Tj
7.832 -2.135 TD
0.021 Tc
[(P)120(A)120(T)38(OLOGIA)]TJ
-6.341 -1.768 TD
0.017 Tc
(A )Tj
9.5 0 2.019 9.5 332.21 551.03 Tm
0.013 Tc
0.14 Tw
(N. gonorroheae )Tj
9.5 0 0 9.5 405.41 551.03 Tm
0.143 Tw
(primariamente infecta o)Tj
-10.295 -1.112 TD
0.007 Tc
0.14 Tw
[(epit\351lio colunar)45(.)58( A liga\347\343o ao epit\351lio m)-6(ucoso)32(,)]TJ
0 -1.099 TD
0.001 Tc
-0.07 Tw
(mediada em parte pelos pilli e pela prote\355na Opa,)Tj
0 -1.112 TD
0.004 Tc
0.102 Tw
(\351 seguida em 24-48 horas pela penetra\347\343o do)Tj
0 -1.099 TD
0.012 Tw
(organismo entre e atrav\351s das c\351lulas epiteliais)Tj
0 -1.112 TD
0.025 Tw
(para chegar ao tecido submucoso. H\341 resposta)Tj
0 -1.099 TD
-0.015 Tc
-0.07 Tw
(vigorosa de polimorfonucleares, com descama\347\343o)Tj
0 -1.112 TD
0.004 Tc
(do epit\351lio, desenvolvimento de microabscessos)Tj
0 -1.099 TD
-0.021 Tw
(submucosos e forma\347\343o de exsudato)Tj
5.5 0 0 5.5 465.89 470.15 Tm
(6)Tj
9.5 0 0 9.5 469.01 467.03 Tm
(. L\342minas)Tj
-16.989 -1.112 TD
0.046 Tw
(coradas revelam grande n\372mero de gonococos)Tj
0 -1.099 TD
0 Tc
-0.069 Tw
(dentro de poucos neutr\363filos, enquanto a maioria)Tj
0 -1.112 TD
-0.021 Tc
-0.068 Tw
(das c\351lulas n\343o cont\352m organismos)Tj
5.5 0 0 5.5 449.93 438.59 Tm
(22)Tj
9.5 0 0 9.5 455.81 435.47 Tm
-0.02 Tc
-0.07 Tw
[(.)56( A e)31(xplica\347\343o)]TJ
-15.6 -1.099 TD
-0.008 Tc
(para esse fen\364meno pode envolver a estimula\347\343o)Tj
0 -1.112 TD
0.085 Tc
(ou a produ\347\343o de receptores celulares do)Tj
0 -1.099 TD
-0.004 Tc
(organismo para o gonococo ap\363s o contato inicial)Tj
0 -1.112 TD
0.018 Tc
0.14 Tw
(com este agente, que parece suficiente para)Tj
0 -1.099 TD
0.016 Tc
(estimular a fagocitose eficaz dos organismos)Tj
0 -1.112 TD
-0.001 Tc
-0.07 Tw
[(adicionais)12(.)62( Al\351m disso)24(, alguns gonococos podem)]TJ
0 -1.099 TD
0.054 Tc
-0.043 Tw
(apresentar mecanismos de evas\343o contra a)Tj
0 -1.112 TD
0.024 Tc
-0.044 Tw
(morte intracelular e continuam a multiplicar-se)Tj
0 -1.099 TD
-0.021 Tc
-0.07 Tw
[(no interior das c\351lulas do hospedeiro. Em infec\347\365es)]TJ
0 -1.112 TD
(n\343o tratadas, os macr\363fagos e linf\363citos substituem)Tj
0 -1.099 TD
-0.005 Tc
-0.068 Tw
[(g)8(r)12(adualmente os polimorf)33(o)8(n)-5(ucleares)20(.)58( A infiltr)8(a\347\343o)]TJ
0 -1.112 TD
0.005 Tc
0.14 Tw
(mononuclear e linfoc\355tica anormal persiste em)Tj
0 -1.099 TD
-0.026 Tc
-0.063 Tw
(tecidos por v\341rias semanas ap\363s a negativa\347\343o das)Tj
0 -1.112 TD
0.005 Tc
(culturas e a n\343o identifica\347\343o da )Tj
9.5 0 2.019 9.5 444.41 288.47 Tm
0.003 Tc
(N. gonorroheae)Tj
9.5 0 0 9.5 307.61 278.03 Tm
0.005 Tc
0.015 Tw
(na histologia)Tj
5.5 0 0 5.5 361.61 281.15 Tm
0.003 Tc
0.018 Tw
(22 23 24)Tj
9.5 0 0 9.5 383.33 278.03 Tm
(.)Tj
-4.055 -2.147 TD
0.132 Tw
[(MANIFEST)116(A\307\325ES CL\315NICAS)]TJ
-2.425 -1.768 TD
0.004 Tc
-0.018 Tw
(Ap\363s contato sexual do parceiro fonte com o)Tj
-1.491 -1.099 TD
0.094 Tc
-0.047 Tw
(novo hospedeiro e vencidas as barreiras)Tj
0 -1.112 TD
0.004 Tc
-0.035 Tw
(naturais da mucosa, e em per\355odo de incuba\347\343o)Tj
0 -1.099 TD
-0.015 Tc
-0.07 Tw
(relativamente curto \(2 a 5 dias\), a infec\347\343o evoluir\341)Tj
0 -1.112 TD
0.003 Tc
-0.042 Tw
(para doen\347a)Tj
5.5 0 0 5.5 360.29 201.95 Tm
0.001 Tc
(27)Tj
9.5 0 0 9.5 366.53 198.83 Tm
0.004 Tc
(. Dar-se-\341 um processo localizado)Tj
-6.202 -1.099 TD
0.037 Tc
0.14 Tw
(autolimitado em alguns casos sem maiores)Tj
0 -1.112 TD
0.019 Tc
(repercuss\365es, enquanto em outros ocorrer\343o)Tj
0 -1.099 TD
0.004 Tc
0.019 Tw
(complica\347\365es no pr\363prio aparelho urogenital ou)Tj
0 -1.112 TD
(a dist\342ncia, provocando altera\347\365es sist\352micas.)Tj
/F6 1 Tf
9.5 0 2.019 9.5 321.77 143.51 Tm
0.061 Tc
-0.07 Tw
[(Gonorr\351ia no homem.)36( )]TJ
/F4 1 Tf
9.5 0 0 9.5 432.29 143.51 Tm
0.063 Tc
[( A uretr)-25(ite aguda)]TJ
-13.124 -1.112 TD
0.029 Tc
0.139 Tw
(representa a manifesta\347\343o predominante no)Tj
7 0 0 7 85.01 759.71 Tm
0.01 Tc
0.012 Tw
[(Penna GO  et al)]TJ
ET
endstreamendobj20 0 obj<< /ProcSet [ /PDF /Text ] /Font << /F4 5 0 R /F6 6 0 R >> /ExtGState << /GS1 9 0 R /GS2 10 0 R >> >> endobj21 0 obj<< /Type /XObject /Subtype /Image /Name /Im1 /Width 591 /Height 396 /BitsPerComponent 8 /ColorSpace /DeviceRGB /Length 19394 /Filter /DCTDecode >> stream
ˇÿˇÓ Adobe dÄ   ˇ€ Ñ ##""'"!!"''.030.'>>BB>>DDDDDDDDDDDDDDD!!1!!$!!1>-''''->8;333;8DD>>DDDDDDDDDDDDDDDDDˇ¿ åO" ˇƒ?          	
         	
 3 !1AQa"qÅ2ë°±B#$R¡b34rÇ—C%íS·Òcs5¢≤É&DìTdE¬£t6“U‚eÚ≥Ñ√”u„ÛF'î§Ö¥ïƒ‘‰Ù•µ≈’ÂıVfvÜñ¶∂∆÷Êˆ7GWgwáóß∑«◊Á˜ 5 !1AQaq"2Åë°±B#¡R—3$b·rÇíCScs4Ò%¢≤É&5¬“DìT£dEU6te‚Ú≥Ñ√”u„ÛFî§Ö¥ïƒ‘‰Ù•µ≈’ÂıVfvÜñ¶∂∆÷Êˆ'7GWgwáóß∑«ˇ›  %ˇ⁄   ? ‰éM›Ï˘≈D‰\y±«ÊP”#IHn∞Ú‚~$¶/ws˜®$íôor[ääI)}«≈-≈2I)}≈>‚¢íJ_qKqLíJ^J@î @ TxHTxH: º% @I†πﬁ)2≤u*√Å0ê6fÑ%-˛U4@—Oy
b@·=L.‘£'©lÎ√5•∆J+®Ö6∑¡J¶[<1Å´-&ﬁà÷Ë†—˜¢ƒË	eì@$ËBãù‡°…◊D)+…qû»ÄmÂ0 È:píônÇëw‚ìYπL◊$B+EÜ„ìñ∏s¬-X÷X‡¡°:Î¢∂Ïj®nÃêÊÿ‚K`ÇﬁÂ+[)ƒ˝&ãXLGu?LßÅ∏Ü ûËŒ•Ì`{à&\>^TM5Àâ∂¨Ì†<SsKfO∂‡Q/¡}.ixõ¯sNÊ¸'≈-Q∆¢”⁄x·1:J◊ª¶1î∂–ÚAÄ–…wõP_“≠ﬁ›⁄ç7ÜÍY∏w	j7Z3@ıs@-‘j<ª#ZÍÂ†ñçIØ£kãIêÇàSf[™«}!Ç_˘˝“ªL§H∏˙öç Œ†@'T6ËOÅ2àZ	!⁄ëÒÏû∂∑⁄„†òwíVæ÷ˆ>
EﬁõÜ≤<ñìqi!ÅˆKH Òªƒ5üùSYi ¥√ö`Ó›`òî©C$œVñ;ç	◊‡ÖèKl∏ñÄ$ê7(sGÇií@&É≠U¥≥∆Õè"ó≈Sc	v÷Í\`ÓÅ–+òÂ∞nc¿}PC]˘ﬁHÓh±ë¡d~í≤*8≈çq˜êw7˜Ω3_"?‘®dÂø*ﬂR¡  q¢ãúÿ3˘“ÅÙTD∏GÃïÌkÄPV⁄ $Ñjâ$˜íÿÉ›7PêHs‹”Û
|>jÛ©ˇ ©U‹»à–˛Tmx °"GiÉ‹È
a¢uÂ1aB6õDY™âÇäObëhÂJFΩë·€è6äd¢;©<d&püàPkıì $éPŸ#ÑπRxô=–⁄fGt‡•‹›<‘ZË—'î'∑PQ¢'Ç9NHp°üDyßÑ0{H>iÎ#P{§„?$¿	—¬›ã'Qû|Q!ÆØe 9“	*hÅœ$≠>å gK Yºh¥∫9˛ùˇ Öm¸â¯˛`¡Ã‘…ˇ–‚“I$R§íI%)$íIJI$íRíI$î§íI%(	S¯(¥)¿âM+ÄXè:ô$9í≠R›†xîŸò„rHÅKÄêjîàñË4Y¨ù{#µΩÇã[¿EhL%ö•H„∫ì[<§<ßqÑÀdâD2‚x·FKë`tD∂JÄÓSp'@¶j,’‡∂u˜!+R0$Î¢#ZwÚL ùÍuUñ<˚å…4ïLôCò◊> ﬁ“	Ì'¡=Ö°å{\7ù`ﬁˇ 5<Œ•u„a%µ˛‡‡¯Jß$¡JñƒHÎ/KdﬁÁI Œ~Ë.2@–ùPÄ<pçN%÷ÇÊ	kDó !J<#SÈF£ÓN\†—Z/"[1. ∂◊…[¡Ëœ∞º[Ì-Å ÎÓÓàöd≤„àó6ªEa‡¥Y∏m˜vÛiÉﬁZ	-vˆïw#¶∂úèMœÜNáüoÔ+}?Ï,≠Õ∂¿\N≤8€ƒÄ$“HÒƒq4⁄o˚9`$1ƒüº|ì—èö˘µíy¿Í¥nœ∆«kE`;n£ƒ´‚uLøw—yòº¬‘±	Lƒò¡±”/ha™ˆ¥=ÉÙ{∆“uÓVUÕ6ﬁ‡∆¡sΩ¨nør—=GÁ¥ﬂQ∞¥&9ÛU≤.«mò°’∏k>hì†◊ÂV1!3./ÒUvÆ†nõÅÄ"eˆ]Ôº÷v±˚w« (_ì}çáÿH(u‰ﬂ[ΩFºóëé¶>hd ¬ÿX˚™©ÿÓ—§…iÏBc™ñE∂9¡ˆjÁ˜Ôœu §ÀAøâ‘F5VW≥W¥éeﬂ¡•·S{ÚÈ±≤vO›?5ó–x(å∂ Ã±≈Ñà$"v9c–I±ì”Æ«±¢¡Ù¯çP⁄`hFÜ{´uÊ∫Îòrü•pÒÀuôéÍyB∆∫Í,ı¿˜Y¥mÇ|º1Ωc≤‰*9?Ùû·¥Å»Â Ëƒ®¥3ÚN‚ëœíîÃ8|tÏ§“[Œ≤Ñ–[©‘ˆF mﬂ0xÄÅZR5„Ö≤P⁄g¯J#]¿@ä’[5≠d·3^ œä¥˙‰xüUÃ‘é·l$BÔ®r;°Ü∆á≤3] 4˛)=†«àF“	ÿ†stë«t7îw›‘<Ò	¡pEv)¡)ˆÛ‚ò>H• ´ÑißÕ¬Fö¢—Ñ5xx"5…˜H›ÀL¥Ìlâ®TÌ§®î·--aé¥Ájñ´^¬…ñ}“ìÄÅ»C‹G∑‚‰$µDç9Pt∑Tx¸q◊W5(Zï√»[5ç˝a≥ßŸÌˇ ©HN‰"≤cÜ&_7ˇ—‚“I$R§íI%)$íIJI$íRíI$î§¿'NJdN=ìÄ£ù	´ÎDî≤H'Öm¢ÎlGí;G°ô≤‹≈
ÅŸJ;'Ä9I†í£∂»4#4öÉGu9î“Y Q1¸P…î‰œ)ÄÜ…UmÄN—‹û…$¿¸Só-c∫MiÁîíê4Fºïwºä^l¥˙ï∂+g:|˚*íù	–ˆM[(í4<,`ìÂ‰à÷Ãvû…√4F§‘#‘"LÜ«ÜüäDÆ&É+0neΩÕ˝∏p2áU|ê=£íèvfEÃΩﬂ¢h 4Ç^ÍÊ5éÈë„ØWÃﬂ8¥S[,mç{à’8¡û–èWW«•æ⁄!¬»ä«.“yü«XÏçÖáê©û&Êfa»¥=£`Ê‚◊‘≤jypytà Í#ÕW≠ßÛtéIDu;â'Bu)ºZÆ·Ä$zXﬂê˚¨ﬁ„ÿ ÜIù5(¢Ä	N¨j˘&eBn hÄ·_¶÷∫pÆ≥ª⁄¡$ˆWY“ûπÂ¨ù›ëG`«,—ó”yÇöÈ≥@>*.µ≠|rÇ”¬ª	x.'Ñ $◊ åìêçÄ—v):ûO*-ƒ2–è≥ˆú8ñ◊?NpB∂∑¿ÚâàÕàe»trˇ e[dŸ—©%	ÿgÇ5+M˝J√¶Ì;¿ÖX‰µƒîËï—û_“s›å[$hGe√§s0ejÄ«ÒQö…ÇÖë∫ÒêÏ\˜÷tÔé!57[\Ü–Ì;¥o.∞4ê73A‡·Ê©‹yÜÌ »Ò¯$d∆\BàKmM…][[Sk 9£ªºB¶÷◊ÑV<˙cœEßÅ]„∫õ≠¡€ö„ÒN ìAGu˘Z!Ä∂BÉF„G*–`kã‹ »o®µ≈√Á	äGÈù
ãÄù8¸ã_¶5Å∂6ÿ‘h„ƒ,´ò»â:ß@ﬁDgs1˝’⁄wêﬁ Ç;¢4⁄¿S-H‰&Ï∫Ëµﬁ¸y¯(Aô+.goiMp(“uEƒ<˛Tr◊jyÑ'∑øt‡ºE›«>
ZG‹¢G$r®éÈ…e«<(πßX‡©œ!1ÇJ@F© ¶ÊÚò…÷ÖŸ‚£ûT\ﬂÅAcÅ{Rò–°4¡Ñb%†˜ÓâÄl&¶:É§&πÇLpu	1¿0Å©ë^‡ˆÄy3PW4öK‰µzcˇ IêÓµ”˛aY∂∑∏W∫[ø§x˝ûˇ ¸ˆTë÷@∞Âã ˛£ˇ“‚“]j:Jx¥óhí*x¥óhíVßãIvâ ßãIvâ$ßãR`]íIÉE‰\@wJë&JÎíB¥•¬~´ßùkQÄÖ∏íå‚æ≠ÅÕ◊Ëˇ Œ˛«ï6i$/√ùØÚÛø±…I&;-têˆ|W}˚˝_¸ÔÏs®°÷ÿ⁄ÿ=œ0¨¸·Ü¥ÿa:Ä4≈$Ωèz\@à˙Ω˝émUÔpI+ZÏä(Æ∂ÿŸ±Œ.<}ﬁi%Ïxˇ ÕDπ¡"/ß˚ﬂÿÊª‹‚FΩÃ$ä“Iªˇ Yﬂˇ ’ˇ Œ˛∆ì~QõS‹«=ÇZﬁJ:I}ﬂ˙ﬂÛVûxÙ«ˇ ;˚ØŒ√vik≠-Cbè≈gÊdﬂ∫@Äq¿SI#Äü“ˇ ö≤‘`lcˇ ù˝çm|Ç5Tìœö≤íGó˛∑¸÷Cœ˛O˛wˆ2c ‰¡ÛW™n ´uñ·2–≥“Hr‡uˇ õ˝¨rÊØß¯_ÿÇÎAq'ì‡ïVù“KÓ˛?ÛW˝ÙU{Ûø±ff8i«ÇÖŸVºÌsâl˜DI/ªˇ ]úà7ÌŒ˛ƒMtA·I∂ñíG
i%˜ÎÕOﬂAˇ 'ˇ ;˚1ÓpÅ©=ì∫¬–wjFÄ!$á›ø≠ˇ 5oﬂ˘ø˘ﬂÿŒZÊn}õ@ê÷Å$†4ÄIRàí_w˛∑¸‘érø…ˇ Œ˛ƒÙÒﬂ∞ÒV⁄˘–ËGèeöív˛∑¸ﬂÌXy†G˛wˆ:ÖÄÒ®ÂV≤êt:ÇDí<ØıøÊˇ já4GO˘ÃùTyMYét≈2I}◊˙ˇ Ûµﬂ4÷?Ûø±≥Q «>j»hsaf§ó›≠ˇ 7˚Vjˇ G˛wˆ7‹¬º’g¥íPRKÓø◊ˇ õ˝©—£ˇ ;˚∞1¨ˆS-1„›WI/∫ˇ [˛oˆ®Ûw˙?Ûø±;§üát≈º»îí˚ØıøÊˇ jæ˜˝_˘ﬂÿÕÌ“KÓø÷ˇ õ˝™˚ﬂıÁcZa_I/∫ˇ [˛oˆ´Ô’ˇ ù˝é\ ¬⁄I8rı˙_ÛU˜ØÍˇ Œ˛«üÑ(]*I„uWﬁø´ˇ ;˚Vauâ'px≠<Õ˛è¸ÔÏyó\í<(˜ˇ ™Ú).π$∏<UÔˇ U‰R]rIpx´ﬂ˛´ˇ”‚“I$R§íI%)$íIJI$íRíI$îªF®«@áP÷Tﬂ¬a›í"£l $´î∑@V⁄G	ì:3r‚ÂiÜâòù•B∑â≠’Œé¡Xh“`çO%W@ikë0Øt∑öÚC€_™Z	˘sÚTò5ûÎCß›Eã/fˆêAÏMΩS?êä‚Añ,.~Üœ|¸‰±[Y≥ﬂ´ %–£acÌsò"≤Ih<ÄèN÷ÇÊàcAq'àjoÇI:ûΩØÓsZ”˘£Ä†˜õl.vÑ (ô„≤#Í!óU2kI Oeb†*ãgRFá„(l‡`ì{'µÜª“‡‚4ë«…4≠:Ë´-}è.t∏ù'ì
K†s‡§A$ 5um‘Í{•j∞—¨ë™)æa;ÏÜ«àUû‚Ω–§;±sΩ–R1„¬â≈"u>hØ•ÀΩ mt¿(~hµ îîFåœ'∫ãâ˚‘»;®ñ»=“Zw”DVqØ=‘#û l&@:§íœf≥ öy:GÇ≤“$â¯ ^·¿·%†íZÔwa¬ßrâ˚ëÅRFÅ_√6WçëxphÅV£Søê>Agí¨?-Ó≈Ø ed∫{í|SñN$ÄÌ|çQ©ºµ•áPLÇy
£N¢Qÿ"HIõªåi§¢‘Û¶„†:ë ¶Î≠∏Æûh#‰àâô˛)∂ÉÁ*ìrÀd ~ÑûG¡Z™–@'I‚SHc1êb*R‹Dj|Qƒ}Ëv0»=ÇŒ¨€i&≥‹ß,gXUà,">*’/›°‰"¢+PËæÜ‰P◊3G4D»©
à$<;´òñ˙f†Û∑“◊~ëöÉ©Ö<¢'(¸ﬂ§’1ó	˘\◊◊ﬁÇ[è Ø9°Wµæïr)ö2Ë”µ¢b©πƒ
˚€?[´0gR<ëûl◊xô#≤É¿pHíàPiÑ‡  ”‚á¡Z pmn≥‚ú
CD©Åßå®4°RàÄ)Q¢D)ƒâÔ¬ÅêSÅk{éB9
$5Nñëbò”i„«B…-tçw«Ç8îbwj5ë≠≠â;“◊qc^°‚5F¿?•≥˛&Ô¸ÙÂLx+x'Ùñƒ›ˇ ûúåH#/Ûr˛‰üˇ‘‚ I%¸JíCI$$I	$îï$$íRTê“A-öìºŒä™HV∂ªè”M∂ˆ
ÌB«JJiÖıdÜ~tÏîöŸ"{,yJS}Ø_ΩÎ|?Ûø±Ë@¯Ñâ:œJRá≥‚ªÔﬂÍˇ Ác“¥™ΩòqF5,™ƒMá∏Ú+ç”≤d=è˘™<Ìêx~_Îc’ÜÄ¸®«®[ˆså–Dëœ√‡π…í?¨£ŒÛcˇ ù˝èP<hû”∑äÂ£øäH}ﬂ˙ﬂÛW}˙ˇ …ˇ Œ˛«∞Æ÷‘∆πÑãAòÅﬁ¯ ây{ãèπƒ…+ëNÎƒ%˜Î-˚Ë˚Ûø±Ìja"b#î≠∞‡∏îÄî>Ì˝o˘®˚Ê∂cˇ ;˚∏øYrãœq¬ÂNä(é_˙…˜˙ø˘ﬂÿıc«≤âÈ¬ÂíKÓ„˜ó{˝_¸ÔÏz¢$ï*¡–ÀìI/ªˇ Y_~ˇ Wˇ ;˚Ã¢b\rH}ﬂ˙ˇ ÛV˝˜˝_¸ÔÏz◊›îÍp„ÚÆ=$~Ô˝e}˚ß∑ˇ ;˚·ƒm ò>*≠§Iéä‰RCÓˇ ÷ˇ ö°Œ◊˘?˘ﬂÿÙœ"L!íJÁRNˆu√üˇ Wˇ ;˚Ö?ÇÁRKŸÒ]˜ÔıÛø±È@E:v\≤H{∫>˝˛Ø˛wˆ=s]Æ∫y©8	—qÈ%˜q˚»˚Ô˙ø˘ﬂÿˆ%ºO*M∂¿Iê4èÓ\bI}ﬂ˙ÀO9ﬂ¸ÔÏ}áÀdÍ#ïe≤F∫Ø3îÚöyoÎÕb<Õõ·ˇ ù˝è£[I‰jû¶˙dN≥›y»y⁄P˚µ~ü¸‘hÅF?Ûø±Ù‡Gk–	cªË'ÖÂ)ä|1õ∂#ú\?ÛüU…´”p1°„…U~∫Ø4:¬	–¶<¡á–úŒOuW‹ÎÒ\|Ûœd¿¶û^∂ó¸ﬂÌ^9≤?G˛wˆ=çÙF£EIÕ-tˆ\‹îëk´ ¯ÅΩø˘ﬂÿÙƒÈ#QŒä.!Õ>>kô*îF˚Àá?‰ˇ Ác—«N8=ó/)•;ÿ◊}˚˝_¸ÔÏzíË”±J4”∫Â•)KÿÒWﬂø’ˇ Œ˛«§:¸S®\‰•){>(˚˜˙ø˘ﬂÿÙ∂GäFÖb•(å4*–yÀ6!ˇ ;˚Õ›¬≥ÜË{œçVˇ Á∑.kT‡òDb£v∂\›Ç8~oÎcˇ’‚“I$R§íI%)$íIJI$íRí§êIIŸHTY™õG∫ ñ°™∂¡¬®√®
„4C6ˆ
¶qŸM≠àÛQoc #O‡¢-†±IQhR¥ˆÒN—†C¢[î‹⁄(sÿËπ‡≤;√π(	·AŒ.ç‹»+¯VaUSŒM~°”h‚|íÆãe†$)5≤ﬂ[û}0@Î'…3!±¬Ä.'ÄNÉ¡XDöWU
IS7Ω≠:Iâ*Óv#1ú÷µ¡‡â1‚®∞ùH¯¢â“PµÑKàÙ±Ÿ°BxV)f»Öõ'Ngå'Ôî”™Ÿ≤ﬁH=«Ç®@‡pQÚNΩ‘H¢p—xÉ°—3Çû›4ÓÑdHˇ Pí‡ºH3°Q24N	ï0≈$Ïå	Â `»–wO/$à˚—S0A9L$Ã¯(¥¯È™ à#±A1q‚x*wS{t—A≠E!rd·›	Œù†ÄÑHH$1'HLëN—%9Jà‘¶%'…í§Ì:¶ ßh’$$híRíS4íòÈ™jVIÁÑ]H h†ÜÉ≈HG=–+K7’¥˚’ºLÜ2±Oß∫◊9J†v¯Ò¿N«º=ákõ®),în4]v<ë»E-‘}À5ôeÔ.t6b@Ó|Uˆ8ñà◊‚öGF¥‚C4áiœu $xi›≠Áü3PüÇ 9Ôk¿ÒD®ùdKXDûTËvúx!ZØªãd	◊‰¢[;$◊pù¿H±Í
'3∑ä´}But†\=•%$"®ütÚBië=∆Ö^»nÑùuTO∞üúr&¬¨› 4Ó—ç¶ÇBåÒ‚ìL)g…" ¢ïú…D3˜°îÇòì'U  ¢Li œd·∫√≤òê¨„{ø‚Ïˇ œnU£S(‘òˆˇ PÂ ›Äöâˇ÷‚“I$R§íI%)$íIJI$íRí	$íí÷ í£XÜï&j	*2Õ†fœ§∂:πW¬ämº&iDn∫°¨–Jà∂√â k◊øh\|ﬁJ¨~òÚV+y¨«∏à1‡ÅQ∫”ÊDZ¡i ÀÄ{ë‚Øg◊àÃZ}Óyó~àÒ˛
Å"LÛ(◊ﬂÍ˙lh€]m 7¥˜?4≠D(›F1¡ßøu*‹œLµÃíH!”«˜©4Ä¶¢Wcc^0ÜÎÃ£‡Uèx{Æ≥”‘ËÎ¡“R Ó«≈r1˝‘åsZA&@òÏõ&¿ÊKLÉ›“«Dd7ÿHÅ†@HàŸ∂Gç4)ßÆ©2)è kﬂ≈'A)¯v’&çu·%x∞Ç4œb§	jôhÁÒL<)*◊wí⁄G:"¥Fæi‹AˆIE≠'Ç§«u˚í{G!3@Q\ë∆AE§é{ˆM∏(óO	*ïa·ï7yP!ê±Dka≤¢∆…çoµ∞'¢âË◊! ítR° +`pà…¯ PS5Äà:#’Ü^ÊéŒ1<G≈ß4t>}’¢–@"
gã£Yıö.,>ÌßXÓò w§I ÛÛDÑA]5d“5%IŒÅ¢™É	Rùl¥d÷Î∂@3¬›»©µŸÌ—Ø<óÖ	‡≈ìƒØÖÔô°û»é:i›yº(ßzU±úÓ˙úœè!Õ!¿é
‡‘Pˆ|P#O£UÙeM⁄èÊÈ#ÏÈVÉ7o¢7…yÚH{>*ß≥∏jVuÌ|∏\ÍyDaÆ¨±ù;`Ã¯®∏NΩ÷g˙ˇ π/Ô˘%¡‚œn£H )8É™»RKÖCW@î“≥·I*§Åm”†íÇÛ›W24H¡)iâ:3ô(¥Ú„ﬂkøÍ\´BtÎX1_Wˇ◊‚“I$R§íI%)$íIJI$íRí	'	)5|)ƒ
5qé:@Q€ÆUCUi£MZé∞≠∑àQÕ±Éf`Æ‚”Î=µ»nÌ$™4}ÍÀ¥»‰(ãlZ$…√8˘ì^-:jﬂvDfŒeè-⁄⁄¥sâÅ>*.pºZ}Œ◊π[}K˝ôŸ^ÆﬂRÍ«—$¯!Wd,ñCìÛ~õÜ⁄MÜ´ù£Gr|6:∑ñ<msLy‘}V∫ê]cu j}æHVX˚.sÏ˙N$ìî:2x´ÙS2$Øöõò`m‘)a„æÎl“y=Ç=’zu[√À{çBiΩ÷ô.“jÉGÇO'@9<ßèôLÓ¿q‚íVq”MOd#!MÚ";®óΩ¡b`Â81©J¬`#A™Id\yRc¯@° Î¡HÇ©5ú›TÄÁü4ÃyÉ¡ÒLÒﬂ≈%†td‡H”T=FáÑÉàHªTW æáÖàGe`AùlÁDê¨—!ÊòüÑÒ KîJÅ(Æi :”†'Ç{®&*	ha‰o0a[•ÅåÚULÇKê π!O‡ê	¯E+Ä¶›à“%H<–*,âã‡Bv∞8LOá)"õ¯ôi∏9¿Ç—<{|9Ú¢	àÌ‡ä4=í+@ ì˚ÃÿÕH25Ïï`vÏ§\{J¿%ùﬁ£@0@û¡jêø †¢,;mÑµ⁄ê`ë®E Fö¬£èh v∫∏‡hìN@É´K4Üƒ˜A´$∑p¯GŒh€ÆÜt*çd ÏöÕ 5máÿaƒ{Á∑ﬁ¨”i&Jyp¨Ækù ìÓû<4MåÓ#·™q U,"¡±Ú∑®*£ƒ>jﬁø$;Y&|D!K"hµ\Õ!W∑A1$wZ`⁄ATÔ huI3DŸß6‡L %ßº#YòBh:ÑÒ≥8ŸfÂ3ƒä÷Ë¢ˆ•z™ık∏pTbQ\ﬂπà¯'ÑDiU¥ù|—…–¯™◊8ßDj«ê‘Xµ“@F≠⁄üÉøÍUfÍä¬=ﬂ§!Çóˇ–‚“I$R§íI%)$íIJI$íRì¶I%'®©òC®©û 3ª<O•ï\œÇ∂√¬©Y‘´U€8[,B)Ñ:Ü°\äﬂéZ∆9◊ÇI#Ä’›πt÷®ÍU˘ø.´Î!¥4:‰
ÑÚãa!§Ê;†wT£{|…rŒ-Ì∫7!√… ≥ﬁ,πÓhq$Ÿ tüÄså•“î"2˝&Ì-k°≈§Ä4ÔÒVqÌ»üLnçI·Tiç¨^°~9>ôˆì®!4U˙æV9âQ0˘ë8ò:êb»◊ÁŸJÀ%Œp”qíEß∏˘$∏]#¥9C–»R¥Í£#Á<¢ºl∞Äú:%6·ÛLNÔ(I,§Ìû
tÖ)0#TîÃm1ÒDkÈï\*$8‚Ö Ö9¶t·	¬
≤ˆôòÄNêÇˆÍàP*ıNÿÏ°©ë§–!$Ïé<S∑È3ù√àQÉ#êí[ùB∫©ÿ úH- àÉ™‘¥íu<¨ã2^d öh’st?Ω"iéÃ!Í˘ô∫è—»”I◊ïôo$x.è"øa p=í!Á¡∫‹R‚B§◊ê·»2'P¢îß3.y2¶”®C¢¡¢πhG*'≈Hë&;¶#∫H]≠'Ö08<˘&`&cMò‚›ƒk"5H†≥kåGäòx·Wi:Œ§ß◊HBêBrO ¿M∏û5è¡¬ © «Ç„]µ⁄≠:ﬂ∫;¬≈0›÷Ü…"≈ñ é$˘M¨Œ§k0çe¨Ò-◊∫ÀººÅ¿: 7F#•,;ŒÑÍ¨„8í ‡wUö›Õë†ÓãMÅÜ!%Ú)‘îútï
åÄ|ª©ºhìXä-'€ h<–oí“{)?Wû“§ÊKcô@3
\¿	tvNY¥*-:˜IÏ‡ülúM`#‰¢‡¯©
âIr'àêÇLÈ‡éÚÄN•<(£w‰U.<Oä≤‚f<UKL∫<–µ≥Jõ°¯£0h~Ä(ÄËB'V(È´ˇ—:„
I)Ï“\\$íû—%≈§íû—%≈§í^—%≈§í©Ì\s∏#ë†@ö_Xªz§ó$“Cï O∏&ô◊E√ƒj¯^Ö%ó_ﬁèU¬≠‰âë4Ç£˜¸˛„€'¸ﬂÌn§≥kügëÈêFæ({˛	˚è˙œ˘ø⁄‹IfO∂;îıÚ˜¸˜ıüÛµ“IVËçÎÿ!˜èÍˇ ŒZyˇ )ˇ 7˚R§ÄA	°üÇ_x˛Ø¸Â}«˝g¸ﬂÌNí§[®¿?Ωˇ ﬂpˇ Yˇ 7˚[È* 3Æâ}„˙™˚á˙œ˘ø⁄Ë§®nQîæÒ˝U}√˝g¸ﬂÌtRTwNA%Ôˇ W˛ræ·˛≥˛oˆ∑íTúÚx—;¿){ˇ ’ˇ úè∏ˇ ¨ˇ õ˝≠ƒï7	ê†óﬁ?™ë»¨ˇ õ˝ÆäK<áxKﬂW‹?÷Õ˛◊A%.õçΩ¿ûG]`4à	ˆ~_˘Õ|º∏ÅÆ./µÊí[π≠&≤ ë›sôm˜9)b•\+±rº•√˛ˆ¶IR≈£◊ΩïN–Û©¸‘,n◊πº¡"GtΩˇ ˘Ãøq√ÓÕ˛◊A%úpcDæÒ˝T˝√˝g¸ﬂÌtYÄ;%˜èÍ´ÓÎ?Êˇ k}%GRFüz^ˇ ıU˜ıüÛµ∏í™–¶Ô¬_x˛Ø¸Âøqˇ Yˇ 7˚S§ÇH4Õ ¸–˚«ıÁ+Ó?Î?Êˇ jtîIÓçåÚTæÛ˝_˘»<ù‚ˇ õ˝®“ZÕ'≤S70Ä8‘!˜üÍˇ Œ˛∆1ÀŸÆ/˘ø⁄–I0`Úúµ£^IÏóﬁ´ˇ 9ìÓÎ?Êˇ jíR∆p x¸äÛÇOí˚◊ıÁbŸrµ˙_ÛµœIX≤∞Á…–àüë/ΩW˛wˆ(Úø÷ˇ õ˝≠4ëﬁ‚âUÏvÜuîá3˝_˘…ù˛ó¸ﬂÌ]%I‰…P_ÔºUw‹÷Õ˛◊A%ñÛ'≈A⁄"3x(Ú?Î?Êˇ kÆí¬y™N;úOdÒ;Ë√>\GÙøÊΩRKòiçJê: <~t›ˇ“„!"I©2rô%)$íIJI$íRíI$îªL¨é™
≥[Ω∞ô.ÏòŒ¥«á+t
®˛QÍ'B8	ì|F§ÈV`ËàKdkP*<`âiMcª¢®'DWÄZgX·
¢#]º\KrúkØ∞íO
$Ë¢@~VÄ:©4¢e÷⁄üÈÜÌs4qCèäLQ\ãtpùçºåÄKcB<RkÄq-’≤b|FûZÔöiZc©)\Kùß3Å ¬ìDRwyARO˚”a9v±‚ò2{¢ΩâRŸKÉ‰ìàÁπI+AL5M)G≈2ÛM:…LjSNà)ì{J3£lè\#∫∞5ëA`Ÿ¯®<âÛF vAx2OdÇÉE©ÖŒÇ
—ÈÙó=§Î™D–TçDósßcÏ¨ ê¥ P•ê–<ë°KQr'"dKW!¡≠$;ùsà¯]-Õ‘x, …ykDítE;lÚƒ‰:∑KL¡¿ÍÊgG¶éö/tã¥&x˜vÖà—¨"Aﬁ<ëò2è˜ÚJ5NÌ4L°Í$vÏìJwÅ»· RÂ `OäiûRôIL§ËT√ÅPGÇ@	IL¡Ò‘©É¡·(ÄZTÁDG*U<áyï ”¡JßMÄ%$ùö\KB{Ç<ìP—¢9§Ñ“”$	8œ“√‹N©àcE,É∂◊ Ç¢H‰rêmÉ:[y≠
3^Uf8ì«iZLl wb z1{{°8¿>HÔÅ3¬´kÙ0ë[Z∑ZA3›Vsâ%J‚w'™xÄ(0yâCÓ•ê
b=∆¬Ê‰Gdù®ìŸ"NËI«BäRÁ@3ŸU1'Õ%—ßâB1¯)‚(4rõëâàN
å§[oˇ”„)$QJ…$íJRI$íîíI$•$íI)Hµ%&)§XLMJ˝QqâÉ< ì<£PÔi¡LêÙ∂1ü]∑©& VCÜ“"I
•¢∂–#UZ[∫P7µCY:¡·oUîÃ| ÏvÅk¡wÖÖIáÃ
È0qæ—áuÑÔ—†q-HYïEè9àà2˘xﬁvÊí“‚dœ^[µµ0ºXåÿÏÔP	≤hŸúHòO 5>√µÉqé•6ò:€¯ J	$D¯)<H”ÒQh#±I÷ç¢5—¥mÆ[©Ó¢I—'>\SJ+¬é•'ú¿T	ÑT®Hê<”ô$®íSÑ“ë=ëR‡ç!L<8C'¡2/3	œ
$pûRR¿I∑˙E|Ÿa0KÄÛ]/I`êÅ÷@0s†]fòÄô°∫	Ô¬±nY(o¨œ2∞snÙ¨/o“ Ä∂Ú≠ñ¡–ÎòÍOó¿3⁄T9H2Ù∂πXíuGï‘r≤+±Ú∆ Á‚©¥∆™J1‡õdÓﬂåEDpÆDîÌ ‚ú@¢øí†5é D 
MuÂIÕ—+U∞ í`9
MÅ Dç|<“RƒàéÈ¿1îIO:§¶`p§	Jà)€Œºy†Ö\c±ÒG∆®9Ì›´A‘$ &¸BŸ}ÇE≥5Nï,¢?»é'ØÑœ0âŸ°w'5ëd«:†µ§ÃËå∑Möˆ@H#éSCr$ÜÊ# 	’Z·¬8ÏåÁÅîòI<E ¬5ÆidÒ‰≥ú·∏«	R¯ãK0´?ÈJDGÖã8AÑVxr£oÇ\(‡ÒkB)íAC∂œiüÇê@†ƒd£Ñ(B'sÁîû|¬’¨rÈt¥(©ß≤x9|ˇ‘„
dÈëJíI$î§íI%)$íIJI$íRìÇô$îífÍ:«ä‘)∞˚Ça2D‘Åo–Óﬁ
Î\#ÇV}:∏vW‡@U¶5u1ã6¿÷
Ï0”Z&AëƒÓ\Ö& ¸◊IM¡¯ÌuñÌ;`7≈6&§Vs òÅ˝w*™Ê…ˆñ˝uí´Ä@´V9çs≈ûZ@#X=ïV’1û7NœCÕ«≈/Ë_ÓV≠ÃÈŸı´{=fÇ[€^ƒéÎ3•Ù˙rÉm/€±¿9øΩ›7Zc+…˝vë†'ƒ)êÜ£“”úc,‰DŒ3˝&éeœ∂«=\t$h=®NnÄ˘$A#U8“el  ®Ì	I∫È‚•pá(¬rÒ≤‰êQ)Àµ*•IP)¸” úƒJ*WöiLIJRR‰©›BSÇíôíùe8IL€°ê∫éífê|BÂÜ∫.£¢Éˆv¸”H5πØÊ›`ú∏ƒ¡"¨AÕÍ‘Õ#“t¯.[*KâÊ
È≥…8Ûßòπƒ<|yk&ˇ *=('îõƒîö$¬ dè ìlïπ
 )<∆ä&RPlTj¶·§ˆCàÛN_°AiªD·Æù”á#∏P'TÒ¨ÑW-„)Sì§>‰îÃ'&TÖ&ë©IKâUº)/ÜÖSï°Ä$Ç{ vY3Q.≈|ö◊@2ù¢≠ïi⁄@‰”≥HìG!¡ƒ˜ÉœílëK÷‘‚ˆÌìÿ°óñáÅ†xÉÊ´çH˛(çõb?Û],gw=”›d!PËjíÁÅ»C™ ı%sâaùU@Ÿ$ïp4Ü ñÅ1› R4m0L¶qSﬁ¬]<8	·îlíÆÂ!Ò #0@ü%VÛÓ(ÅrA@‚u%U»|¿V^t¯*6ô'…O≠µ3Ãà”{ß%0¸T‚©¿ºTgTâQíú¬_ˇ’„'LäTíI$•$êË5)$•$íI)I$íJRI$íô4©7È†
êÒM+ÅnTaÕ*ÊÑJ†«Ay∫Ö^cWKó6J√ƒ-:jeò¿áﬂ∫¡ÿ,™ñèOÃ≈≈√p#∂Ñ|e›öbF7ô’ñÀO“òpChA¨+éåuˆhl›±ßYÛïE¶I>)´Å∞ËÙÎ´¶›œë[ÊÆu=ñEÇÔY˙¿ ;àY2<‘¡ ÑØJXq‹ƒÔ‘í@ijxÑ“4LA:ù#±Pò#¡Ùé˘ê|P@Vû›Õ*©‡∏ b¬bäU0î®íî•HQ)NâäS¢*µ'0)OÇJ∂`©§!Ç•:†Tÿ«g®Åuò5Ï≠£¿.oßWπÌ'±]U m	£Y4˘©~ã`ÅQyÄTƒ–i´ù‘2Zy Äπ€é•juWô j|ñA$˘BÄjm”Â‚mù,ùOhØ†«t™¨Û¸àV€ÓÑ∑,öô"t&lL¶$¶DW$.Ö Ìµ0§•R«ü·¿r†O*2Q§•$*%Dú5Bî»?‰x&%'Tê∏1ïØ”Ã¥CAsÄïΩàÕ¨¶êÅbÃj-¢‡Æã?-‡¡@uÛVÔxë‹vXÔ%‰ìƒöu,8£z©¨}áÿ7IÄ‰I¨;°¬0eºá◊I©¶Ë$é~ı
öwx¢Y¨Îmä⁄$Ë}‰ˆÏû« #¥rjy.  ≥]€§”DÜ(AÑê$µ“cë($˚Ç!Bp+ƒÎ£tù4T≠2‚Pa	IJ3±≤ˆ∏
°◊TXCSD”Zp2;®Â⁄($ül|∑b‚ò)§àí√Ü˙øˇ÷„
dÈëJíI$î§íI%)$íIJI$íRíI$î•&ùSÇÅH4[:%}éˆ<k!\•ﬁ–Ó^Z”f≤%it˚j‹©—∏x¯,∆	í4(≠éê°#VÂ\hªﬂXM;)Ù†Ä xx,&v’}µóÜó1£Sÿ*‡¡(dîbàÑDoãÖ∞«@Ä¨b“r.µ¡§Î'ÖQ§"5›∆Ñw	´§	õá˙ÆmÜ\{˘°Z–«5(ñ±Õ~Á8KáLÒÊÉiê	—®ã24—U“!Z®Ó,ä»2à› ÎMp`% â)úπD$D)¶ä§Tgr•:(êàAZNäJ hOÅH„ÑP‡ÍòSêfP+Åt0Æ±ÄÒ+™°“–WC∏çH<.óß‹Á4¿®ˆïµyòX‚®>7<ôR. I·gd⁄„¥ÀFÑ'ŒTêÖ…ŒÕ~Á≥IÇØÂê–cícéß∫dC•åz[-t∞vUﬁ5Sk°à.v®Äº
+ávLtQòNßRô¢[ßEÑ•*S"RÄõT§Ñí§§¶N5ILÅ0úH¯(ÑjX\·‹ PM6∞®‹‡„®Ï∂ ⁄q‚ÅãPhR…∑cOü
2m©2e*2ÌG®áLq‰ùÔ.$ûT2cæàÄÕ–¶`œ≈±O(,t·Ó;˜@®ˆF˜ÃÑ\fKßÄ“dÛ+C∞+¢D“Ÿöä≠#øo≈fÂ>$+óÿ5.˜I)DYTV-3™ãµ%M≠ÜÇ†LòRÜV∫*èw3§+ë0®‰æ=£ì íÙ`Õ>íÅŒ‹‚J@DîÉtÛHç 
«ÉC] â‰°í§‚ÜyDí*≠ÇGhˆüÅHùeˇ◊„'H&;àE+$ûLGiî…)I$íJRI$íîíI$•$íI)IÅÑÈ$¶l:ÖoÍB§”Z§Í
äcF∆R˙å
(†HÆ‚–¸õ[Uqπ‹NÅV.ò Eø“rÎ¨ú{àmrxÇ®g2∂dºPÌ’O∑‡°kns]°i ¸Pâî—" LÃô .§y):5î@‰
ÊÓ>Ì∆vH{CY Ç} ´»çÍ>ƒ‹π«vC¥Y‰!éôNˇ }6)|B.C70¿@«0Â|GÀT”∫$jV‚9∞H*2¥rqÅ‘h|U⁄‚¡Â<^ãSB3i%¿"uÏ†ÊÜ∏Äf?≠sJî$Gﬁäã &Sÿ"4ÜÍFÔ/8‰¢∞ËÕÆéxE-‹Ÿ £1–5@§´ycÅµ∫Äfé”‡≥Z◊=å.k5qÄ<–CãSHµ
/VsZˆùΩ«uP∏0jeb∑)‡h`$Ïóﬁ∆0Å≥c&˝ƒ˜U	$œäi/ q= ë≤9 Ú;ßL¿ (.L(FfSóJâ1¢  Æ
SÆâõ©SÑR-ê
àSÉ¶âÄAK IvQîí»Ñíî§§•¡*Ó‹·:¬¶∆…Ö´É@`¸JiŸd»-Ò£tT2Ìì∑¡\µ·≠!f8Óyq–Ÿ0n¡åkƒT4„Ÿ»wí-æÿ¯!µ¡ƒy'a›≥XÜ…ÓÇ˜o08NÎOàQhéÈ‘∂id	:˜ÑW\"Ä™Ê–—ÊÉºì‰õV∂¨Ÿek…$é?*´¥πﬂ≈ÁîÃÄ	Óû4∆Åã¿ w>(ˆ"©cπÏúâ†ä«rOeûNÁQ≤,ühÂp¨¿P∂ÜyÒKÑ~äƒ…∞Hê¢O%Dî‰©«T¡$‡',‹Æ—%Yc=é¯ ∞p≠∑ËÅQÃ∂0ƒ´ˇ–„I$R≤I”$•$íI)I$íJRI$íîíö$¶iî$´Hä¨$ LÜ<DìH∞ò»Én√πæjÊ˛ï≠y◊iíππIFq_V–Ê˚√˛wˆ=ﬁ_Oı©˚mn/‘÷;,w6;%6®{>)á:@£/ø±ËÅRiò\‹•({+˛ˇ ˛Ø˛wˆ=~1…πµ¥√ùƒãôÜ¸[KÓéŸqrî•˜q[≠˚Ù∏Øá”˚º_ÿıç;O≈[§õ— ‚%)CÓˇ ÷QÁo¸ü¸ÔÏ{∞&Zyä°ïLBÂ—!À—˘øÊ†sî~O˘ﬂÿÙŒ©|W=)Jw≥‚ªÔﬂÍˇ Ác—Lhö&=)J^œäæ˝˛Ø˛wˆ=à–wïs°ê∞e)KŸÒWﬂø’ˇ Œ˛«xsîÁÄπÈJRˆ|T9Íˇ 'ˇ ;˚–ÁYâ]5Pˇ n›ˆ;±Ò≥ûÌŒ$ÚLÈ¬ÁuKTΩüÎ-è8ÿı˛˜ˆ;ƒk¢ìA?œJÎ´œµ’‰˙Oué¶±x5ºŸFÍâ∏⁄k/{õ≤¢	isã´∑u∞Ωü˝˚˝_¸ÔÏjí‰°óJı	Bä~˝˛Ø˛wˆ>^A¯&âÂzÇH˚>*˚ıˇ ìˇ ù˝èô4ÇëzP)á±‚°œÉ˛O˛wˆ>i¬K“íGÿÒ]˜ÔıÛø±Ûb ·B¶§ˆ?¨èø´ˇ ù˝èô)Èi#ÏxßÔﬂÍˇ ÁcÁ¯’I≠F;hÖ’¬Ißñ'ÙøÊˇ kπæ/–ˇ ù˝è}‚Ke≠ìØ≈w JPP˚∑ıøÊ§s`
ˇ ù˝è	q:¨&e$I<ïﬁBPè›èÔÕ˛‘˝ˆÖŒ˛«œúqï&Øuﬂ§ó›ˇ ≠ˇ 5?}ˇ Wˇ ;˚…‘ß JÔKÓﬂ÷ˇ öèæS˛wˆ>}cµ rR$BÙR’/ªˇ [˛jæ˚˝O˘ﬂÿ˘µéU.≥h’z¢Zßå u[.lëB<?·>8ÁI'≈FOŸRRµLâ6¯ÀèeÌ!K≤5KIÍ¯®
mi+Ÿ¿Ñê"‘R≠Ω˚+@{Jı}hòa}Y£úD|èˇ—„I$R§…“AK$íH©I$íJRI$íîíI$•&Nò§•$íI)=/‘+¨~†¯,∆ò2Æ‘‡<T3èV◊/ìÙ]Z.{√ƒ.ß¶]ÅóF€É}Hár|¡\u.”^UÜºà#B†ÜWMÏò∆HÔ√&˜V√´Ìµ;sHù{k¿Y¿©=Ó1∏Ãx®SYbà<RMQá‡etY=g¸_IÃ;Àt”@Ô%Õ¥}ËÄù'ÑÅ"¿˝%ô1FdJ_¢í÷ÅËêJÉDÍu'{‹÷ì-`Å‰ìAë‡
oE‚ÎVd tÏ¥∞Ìk€±‹ÅÌ*Éöÿe‹ï,wñøN	Ñ≈≈–∑ÆY98•§ê4¢©°Ìì©	e`$∑C™@J¨0C7∏dÚQ!kÂtÒ©hÇVkÈ-$…‡ÇŸ¢ÆRx>	Gúﬁ{•Ú'(n∏N(Ä¶+É2‘kÒRa⁄DÈ&ÑÚy:ô@•≤Ûy
´ﬂ?ÏSµÊ!WîÄ[≤£RõN…œ)ê∏)‡|”‡Ir‡xß— 	Ä;©Ω†@n∫j|”R«N…√D¸Úíîa7dù¨.05IL@W±qœ'ï<l"‚	-÷+jòOf)ÃCØ#≤¶ÚIì«dkﬂ$é¶4’ ®ä‘©≠ ~Ev∫¥≤-dÎ¿Zh>i∂r≠=°çÛ
çÆ6º±¢|Çµïn–@ÂQkà%√B|0∏òë È€U"‡ÚI“„'ïZ˚cD@≤øvbÕL)bx>
Ω2uÂƒDwF©E`Pmx◊øe'ÿ ”ER€G≈8+d@¬˚6¥ûÎ4ì…‰£ﬂf„Ç:ˆV`(9πÁ≈%¡Å%@ôI«≤dIË§·2p@d–è[IÑÖf£2GF|@™v7É¬0:!i¢ê:∂ÙHÉˇ“„I$R§íI%,íI$•$íI)I$íJRI$íîô:dî§íI%)ó√°	 uêÅ)1$≠N–+M*Ü+˜ ;´¨*§≈_Æ ≤qN“]ƒ¶i’2ô≠8!I†∫ ‰ËÅ·\¬»m;…¨=—Ìq¸√‚(ë Xµ1òTåºí	n¢¢9ˇ jÃ…µñ⁄Á±õu
óÂmyqbﬁôëF3o≤◊p;¸“:¸£“√bx≤O◊/Â¬Ç†◊\v¿ëÊ|d»=îAHçQ) ÍN†öYNñÌb8Ìi¬‘ı⁄Ía⁄∫#‚≥hn∆¥xâV#	J6üê+Ce@É¢¡À¬™u–ù
ÈeVÍÉßπ([2bôâyÀÒõ]eÆ“Ê:jR+k+Cª„›d⁄›§Ñ‡m∑b—ÄêJ<ÑÂÃáÇ}–c¡DR„TÕ¿ÒC,’I†∏œ¶ÍÃi©JÈi’≠
`ÈåÇBpNâ≈r%(O)'D(™ê%0|Q[Sœm|%H·8a<+¥‡ÿ¯—h—”@âM2Y,ëéÂÀ«¬≤»$h¥ÈÈ·öÚVïxÕÆ '45gvº≥íh5CFú*ˆ‹Å˛’<ºÅ\ÅÃFã9¢]$ÍSw_ÿ‚ì∫I˛*U‚äwTyÁÕY≈¢'ÑY	-ä™4>iÌ∞0E&ŒÕ~ÉiùÓ´aà‚ñ≠kÆ/q<ÑÌËëvŸ=¯A{¯<«äxê)+Ìi*é‚˜i¨ßµÂÁhVh§5†î ¥õ4WXkD®XÓcE7º cÄ™æŒ{†ïHÓ*ï∂Úâê„«ﬂ
õ›*ƒ#£Kò nÉd¶'≤S&S4…RI$äú…¬
	QXËAH“-ñ&õMrû™á©ÓL1g4ˇ”„I$R§íLíîíI$•$íI)I$íJRI$íîíI$•íI$î§íI%'∆~◊¡‡≠fê@!aŸlc?{¡WÃ?IΩ…œxî≈CÇ§A‡®8Í°€J◊)PöQ	@Ö‡¶c°¿ù@<.æ◊’ì”	>ÔnÇ5ë‰∏‡¥0zìÒÍ≤†Ÿ6wÓâ´˛≥|fB2èÕµNá…;ë	£Y:y#–…◊≤ae&É©Mßkw@Å(˛∞s¨ÿŸ‡*éÕtêEµ˝Æ#nË¥πv>Q']ˆŸ"JDê«,dpÉ
WªC‚±Ô2ÙF´·áã´~aTÑŒ1ß)‹+æÔ˝o˘©°@‘•“·W›ø≠ˇ 5Ç+MqïßÑ‡@YDö[.^Ö€Œ¬.ı¥É‹(YÄÀ¢Qk£oRÜªwtR˜Ä”¥{-}Z®}+$G0•éC/ñ<Jêƒ7…ˇ 5ÛxLΩ2ºÈ;Z4Oä≤÷	«˜Á1ë±|©%Î$®–î§r˜|æLû™Z÷ì·›ae‰ÔqéÏöyÄS$1ôà’-BÓÈ¿ı±ùê˜˙ll«â*:˚qÌñÑ}Í´ŒA·ó¢…·zÖ÷3"¥ée@à	‡éöæbû
Ô≥Ì ,{d∆ß≈û˙3Có‚o0íﬂπƒs M/tˆNl].<µ„ˇ õ˝ÆBK®©Å≠√≤çèÏáΩ‡Øª[˛kÃÍôm\Ú&UÿI<ßâì—éxÑwìM%+,/2TÄ5å≈Ë∫IíFëÓx.ô$í·WÇzi∂ÁäÍc¨{∏cAså	–%È8≠ß¨\:*¥‘ˆªkÀL3hﬁM§¡iq<G:@^^ù2x¯∫ß‹“©Ù^∑÷ô“ÍhhmôN⁄…#hÉÔ08ù#I÷Öbtø¨óv^vKãYåp∑‘›†≠¢[Ù[Àà2{ÍW+*@¬DiB}¬‰§8Qï tO·^2Îtˇ ˇ‘„I$R§…“IK$ù$î§íI%)2t…)I$íJRI$íñI$íRíI$î•{ÿ%ß‚:ûX‡·ÿ¶LX!ì¯f$ÓÅ"B†*tX–yï+X$*õ.≠‹l"iòD*Õvê{#1⁄Ñà]a∞ÿ´›;%ÿˆó6°sú c‡≥Å+k£d‚‚’mˆô∞h¡‹¸àıxVÊ5ßı\ÎÉùkú·µƒí@“<ïºfÌh<«b´Ôı^^Ó‰ïi¶ <Ot¬©M À¥êiTº˘F…|∏é¡ FàÅ¢¯ääjZUº∆´:ñÎ¢“hs:¶…fJAëaÉ‡V[å∏´πnTF≤Qà—|ByP*q®ûS◊¨êô<§•Ï<’Uﬁú7\dŸl≤)zJövÇå:®R› V J"√ô#´ ¡¢ñºIè8Q:O™[vãl8œ…JcÕ'ï^ÎÉA'D¬ipßﬁ;¶.–™8˘ÃÒÌ'W–7c‹«9áVé»èTn˝IîeD4sm⁄«G∞….:k‚Üs∑¥ÄVslu$ñs*1Æ≠ÃB£¶ÓàÍ¯É∞q∑w˜¢c“VM%√ºïπè«äq$ùV‰àÄ®˛ív∂Pπ–'º"ƒsUr› ü»ë–0D\ú‹õ§¸U+\ë¢{ûKå˛
≠˜∂J [t #hn~ÁÜéÍ÷; 
ÖFLùI¸±lÓûE
˝Móº!W}†	(n∏IT2rπ Úå I•ì…FÀ¨íIT$ùN©â$…I[å@…ŒRëëRIBPú±I$î$•$íI)I$íJRt… •” `íJˇ’„I"äVI:I)dÈ$íîíI$•&NíJY$ÈíRíI$î§…”$•$íI)IJI$¶Ê&A¨Ì<ê∞8B¡ïb¨¢›
ÜxÏÿm`Ê8GõV∏µƒé
=N®Ÿk^'∫&5–vüíaÅ·gÜXåï~ô:ç3¬ > VËFiòî7R	"5íØªœ≤:˘ç“;£Ù^õ^C]eá⁄” x°:áﬂñq©üH;P8Ω“·4	3^Yëà?Õ¸ŒCâíO%3[$.ì/ÍıBóæí„g-!`
À^ZÌ0Qîe$…è42âOéœÇª;X‡5ë…ÏáC}±¯¢ÿ cèq¬àïí7''-“¯Ï DºÀ…Qhë	„@ÿ¬ÅÂ¿°¬!+'§R,VóI©œ∫@ê—$˘*i'E∑“(se«@t#≈6GJbÃj⁄©†4x£⁄`#V“Ó8ÒNàΩô#’cßÕÓÊñ	'Eóóî+i)LòöL"dt_+1µ¥ìØ`±ØÃ}§ÎßÇÖ˘&¬gQ⁄{*Ó:Ä<;(ÄΩK°èà‘jÿeÊ@s∂≤d∆∫©Qö˙‹‡éÊ{™∞G DDBuÊ1:›ˆóÌ÷gU<<rÀ√hhí]¬uØ€[Küÿ+© Îd1<2iSYu ˆ[î p≤a≠VŒ]^åëVnm†»ÑJñ«âªeu°æ‚≥\Ûkâ:7∞V°	IEÛZ_•L£NÍ/∞4IÂ
∆ßTjÉ≤„V$ÃùUΩTd©DÄ§JFÃøÊˇ kZ¬:I‹~>Ô˝o˘®!<#$áæÔ‚áj[QíKç>¿ÓãaKaEI.2ØªéË∂€J2Iq£Ó„∫§%D¥Gè¡_w˛≤I$∏¸˜ÎÕˇ÷„
IëJíI$î§íI%)$íIJI$íR…$íJRI$íñI:dî§íI%)$íIJI$íRÅ*A∆A¢î°JáW'ë º«®\˝v8µqÔ´dÖj6t˘|‚Q·óÃÏ—’≤h†—Ykâ3˘ﬂz|.£n+˜≥W:gv≤≥ÉÇA›¬ãVn_7ÃÌ‰ı¸ãÎ¥zdÚÊ¯x*U6H'í™0ˆÓØ„âÑŸu%Ñj#Öπ[}°)˚Z|¸í@oö°òÈpcR≤‰—2ÁËçaè%Ë|Q∑∞9R¡D·j∫) òÂÑÇÇ¿"6¢Ìz´ï•ã@–îâ•≤êXò§ÍH÷{-jj #∫Öm≤ôxàÓôw©iŒrëN=YLh ò'Ç≤/ºÇy>
»•∂9π/,-‡Lß¬r‚∞‚∏ÍÍfÊ7–%¶Kíπ|õÕÑô“xD…ÀkŸµ≤I$í|;*g]R$ \Rl·¬  üÄI£Tf—˙πªxÄvÌ¸Ôåx!∆¢fe»–¬M$Ö=ö÷Tõ\°j∞µ.≤∑Ôa-wbÅ[›.w∏∏…'î™`<´¬∏xêöKé∫3¶∞¿%◊ÇUÊµì*}LA ¸Ç@Hù¨õYŸ¿4Äπ¸úíÈ Ú°ëîÁÃ™≈‹˜*÷<T,±dÃ ·ä@@Áíô÷¿—∏Û›@íT‚-cêÅAìû] äI¿Gf"I6Tê	*MjDÆ‘àù≠DkS	få-ãXà+Dk{©µ™3&Ã1f™aÅ5L50…ò@aä[TÉI^"©ˆ¢Ï?$∂¬öã^òE€™D%j†Ñ∞&ÙÇ<%ÇPbˇ◊„
I˚&E*I$íRíI íîíI$•$íE%)2tíR…'Líîô:`íîítíR…'Líîít…)I'LíîâMŒ¨»„∏CH jµ]øK≠NHx·√≤∆Ø|˚U˙ΩNÍ¨Ñ/BÍbñZı√_0ﬁ¶I—i„uôèŸi—¿¯®f…=õp⁄g∑ÇŒΩÚÂfÌcàTªvº¶«tc´\0úòPdÎ>iåŒ©Ï´œÇa©I;#v©)–ƒ¶bV•Uñ¡wUqcHWÑ¿Qù⁄πx≠ÖóaWh»…6Ky)ˇ ÌE{∂Ìüt•Öˆœ¥_ˆ-æéÔŒ˙)GÜ˝[,õãÒgÉK2juFø”∞À‹ÌO'©c∫åó±Õ€:¥D;¡_gÌ∂[Ë«©˛o
üRı˝sˆôı r§“áu¯ƒΩ√ÆùZœ	IN"uS;†Ÿb	êã[IÁÄùæúÑ]!ÉkÇ ’A÷Å∆âåGÕ
ŒË-?,ç|k≥ﬁF¶S[™œ⁄§èTJÎ“≥Úû˘ÏW∏ì¸Qåv@±Oç\æÂjâŒâÒPîÊ'YKŸÊ¶#vƒÍRS˝öqÈ+Ej0ÄGŸ=ªw}?„ÏöO©ˇ E$ÑM≠n†#7ÏZ9«ÚQ[ˆ?ùˇ ¢òY†Ö≠EkUÜ˛œ”˘ﬂ˙(Õ˝üˇ ˇ EF[0#˜Z≠j#B∂ﬂŸøøÙQÏæ˛∑˝ª8ë˝…˝°¶ò
˚dwıˇ Ë¢Ÿ'÷èÏ¶òˇ []∆Õœ˘}\‡’0—¬—±c¸?˝?Ú$áˇ ¢á˝Ë˝ÖFrˇ 7?√¯π°°1h:≠Q˚˛S∞„¸7‚á˝Ë˝Ösˇ 7?¥8•©ÄÂn∑ˆ¸'œrêˇ õˇ  ˘˙â‹#˜ˇ ØrÊ•˛0˛.°tC˛oysﬂ‘Rˇ ±Ô‰ˇ ‡âp«˜øé<üÊ•˛0˛/ˇŸ
endstreamendobj22 0 obj<< /Type /XObject /Subtype /Image /Name /Im2 /Width 591 /Height 392 /BitsPerComponent 8 /ColorSpace /DeviceRGB /Length 30378 /Filter /DCTDecode >> stream
ˇÿˇÓ Adobe dÄ   ˇ€ Ñ ##""'"!!"''.030.'>>BB>>DDDDDDDDDDDDDDD!!1!!$!!1>-''''->8;333;8DD>>DDDDDDDDDDDDDDDDDˇ¿ àO" ˇƒ?          	
         	
 3 !1AQa"qÅ2ë°±B#$R¡b34rÇ—C%íS·Òcs5¢≤É&DìTdE¬£t6“U‚eÚ≥Ñ√”u„ÛF'î§Ö¥ïƒ‘‰Ù•µ≈’ÂıVfvÜñ¶∂∆÷Êˆ7GWgwáóß∑«◊Á˜ 5 !1AQaq"2Åë°±B#¡R—3$b·rÇíCScs4Ò%¢≤É&5¬“DìT£dEU6te‚Ú≥Ñ√”u„ÛFî§Ö¥ïƒ‘‰Ù•µ≈’ÂıVfvÜñ¶∂∆÷Êˆ'7GWgwáóß∑«ˇ›  %ˇ⁄   ? ’6^ÛØüÎ['Ωè˚ õπLBÕ;"˚N@1Í?Ô*/ »Ìcˇ Œ*NØT3Tó
ÏÇÃ¨†d]g˘≈R∑?0q}É˚NW,fÑ¨Î⁄eºÿ5ÌÍ9„åõœw˜™∂u>£ˇ r≠ˇ ∑˝ÈÌiïN¿êa»û©‘ÓUﬂˆ„øΩ/⁄ΩK˛Â]ˇ n;˚’2ô9Æﬁ˝©‘f~’tˇ ∆;˚“=W©‹´øÌ«z¢íT´o´‘øÓUﬂˆ„øΩ7Ìn•?“Æˇ ∑˝ÍóíI)∫zØRˇ πW€é˛ı!’:êˇ µw€é˛ıCí¶'‰)∑]’:àh˝nÈ?é˛ı’zê„*Ô˚qﬂﬁ®û|T∏	+Øf¯Í}F	˚]⁄sÔw˜¶_®ÄG⁄m3ﬂ‘w˜™út“ÓËÖ.æÕˆıN†˝ÆÔÛ›˝ÍMÍô‚?Y∑¸˜z¢øïL$†WƒÁÌN¢„˝&–?„˝È;©gÉ2“#ùÔ≈U±·µÜâíKˇ 9ﬁHaéy'Ä“GJ≤‹S©U±„Ωﬂﬁäﬁ£‘NÉ&›;˙é˛ıYµ5ï8⁄\c”1˜ÑıñÜ;t…˙1‚öOfHc˝Ê»Í=Dˇ ⁄õœw˜©˛–ÍA6Îß”w˜†S€∏Hë>0ßìÈO§I FÿÚ!6ıf ZVı>†?ÌM∫-ﬂﬁ¶zéy ˝¢›ñÔÔU∂9ı:”$¥ÄJê`ËÇ “õ≠ÍYÕ'vEß»ΩﬂﬁûÆ•õÍrmhg{å*Ê6 ÃÅ:QhéûA·OÏèÍ=F«… |ë?Lé?äguÊ»v— 9ƒ¯™[ÍÕÇZ@"u‘O%€DGx˜uÓ¥Ì@7GVÍÖûΩáH's§|–áTŒlÕˆ∏ù ﬁ¯«ïO‘yO∂x≠≠Æ‡$ ;n∂∏∂0Í]FcÌ6âÌΩﬂﬁàÏ‹‡–·ïaÒ˜ª˚’Gn≤x„‡âsC=ßSÃÉ‚Ö§@Q∞øÌ†NôﬂﬁÔÔN:ûnìëwúXÔÔB9ßugkà- xT\»;¯#k}±“æ∆≈ôŸÌ å´vü¯Gi¯ß9˘€u ¥¯Ó˛ı^ ﬂY5ΩæqÒ!D9•≠‡í8cgM€'?.L‰Z!Ôì¯°?;©VD‰›<è“;˚‘w“=˛â<ÈŸ;Ÿ-ô”„DD±â&mÍôªH9n<{ﬂ˝ÈèQÕpëìhp‰ovøäÆˆÄuS\x;∫>,|=&gTÍìnüÀw˜£~–Õ0FE≥…›˝Íâd Ou68iÌûe#‡®
“Mœ⁄∞2,¯ow˜§3ÛàëëfüÀw˜™ÅÚvüöou)í«m:˘∑~ﬂö·•ˆi©˜ªèΩCˆûdCØ∞¯Ó˛ı\ÀG2<T6Çﬂ4Ç•‡5l°ö„µøÁª˚”˝≥0Ë2-ˇ =ﬂﬁ™∞∫∑nùgFeõ\K“–|—>`›'€≥ZcÌèÌª˚—QÀ-÷˚û˜z®˘ì§x àˆë"|äßbt˙ßvv`‘_o˘Ó˛ıÁf¿>Ω∞ñÔÔAx1·(zçd‡≈.∫7F~Yâ∫œÛ›˝ËåŒ Eˆ„ﬁÔÔTF©˜{P!|d›Rœ|dZ@‡ª˚”‹Æ˜Y˛{øΩSJRH≠i+≥2O¯Wˇ ûÔÔIôY$ÎuüÁª˚’buF™;¢≥rÈ„]yâ±ˇ Á;˚÷Æ=∂É‹~ec‚üt}Àj¶ÀAD})ºÀü\tÛP6Ω«ì˜ï
 ìòAûYAëﬂŒ„˜ï&ó$˝Â&ÃD)≥€»IìwéÁ·(õœâPc‹D∏ |º'…%©ò‚{ï"¯ k™·3¶sØÀ_‡í)ˇ–‘sµO∏F®d{äbPn“bZB†ï„
≈% µ≠h≥ØÆgE}ˆ}ﬁ
µ§BLÅ∆πö™VÖ´sF•gZ©´f4h9EÌB)·©!™Ç]“Lí’˘H§%.È%êÄô≈?c
†ít•⁄<SÄ]ÚL50à÷Íë)à∂0{h§Ωë6çBãö$¬m≤pV´»"cNÈ¥¸ﬂ≈;∂„¯(& Ç‚z,78˘J—´≤∑=Ìx{ ⁄Ÿ◊‹|’oM≠Ç$«3¢{2,y%Œ2Ó{LiŸ4ít·e∫ú‚Ì'⁄à∂:∂üc∑5†më¨ùJ™,Üë‚ßSm≠`’Œ ö~Ñ˚jJF⁄Òg©§É#M>‰B˚-±◊?‹Ió5˘' ≈v5œ•ƒ9Ã0H¯Jp“( ˝ù¿Oª¿î”LëØöúCò\lD∂u2†5yÛSΩ≠`;ù† wÚP±Æa⁄ÓGdûÈkó"H”ƒB{muè‹›ÁC¥F„‚|“¢†˙ÀõkZˆÇ\◊ùæ—·‚OÇãeª$ò˜OÔy%Z¶∆å\Kx‰Ú£≥Ö#ªv„…÷Q©ÿ.s∂$:'X”ÔF÷ﬁËEd"%LÔcf˜GüéµèªyiÙ˚2xQy§Ω“Kõ¬ i.ç$jÜ©†ãΩ‘?”eMp1/såÎÂê6∫‡§Ò‡6 %’]v≤ ˝OQ†4Œ“¬ (,wK˜∏Ôûe&Å«?Ó <k5"˝Óò ˘ êSöYŒ∞ñ˜Ú/kö}F˚fb<$«*~«H ç ÆΩŒ®Z„D&<á!D HÑM«il—¡¸T_ i¡÷<ñë•∞x$Çuî74ç8(Äì$£œíg4ƒª∫ ±H≈ÜAÊòLíã¥ Ö2eÕé˝ìñxãYXAÁü$¿â~É≈<ÓûÍ%¶u–¯$Ç5∞ó8Ä¿dx)ìµë°=–vñÍ8<¬î∞{˛DóuæÃ]∂IvN«Ädh{'Ù» Ã«e÷ttDÍ<”e§HkI\wƒÀè(`çºÍë14•ß=ê§ô[8¸ì!I√I‘ÉØ´!ÌN∫°Ó¶
D @ª•)±Tjƒî&	+Gë ¢Ué$ñˆZ’q±∂ñ √%É4èFl¨ák†ÒV]¥uB—!.:§Ì©Ïë%1c[™#Ì8	 ¯,›4
{tî«⁄§	pÑñï€@KaÓ£XÿtÓéHEˇ—’,2Ü[©Â¡pòA∏º@Ö"ºTb$πÆÍÂW∂®”≤æ®V4tAp.=¨0af⁄”Ò[∑÷LwYw≥î
‚,9oÂ[∞*Øß¶ALSÈëb^R2êI!c¬dπ*Ll§≠Œã±ßÔFnáQ«	ö#‚ß⁄Td∂aÉ¶ørﬁ|5ÒLÁœôÒL–AìﬂÑÄT•zµv∑π?$FÌ<Ç<<T7Éß˜¶u“6ÄöZïßˆ{tlâ«hÅﬂUXôt¥}È Á\IÅˆ
¡®¥∆Ñ¿:)hÍûßDT‘Á∏˜çOêEi-p-$‹(∂A–ƒÚ•…Ä4Ó…‰Ó ;pÊ|S˙èŸ≥qŸ3∑¥¯¶ ©Í	?π1î°=π®íÁ∏πƒ∏˜'U7A:Dy$	-”Sœt≠$0H’(RÉx	Z@fO®I¥ â≥ß‹ìAñííQÃ{hòÖ î	IåÃ%(∫(ôF÷ò±!Ö∞53=—j≠€=B=ìªnÊëjÙÕ/$≈ç--#YHÏ†hÖ˜ƒƒ—Ÿ-«YÂ"A/MÓcû∂∏‹≠¬k!(…$»rPvÒœS,ê∞|TZH≠§f@ñÈ"
ådt¥m,p.⁄Ÿ1Ÿ«˚ïfÜêA‰pà+%Q<@h€~*-€#ƒrà‚bËÑÈ‰q‚û•°¥¿w8Ë>Úòèq ÈÊ¢«nhŒac0Ñ˘ËSv+∆¢«öÄˆiÒBtD©4±1)∑É§ A'P:h≥2†©ÔhÆ'‹$‰{°o‚ù˙ë¥@Óçj≥ãM5XàjÜ‡ä‚ ~˜tœ’VJ#Ta⁄AQ—<Ú"e#Äúƒub>î)SßhîP;3ÏòôLRn¶^ODµ3UµÉAt*’nÖΩÜ¡XK´4m≤ ˆ68S,$jâ ∂SΩYZ∂"ÏI¢ßIi,ö—›3åjât{¢ ◊îê≠JvH:ëÜÑ”§§§í'U A¯Ñ:‹
$QZ_ˇ“”q)Äîk¢@Aπh%O∞
[\L¬	XËnÂË‘	◊…$ÑÜ∑QﬂïïxôÖ©n§ïG"≥¥î rl`TÏjøc`¯*ñrêa»4j¬e# ä{YtÛ	¢âI[)Çüd6	(‰FΩø"lèFLqÍπ: HÂ©C&tÓ§‚Éî¿¬k!◊@†–ÛS{°†sêˆNÍÏã#ÿI ˘µ7⁄wKtù¨	í§∆Ó?¡ºûc∏G°±œ≈8öpâ2…Å¢wOíNp'E;o2‡ﬂk∑‡Ñ–N™?ÿ±ÚÜ{@D®±≥Ωª‰5à'Ç†ì˙sÜ%πdÏ{X+èﬂœíi,Ä≠!¶\té˝æjvæ≤Û64⁄|By-‡6c«TlzØs€[IçÓ˙!5îl¬∫üuÅïç\t	ü]ï=ÃtnÍg{7ü`?KÃpTÁ8ó8Àé§üìK67DÈÁ¢gIÃ&Ïô√ÒÏä“td?xùJE¡û 2ç-3L 	RÄPö	ÂJ|uË b‘Ò›"†∫ë80GpBqÇú≈jõÙf∂ù√Yë˘ÕèÔL◊9“∆Í]†
®π•¬ D…ÒQ>” ¡¬TÆ#VùÕ‰ò›†”ÖÜÎÒOU§6Zb¬`òülxïV¯hÖ.æ¨õ® ë'ÕD [Á)√I-÷ŸÅÊRMlƒÏ;ãå–ÓU] û—€≤≤ZgÚ®X∆Í"e:%ã$IpcVòÑ~Z„©‡!ldûy8v∫d'ÿ”øÊªü.>)6^vùΩ6ÚÜç‹D¸ê∞øÜW´6ªX¯ˆMøﬁ "%¿Ã†π¿;OíCTK”◊™÷I≥p“uO$à'TŒsãß…&∫	Ó)›ÔSÆÂá¿§úËuQùSòŒã∏àHh¢Lï.JJΩW(¥∂JíπâQq@ÆÄπ:8uÍ√+;UljÉ<U¿\tçlÃŸÊä–≠$fÓ"QZBaiÚQlÓé≈JÜ`œå£	Im÷å\—Tftq'@á´Lîîö›ª|òª"xN8◊ÑÑGäHµ A–+6¸êª)µﬁ¬;¬KKˇ”ŸsµP›
πDŸ5πIÅòPpíS¥Ñ•%#{Hj¶u*√˚(Ã‰ÇAh∫ΩJ´ìZ—–™˘ }…2·›Y
Öç’l^k¬Œµ¢xAS◊à*ˆÑ“ê¢ºË¢Tœ†íäVh’2@œÖ®¯$6ó˘&≥ …v6O˜ß±“Ôhè#∏k˘ß∫ìó:wB˙Ø”Ñ#1¡ïqÓì»c_Ω*¿›∏¸—ÒYπ·fèJ%/cÔQõ∑ií6üwX	.ÓOê√úD¢cU‹B&áFF	—º!µ≤é÷¬~0IæÌå?H\ufÍõÙò›«∞ï©‘¨ n#+~9«eœﬁ7X—h∂Öõ[-ÆësHÓ⁄—ª‹›wBÿÎyf‹Ac∑\F˜…í4◊„£,ª˝m¡≠<lló˝ûÅ˙J2]øk.ˆËÔÅÖò5’_ÈΩCÏVõ óm 	îóõ≠7ËÀ©]å^(∆®‘ âª[È¸ÔÇœÇxR±Œ{ÀúeŒ2OôDßk:{â˝‰Å—É¨ˆÜ≤@1 ø2;–àA∞ÒRV±È©Õ±÷;h`ê;∏Ã@OíqÜCæÃ	¢F–˛RµÅ•5¿N±Öâf]‚ö‚H'SÊÆ˛¿ÍsüáπøﬁÜ´å¢42àÛ.gdÅW˙áI…¡um≤Í	d¡Ó70∑ÈÚ(x&$HX6AsAÂü7x¢!h5kººT‹A‡$APt∑Pùª fmâìÿ)|Fß∫ 2|ïä›∞µ·“·àL%i,kÎ%èÆocß*5â1Ã©[cÓpsµq Ö.èök!=“êE%¸ËèÜ® Jñ˝Õ€LœôP1§¸$X9§kwQ{ã»q>„ 4h[>∆ø`#‚û¡Tç%⁄xrë#oŒXC|¸RçŒ ∫Öjõ”πY∆B‰&<Q¯y…qOàa…!cVDƒ&fÌ≈›Çbtî·˛Õ£ø(±ÿΩK'{éä:&¡Iz¨urpSwHjtEh)jfÁ-‹,xÇ≥0Èqp—tòıÜ≤
kg®ﬂRñ∂¯´Êª…XstêQI,M@¢÷¡µ@9◊¡ŒÄí”lÀ⁄∆È /q›ŸA‡ñiœdÙo€“Eikç€ß≤õ@váêúêö©Ü5‡‘jA,AÏ;(êwJ ⁄è∞'∫H∫X6Xò4Ç]ÿß`!ª	R–ÉØÇ+owˇ‘’≤±πAÕÜpãaÇñÖ®7-Æ›ÚùØ<#ÇÇ∆K¥4j≤»pKñöÍ»xÉßÇ(oË“W@ÄBµ°“çÈ∏ôUûD$∏9˘mj ≤I+k:∑D¨á∞âî
„≥üh(
Â§x*áî‡’»5Wdö$¶)Ÿ K:Ñé>)Í*'X
S‰õ—òUﬂeÁ≤ê<Goí5*.ÇL!I‚°k8çﬁ)S w‘£µÑ…:xîI•ëD¢kµ<#5É‰¶÷Ä¡…1Â‰òdŸÜ ≠ªe¡Å‚‘H›D’Hê$4ˇ π0sØÇc= í€lπ˚¨2Ì†·Ft‘…‚nq‘ùS¥wI>KFæJn¨Ä◊AÉ:îÓ#^R$è‚Ö¶ò¥IDÑõ§®¿1"Qú$!¬V™ZtÑä~…íÿ¬Ã∑
Ò}@ÄG∏HÇ≠◊‘Yno⁄r´$~ÌN5Í≤ÅF
EoIæ§Uız¨Æ∑[\]UÆ,,o¶¿÷À\F≤Áãì’Ó»±Æ∂∫ﬂµ•û·3=˛*•ñ@ô’+'u±≈Ï5Óº&:´˝++'‘…¨[^“"&é©uºl´]e4äß√IÛIuû*·“æg<4í O (⁄¬ŸkÑ0Á4á4ê·¡®íO&Q
#£\iØè(’L@à¯®π£T’ñÜ˜‹8N:Üé3sÜ‡Y-á0T¡sàoËgÕÀ‹K[¿púÎ¨˚°
^Î9•é à2ñ“O‡&yÂ3∏ÌEnñƒí”H–Çïí‚\{©∏Ot⁄"
+Ëà$Ó–œ¡8!¢9êâcöËwr<<5F÷¢'0ê‹°êÛEcÀKÄ$Bsµ#Êú-dÍ≠ÉƒË>a<44A‘Úh%1SòºkuÃ@˚¶îÅíò§ÇVÓ¨c÷\‰	+[
∞$W‚çõt±1vÄHZå©•∫!çæòî|w¥ LÚ,+∂AÓéÔ.û5êÿ–@îñûÏY©èÔapüg1≠f· ÉüÌÅ…Imˆ^Ω§|Ù'¿(R›(Å≤ ríÍ-	ÎΩì9Æ)ÁI·$3⁄–<”ÍÒ ôÕ·›è)öËv—«ä(SöGª@éI 4â({]™ì79ßGFÅ$ˇ’⁄µõéä!∫'s»*.~à6ıH= Lp!Iëπ%0µ∫çÜçàèÇBñ¡±$^»—*µ’˚Â\c`®ñÇA¢Êe¥mˆs¢ËÚjò'*í¬D3@Ë‡[^™ìƒ©sH%g[ AÉ,Q&(ï6Ò(ñ(Ó†d òÇt·A£Ràû	•í6≥…’≠—D8µéáà#·™'}fí†»<v)»¸“»á8h{£¡p⁄—3¿î6æ:"÷Ì§8#Ç42$NÌå`K f#Pñ¯vÖ;û‚Ú^NÁ'∫ŸíáöÚkfaôÇyAí4Ro(ò… ’ûô≠Õ#ÙÑçÆòlwêÇ™dá=ÃsÎh‘∑@	‚L÷Dœ≈®a∑ \•€_I‡;‚™¢zÑË=Àèá
.icˆíwGﬁíT“úròÑË.I ÉÑ·⁄(8¯†•JÉå''IÏá©·<9I[ºSáV„˜?z8†GdÇ—≈›ß∏ì©R∂Q†GﬁéÖ6BPÒ	rÜê¶@m=¯∆Ä›Óis¿pkNËƒÅ¢µV÷„Ÿí ◊Tní7} >ç¢è\;wvü	AZwjëB≤÷∏∏ÍO√ÕÖ\∑›>	Òb…°Õqh”íe'ÍCá'ëŸ=Ni–Æµ›‰$˛˚æîÎÍûàŒ‡=⁄yBÎ!ó§g‚ÇÒµ¬ÉÙ’01Óâ¯†õ …F¢}Œ:%§˘ ⁄[∫\$€DFËô< ÉLúZ‡Dx¸Sò- Í‡ö≤ tÓ§KÄôë™J_t.Äu:Ñ!‹©⁄dËôÓ›DxßÜº™œÇı¿‘§\Léﬁ	À[Ø‹°2ÒQ∞+eÜÖ1‘ßL5rs⁄í“¬\EÖåvD|U,iƒ.Ç∂ÅXç›≥è66¢˝L¿wk$¢ÿ4”î[ :úv–ûñªn“5D€µ”¨%ën·5m∫ÍA:©Ó‹ËÌ‚ÜmÆ`◊TêôÓlö‡”=îNË”î„˘∏)-d_Ω—¿Q≥Ç ójb;x"è•›%l∆∞˜3kŒ®ÑàÜèöãt|ï0&xÌ†Ø2|Rö¡ qL√2ëƒ©√ßO°ﬂDêˇ ˇ÷Ÿ¥j¢ÊÀSΩ“R.—Gm≈ò&ipyîZ»!6õì≠‘˜B3I,Bp£˚AË≥JÅt#V9ï}4Qh-
ÜKﬁùç«ÕS b‡vyÃöƒ5X∑≤ã¢»¨ôÖè}\°z≤dçá5L	
.©7Ñ‚‘éÍZ4A÷HFiÄõ&\{¨Ák3œo0öñopíû]£~i>á¥<•.ä´ózH”¢õ8;ËàN∆»„^∆x	Öû&éö≤xô•°ßCª±ù#‡ô‚t°H!—q:Æ Ëà¢¡›Y©ï∏≈èÿ#ê'T“Ya-ë\[Cwh¯sòû[íç∞˚§4Ë‡9˘Á„‡É%.v9ÄqçDxLúy†¶`hö!8xçTJIb]
rwI fP©‘£†›åívk¡:ˆVj¨m„ÑFÜ7⁄·™ì_.à—$ıL÷ò–'£E KZHR∂k*;J+@ûÀ=‡-7á7C®Öùpá|S†U——8! Gu Ÿ‘'ï—V„0¥Ûm•ÿÿ‚Ω¢'¥Kº˚¨»RnŸƒÌÚ‘†í5≥T˚îë∆ö‹„»Äèä("⁄ÕN»Œ˜¥p·±¨!A>hÜF◊j·¨vÏâc á¿é˛(/˘<vEpqh’≥ ÉÃÎ<SÇŸj(ÙWπÑç$i FûﬁÚä‚K[Ó.Oo Åaók»’:;∞d>í;≥®ë£î¡Âﬂ(¯ß.sÿ7êL»Ä>hgâ¸›p– ∏	%3F† N=”÷'_Óå$∂ ÅÛ(<)∏yHlôõ,J.;¨
&û7∫6®BÂ‰Ì‡‘C #Epñ¥mÔ;!I¨w©.ò)[9›,ÜêUÜ0∏vL˙Z£Såm< ∑q£a∫:Bw”%DügözƒâÑVx±dô
mkwn#^Â<4{Ä¯®ö‹‚`¬Jø¢BFÈn†¶'ﬂÑô"≥‚Ln;Gó))òÔ8˙$;C⁄Óù•£N
gX–ˆÉœ`(X7t8è0f¡∞ö@<ÒJyoäKJ’µ¨y'YÊN®Ñ∑çvœs§éìà‡6µƒˇ Ω%ﬂˇ◊‘Ç]!9$r.ôùû`¡Q7R1»ç‘†ÓÜËßSâÂ8 ÜDç–ç0‘(óJõŒêä“í≥3
1ÓMY!©ÿ	2R[›ÖÄíÖ}SZ¥F©¨oµ$É≥œﬂNÖa‰∞…]çî√¢ÁÛqà%4∂"xÖ<≈çáõ¬6Md8 Æ”¨'CZCÜt¶˝4pcT = n>ﬁP)Å†X˛qµùx–°µ∫Å˜´!–ÑäÏ`›¯≥ LrõQ¢îˆ2êœ#≤çµC£ªiÏú50’ ﬁ>9∏¿pi& =…Hîƒeã1o5:Ê∞˙MÄÁˆ¶^”HaÊùëÏåÍoØ\l⁄«Xk5IùÃÔ*Æ{ùŒ∞òÀZR'HLT5FîM3	‘vëØäòcàéÈ"ÿJõ+s˛
T‚=Œ˜ÖT l§»≥◊F´1{Å(°õ\˙=†+X˝0ÿœ_%ﬁÜ8‰ü§ÔÍÑ¿IAêà≥£äXGs:B–≈ÈY-qÆ!ºíc_d‚}¢‡ŒüSô[t/'Wy∏ˆW˝z:N3Íc˝\ó˝(˙-)√«ÂÔ¸O!†!Ûûáˆº›ç-–â⁄`¢∞‘q™xm†œ'U+>	ó—ëØkµ$+]:¸¬5ˆAñÍ´…<Ë§àÍ£Ÿ +	0AÚD	Â)©@Ï¢üH"?÷UO®ÚD»}NπÊÜöÍ&X¬fò»i∆˚;ö÷ÄK∑µ†ÿÁv«≤¨Aêí‘gÈ…Ev¿¡∂KµìŸ	⁄ù;h§¿)ÀÁ≈Éı
‹ÿ∫õá¥ü™Önˆ∑X>i√f)|⁄ıæ∑WÌ$&º ¥√√ÁòùlØsò∆πÒ¯¸¢XÚç4SA,”Å©ÚI¸iDöHah‚uCp1Øt∫†öè—â‘‡√`$·úß1lKä~a©E™ìcÄÒE ≤¯ıπÔ≤Èqq∆¡¢'Mh”Uµé÷äˆ«∏ œ¿+ráÄ◊√‡Æ“8·	ƒÃ˜¢{Ùw$N¨ŸÜ«
§ã$}©∑ﬁÌ$ˆF≤“Y™+uc≥Äöß¥nhLw}Èâ`p s Jf7‰˜˝;ËaBGÑ˜)Î⁄IkÅ$/0u§îû%ªFûpö∆p˛cÕ$‚S5ÕiÒÆ©8¥ LüS–èºLß±Äíÿè#¬HΩVç§ÚtN˝˚â&|{'fç>ZÈ¬Np‘à„íÇ(P-;òu 4Qs»Ä“4ÚÓ§@$yP ∆Iga÷u2PHØ≥Wˇ–ﬁy hÄ÷Àâwu;å
$âL¶‡ŸVˆ˘'≠¡° π∆¿ﬁ∞"IŸ(pQ±ﬁ`tPxx)ÀkV›G⁄¶«	Ñ>•S√äKH›<ÍùÁD2ÊÓÖ;cjHÏ¿âcg3W@[#Ë,Îõº∫8H≤c4^C:≤\L,æ
ËÛZ–Á?háòB=ïû;Iéõîè0¢œ∏y¢ƒÊ »–Úä-:ˆ>@k¢%mﬁÈ:¬iÒeÖﬁõü±+I||Ú‚ÁG~∆T∂¿:p|“'sèfì04Q€f∫#≈⁄´{öA"]ám5Wê`Wtñ	†y õ6ËNûWGMÀk'6ÏÜ2ßCj¨í÷¥â=ÃrUT€ìjxJóX2ô05(¨ØI)Vﬁ¡YkA&ü50πÁ€«ueµû[›™Åë„›X´¥û˛2£îëtÖ¥<Ä£«≈^∆√∫«±•«ø˚UÃ:_/µ·¨i‘J—˚~8,°≥	¯•πHF?ãÚõ·Ñxè‡æ/I¶†hx‘ÙZÉö¸˝Ÿ7πøF¶Ë∆™WÊÂ\„π€YŸ≠—TpÓå≤∆∏a;ïë«"xß-|du+ﬁﬂN†)´≥Yß‚≥l„]Q›ß=’kIM≤N≠àD ¶®%é:˚|Ó∏∏˘&µﬁ<©@Í»ºÏötDÄ£QAà–©3QÊ¶Fäº£hã$ZÍ}á⁄'πÚ	®§X,÷\<»ÏÜG …iÓ∆}?H¥é–eWy·Kvö°ø]QdtIcZ›Ñ}278vì¿P0	‹ 'étN"w;wQ%⁄IEiGkö‡BÉÍ;k h‘ô>•pÄI‰ˆ*L%≠“ÌÛO5Õô—`ˆç«nÄù2†G∏k≈XB¯òÛÓP!≈≈¿∆œ à+& Ø…⁄“;ïíN∫¬wíLÊRˆÓ:x#—i‘È—c%ﬂŒ–Jvç	)£s¥·áo≥\Ì£í∑0pa«≤L¡>†{«µt 1≠;Gdé¨∞è≥∫ÕiLË¨Ä°„wBwæ\;óÈ3⁄5 ˚ºT´ó¥xQ√ß≈Äo,“ZvZ]õÄ”≈¬pÑÁÌpé… y$äÍÃÄ◊l$j;!⁄…Ç~a∂z‡ò€€≈]êf~	+jD À⁄Ÿ”≈N∂µèÄg D$wA|A'πEmﬁå»› ê ß`H·™ndç?8'c~”©#II¢œiç‹|ì[lˆâì®N˚ÕíA‚%DIwvËe$ókÏ-‹"4B`–†h#Mœ·CÙÅ·≈≈¿}Üƒ|J≥¥v◊‹íNå&π>Ë<§jf‡„ªD`CµÔ	Å“¯8Imˆˇ—‘Ω⁄mùOäAŒÅ ê¨Ω˚ùÚ
N,näKw¡©I>≥Éß¯+n„D*ÎnÚÔ≤krSÆ¬N•ò%°1ó8¿¸€.úûª	whÒH"ìπ≤›„∞ÅØ)úÊÜv˘ß¨»ñä”≥(>¢-ì†C\J)—≤QZYñ{_I†W⁄ÜA-IBﬁ{?ü5ŒfSÈ∏Æ√-§XW?‘kkän≈úé(WÉÜTˆ3kìS⁄ª=¡i*Õ>õttƒvÒ@tâ˘|Ÿ©ü¡G#£g’êûJ++iÇÁmí{O8€≤<Ë|ªÇ†£∂–Àﬁ„π≠‘ Åyì'íâæ;ïOyû…5+g®°’AƒJæ⁄É[Øﬁ†–ÿnà£ﬁÿ‡°#iÑxEn¡ØÂ¨Ô›\™∑DpOÇ||W<µ¨a{ßÄπ¿≥°˜≤4‘R=Ü îÄ–ùOFùu*„KvÄ$k=‘∂t·Iæ“O~ VUf‡4Bƒ9†üS=«¿&5î-ïàaéJõ¥	ß€)(5ﬁÌ!√Uõë`nì*ıœ j`¨õòwí5ï4,Fà˜{®…HÇ9RˆH–ƒwS•õLÚß äç`ì‰äDò	•(ãy@ïj¿œu]—πQK≥æ±¢âNÆ‚ÂQåÖ€K]ÍCôØxÚI'm¥b{®û¿îGêI<N®2N©¡l®3 'Ëü‡ìâ–!12d	é·&4#OÇKI—∆@ÂN∞—!‰Ë4˚–§∫Õ;"¥©Â<ÌMxÎ#/¢ˆ5ÉHPcîºmÛ:¸”ÿÚÁDË9Q:'¢… Âca¢Äó~RùÓùwö_ïYzPÍ±q:+∏Ø∂–õﬁˇ ! Ë©≈9Ö°%áÈKËÿ¶ßUNÿVY∞ ‘˜N‡f–Ö:√CH	.%+>feH∞;‹DBw˚}ƒJhsı‡ï‚ê=•öGÇÒ∏;Y&‘Êù≥"Y[åh4Óí4Kaﬂª·»R°ûÿ2Ás™5lˆáv:Ùê€`Ãq™KI–Äƒ¥7‹Z‡ ƒ˜Py∂ÍTIÄÃû
+w¶Mh6√H‘$⁄Éπç∫¶íH&[¡5ï8j<â„TïıJ5S ƒ§_∑MLœ¡	õÀltªônÉOÑ9§∑ºò0í´Zec^ˆµ≈ÆÒnÖ,f<VXÈ›⁄ì—ƒ≥#wáíAª4 í/JV“‡=«‹?5-\÷íHé~	ú◊í|F£≤LÕsf?´™H\πƒÇ&y'Ú"à2gY&ëº?l∫9òèƒCCßBIG¡ˇ“ﬂ#ÑW∫…Ï¨qaû È›B[ÄvH‡ ”≤±Ê9¯¢>v¬Äh ÚÜ™ﬂP—ó€˛PäÁëEàYª¥2IiàêèAˆÍôÌ›h %íˇ N©ÑÓ l1Ì'BßeÄ@ÒTÅ{wË÷0õì≠iÈ∞@î¿ÇZß¢MdW Kz9ô$9Ói˘,| Îèªˆb˝ŒûV&}oeÅ£Y@∂ FŒU{]‰´0¥≤Î j7êQFêı˘§n¶J=mÅ1(mlB  ÛŸG"Ÿ«d\[-:v!@º≠x&u¯ùPká⁄–„ë.(ÈiûJ £]xıKàc=ŒqÜÅ‹ï†ÊÙ*˜T˚2ò÷=∞“H—‡èò◊CZ -$ÓKÔ@¶$ˇ æùî^˚ùLEç0ZHÃF™÷%◊ÂåaÌ≤Hp=£ïIÃs@.Âﬁ·‚µ∫FK±π;=W⁄uêeÌ≥ÚÍõß]óKàD÷ßßõÿabQã^ ‡ªáøπ+/¨^€—ÉÒK•ª+Î≥%éyöÿÔ¶]Y«}é/q‘ÚõñcÄD¥’«èıíëói} ı∫@(¿·Â›	†4˜Rsûú™•ú•tjPIh4PiµÔ˜†)Ò›*UR;^k(ãwW'⁄J{∂πÑY˚C@dóFÄ' ºYı
ã‹¬w⁄xî"I·Xåiîh±2¨Ÿéj∆¶«ç∂ZKöz«ΩKÏß1Ü∆∞ÄÊÉóv¸ïπÆ◊Yêˆöv≥ÄÎ©Ω˜v·9añ¥5Óœ~Ø-ÇL¿5N&f!tXΩeóüG6∂›Ì$6≥”F°’ÎMö∑À…4±™ÿ‰<\è	;u√!€œÓ c	Y!…F¢%F$é…•6¢«·XœÕVy-·»“ûÓ≈EÑÒ€≈B±ø‹N®¿xG¡<È£Ië‚Ÿêˆœ˛Ù+,;ígÄà`„Ê™óÉlQ¨í°WæåÍ[1>)=·£M|Jó»†<…⁄Ü•äGÜ4›dûÈ8ÎRs†y°èqíú;±4®x´∏xVdX {R∆¬}ƒi+§È‘
k,"ÓñÎ„
X·a∑ÂÆ‡´o.GÄ§ˆâké®¡í}£HIy=Xá≠sé©˛–¬¡…Ó¢⁄√åhO0m¨µÌ#Å¨ëAùå{C}Ó<IOKüÈ ¯‹ﬁaÄË"'n≤ÉäÌ€ÿ9ÚI£ ˜Å3ç4F∞\@⁄xHènÔI)KÀßƒ$µï.q®Ô2F∫p£√∑Ë5Å% Ú∆πØª«D¨¥5≠Õ ∆Ñjí∫˘§y$∏ÚH˘&•¨k\ë¨∏';{€Ñ;¿•KY⁄⁄Ω&bL +z1|9¡¡ÔévÅ-S⁄?x{ıP≥{Í·‰Œ<
-`
¡:òÉ J;-NÚˇ {ÅÏ h¶˙‡Z˝§O'≈¿ÊºYΩ«n¢∞4◊∫+£~§ ·>rH=¬Õ“’û
D6'€ È?I3H. I“5u
‰An›¿Í]€ÓIIúFán§k‡ö	{ck@5ºœöf k›2F™SÈÍí≤ZZ@&yrõD∞âøíb!≈—;á~X˜j≥‘Éi“;JHËˇ ˇ”Ÿ»√O)ö6àNÀ-2u	¨pee‹ Ü€ΩÇ∫«8âY{úFùí§çª£ï;lÄBh⁄“w™`√2ÛÚS{àdéS≤ÿp’œ·Ähñ¡ñUíFº¶∂6∏L©µ≤Ë	úﬂxÓú-W™JX›4
Lá8ï¥Ëö≠ùK{ñ√› :C|êú&—‰ßyä +kdCeee3‘∫bZ¬CÃ{G¨Á †Y°πqÛŸ¶°d⁄›Æh‚Vﬁl9¿D¨ÃñI vA|ÖãG^–‡O \Ç!†±Õ–Å:˜îÌ‡ ó∑oªø&V∂º@‚\a∫»Å…)5ö…‰£	cΩÜH‡¢O@∂◊äLôP%°Œ±$èwÀDˆ
ÿˇ –óú6ì„¬ò«∏≥‘ÿÊ¥ç€éÄÇyπ–÷1ÕptÃ÷—>2òŒ GmåºÓ◊µ†FáhâB≠ŒcÉöa¿»#ë
')*›:ÚÔ∞ìméyÏ\Kï°s¶#Ê≥qúŒÎJ¢“7©PLj£U†m5§Íå  âD*¬Y;Ñ"3¢ùé–ûPI#∑µ ê›tÏ≤_u¨¥ΩÆ--˙$ii[∏Ãp≤ÔiôÌ1*ll— )¿âC‡¥1z^[ÚZ◊WÌf◊ÿIˆÜDë<©‰]M=a◊>ô≠èìTà–} eq°Æó¢Nõ’OLg¶ Kû˜cúHñéÕ$÷˚m∂∞—Ω€ö◊ˆì1Ê°ùî€¨ñ˙@í—ap.’⁄™NsøπJF≤™î∑lΩŒkœº._Vª)≠eÆ‹+—£è»≥ú^†–eJ¨i®ÍïÓíà÷5Œ çÓÌPÙ¿ ∏Ë{çG¡J—@-ÙKàÅªwÔy$πdGä´qq vV• ˚¨Äùÿ≤ã{Æ«jˆ-:ß<â”¡8Å¿Úïˆ∑„‡éÂn√R¬◊C@û»M`˙Q?ﬁ§‹\·$§˜ùøë<v6xèMÇ¶LÇhû…ò ‘˜Qs§¿·Xe•ù÷‰œe{˘Ó√¿≤«5Œ“WQ^-T√[†!—áYuË¨Lp XÿwVwX[¡!hkc‚¢m∞’%⁄ñPC"a<Ià–Ñ;7êL@Ñ,w¬<<REX¥åf€	nÄàL∑Q0≥¶{õ- jùÃ›¥É‰RRÖélçí°å®\]°–iå˛k˙¶c≤ sd3œdë‹R'0˚£C‹Úã√¥ÍS=œhy∞ÇzﬂLûcP~)#£∑˙°≈é€˘œq–ü à@%ÕykKNÜ7≤ÕÛ∏Üç~îπs¯aÇ‡z|RAY¶ŸíCµ#€œíw À7∏5£ƒª‹O¡F∂á9€û\ªsÑISµç!Øskë¡w“è$ï’ì\Ú√¨ÄÊÅ¶áÕMÉÈ4˚t‰˚æÙƒc€ ƒè¢¢›≠>÷ÜÓÏ‚È‰¢µ!q-ê\˘–ƒΩ v√â’¶ ÚÑCÖn.|ˆË·ÚOS(#iö˚µ)*ôÇ‚˝_#∞à⁄ˆÜπÕ›AÁC∂»sÀ[˚†Lû…√•˙%∫9%S77‘kòN‡˘=©KYWπ¬∂∑π	©mÄÕñô–!©ßÙN 4LzúI∑4ÏsI-<¬BA>∆4»‘ª‚•S∑≤d<É©o—î˚vª@–]…¸„‰äºˇ‘Ë=*€$à'∫’¥∞4)ƒÉ3ß*.q⁄JåçbÌÄa≈Cc∑ÃËå/ØFB›i≤åÆ™ÂèìƒhÄ◊Pí&áºâq‡ ∂√∞∫4@Óëtôñ7n„§ß¨ Ì” †⁄Ê¥QÍÄ‘¯ûà;2ºöwRc<T,s∑ÜˆE$5§¯ıù&à¥ï,Ä^ŸÉ(x‡∏9˙ÍTKûo I≠|õçZGïûÊ¥TÈ‘ûÍÌÆ%è#R4Ö]¨úy"	Ïícß⁄Ûπ->¥4Ë+¡i'ÒZó∫/-ë>
éLÍBkc£A›ƒ'xf∆˜váN é>)¨—ﬁ)ÅéOäj∑—ì|c‡â[Küµ±'π–}ËmåIˆÀ‹~óÄ	•ñ;.r≤FüQﬁëÂìÌU˜ù„„¬M0e%§ÍåªX+jéâ]‘5ÃºΩ?YÃè`gÓóˆrÕÉXÂ∑k¢y"O@é˚ Ùù[¥’Ω¬º€X∆»òlk›Tkl∏Å:Ë¨¨∆√´;¸TR◊r…NΩ76∆i›Zaç,z¿
ª√eW;Ë≈-ÿæ"JÄé>H≠™◊º5æ‚Ì#Õh≥ßQC=\«ˇ dpùm∞‹ùñ∆;ùOAªœ^˝†Ä-Ã5 Hı:{∂«]=ô}-æ÷„o%f‹zQ±∂[áeTì´öÌ>AKP~÷X‰?π!ˆ6Ôci¡ıqÚ≈xÙ≤"∞7ø#∂‚πö≠µóöÔ“4Ó>Ì~jÊWSı±#*k+c§8}"—;gÔU+lâRªã©¸X‚Á…‘ùOƒ©‹˜;k]˘£EZ7+ÔLef∫òo±ÃsãÅk˚˚x—ƒ—ÿü&Éw®Û	û4S L5IsüÕÏTH◊Nö0LÊ%3ã <˘‡ä9–#è46Û=ª$‚\`'$1≤Tï¯µ…≥}"CDî¶È?%/2xN]≥Ñ‡+ÕäS‚àd‚'¡@8?Gi&-såûYSéç£ß’o®ù¥F˜ a¢UÃLæ∆Àtr∑“˙~Ú]`ü	[w1¨uq†.ãÑu≥øAŸÖU˝ùõcÖf∂nk\ÌwpäÍÉÿH˘¶≠ñÑiîîJ
Íõ“Ôj%Ô¨06∂…ú•ED^AÔ›ÏımóÃé!%ƒ8π¨ôò‘%Mm>°?r#‹Y§	P®Ç^ÿâ<§∑°QcúZ‡wR‹ÁlpëP¨±§1Ü4.q˜Çòç˙∏	o¬JZ´=VŸ/í8sDpôıY∏<VKcÈÓÄ>^)b∞ÊÓ6!§çì	Ô≠è.kãÅ˝Ël˘Ñï±lùÆtœ-; ‹Ê∫OÀn™e§l.ti'§i/q'∞p—ΩŸW™∆ÿZ`òVF∆ñŒÖ√hKa!√h$◊ÑŒpkX7h	g…$]Ëéë∂Á	{ÀøËè‰µIˆ◊\û÷ƒç¿GÇAÌuªv<…w ün⁄À÷ç¶!ﬁÒ	'Æ™c⁄◊◊%§∆··Ê†÷4dKi#Û√π˘)∞ëQ$Óí ∑O¡¥Ç÷¥xºùa$]/∏Ω÷7|9¶%Ç|Kö«5ø§%¶7È∏˘¶}ÑZIÄŸÜèyBƒ∞dÀ⁄X‡@6ç§§ä“˚#ÃÃ´¨m÷öKÑÌkwn”Äa\Æ‡“eºü¬P≠,c^Ê4°≥]ø4ZıcÙõ„¬*;ôk∑ ˝çtËgp ù’∞÷ZÊÉ&a⁄éS}C∑k[ÃÓ'ÕIÏ.› √S˛Ùë‘îVZﬂvöFÉ·)ùÍ7l85Ñj˜Ï
j	i;à CQCèßÓh≥y¯	EC›ˇ’È®ìGäÕ"¡±⁄w
lsK\40SªGr≈1≥±BhÆw~tr©÷2[söcoÊ≠ÀA!≠\DöWDËzµüam$Ω≤O '`a†˙GÑ˘TÓ` Ìï:Ë5‘“êöæ≈4VõZ—»Ï¨µßS‡6n9;â◊√∫±}éÙúd˘%K†U ãúdKﬁz:%†(ô üT¨xıY2|à;˘6hÙ√I÷9Uÿˆáò„∫.ˆ¥9›ö8
æ;õh{¡1Êä—‘≤»“Ø•≥w	›V⁄⁄91*60÷Ô§£<Ó Og—^˜:∏éÎ+:∏“;Æí§Ú˛Ê%dÁ—Kû÷ß“ÒM!ú∞·ÿ– èπAÅ]æ†”¥vïT#…0Æà’òÇGîÌ2O$iÒQêñêòÃ≥⁄Ò£§G ®ÄxDﬁ{˚†@≤!…¥±¨–˝∫+h ”ø*Nc«h#_(HÜ8˚A‡F≥ØtvÂπò˛ÉZ¡¨Ôâ¬RRLG«?5¢⁄õÙ∏'ëŸcQkXˇ w∫ÿ¶÷9Ç®rSz6Ak[<¬ò¥9≤”¬Ælc5'EZ“xè%-·l‚‰€E°„‹¸Æfn.M∞C˘K¶GøtÖ`ª€¬xë ƒm%ì«!.£≤Ó5VÈh/pÓ~äœÍŸsãÏyth<¿+Nq–¿Ó™Â7⁄`%Xw’Œ¬¥¿"¨åÀ@
B»…Ùí–IÑ |…J€KÃvQˆÌ“Kø@C&â)<Ö ¯¢I(“≠s!U≤◊ç RuÌ&æhNÅ1¨©#Ìlπ,TOöΩH„îé‚eﬂr` O∏ùì˜?Eã£@ôÄìÊUålW‹Ë‚∂iÈu◊µ÷rRHÅ4NéUxóXŸÉ¢⁄ƒÈÌcX˜j{Ö}ò¨ÆßmÄ®¥PÁ4–•KÏê“X,,nÅ–^§¡Fßå∑›{£=≠k@ ÚíÖË≠íÿÑöEu8·Ÿ'=ƒÉ†~Ù6=œ2!æiw5∞AìﬁﬂakHv‚g@ﬁuC±ƒ9Ç~óhFÅµ∆¬·Ü˝$ïT∆∂÷◊ÁÉœ¿ß©á’–5Ü|fSµŒs4m=Ù˚–Î≠å òsK†ìÀRWu[[bÈ˘á˚ë6ZÁ)æñë≠m≤5áÒ=í'ÙL›k∏<k‡PU™ó⁄Î∂Ω≈˝ö"~j.≠Œ¨¥4=¿Ëcøäñ˜z¡ªàh‘ˆ˝ËÑjˆñ8û`jí.îÈ4¥iΩÆ÷x◊òLÁpŒ1¨~jq-fÿÇ!£P	ÛC≤ õê⁄\˜˙ßP–ﬂ—¸ek79«{[P;NçqÜ∫uÂLm‹‡Z‡HÊèÇõ⁄◊πÕ-âìÏ(,¶ß49¨kbvíÊà<JHgËìh∞9?4˝8-ı!¢∑8ŒÓdx†YmM¥n6?ËV–K£∫,XLÜç≈ºªVœ¡%k’ãXÔMÃ/›aÁ2=æ£sd1Õ†‹ˆƒÀ†|S„ã;ˆA“æW÷[AﬁÔøù‰íz•€Å–K`~MPs≠uÖ„Ä"X1„ b√ÍIq#Äﬁ EmÓ±≠õNXdßi⁄ˇ dÜówΩ∫x©1Ætê aF≤ù;úO%˙	ÚIlqÿ& ˜|ä8ì∂8à$®π¡¨í‡ﬁ”ûeÄÅ¡ÔÃ$Çƒ=æÆŸ‘vÉÈÜœ
%¡Ø…=ÄENêQAˇ÷›∆}÷áõk ˚@<©ZŸ±§¥@Ô<(„VÊVIq'ƒ™ŸTc[ó[Ìµ¬∆Í+9Gz6Î‘cy€a⁄<P*c væ<¢ê◊'¿ „\'ÇyH†lW»,7Q<#0@>!^·#Ba¡i3µ—¢r£∞A]a◊∏∑≤Wÿka7¶ätnsöCú»óºµ±(Äõ’ç0Õ !¥5˘“vV6è ;*∏‰ÁÃì‹ß u)/qms∏6R•ádÃwC €`mnà?ïZ≠†40àkD§£†Ac?L%ë]ﬁõùTvîV=ﬁ´úÚ= 4)≤Æ©ålì>”ÒIVlùUd”8o'_óócëÈÄFõatUÌVDÈ+9Ù±˘rÍ@èù ·-O⁄‡Â∞÷‚	2¿–ÆÉ´„Ïf·OµbX◊m0HÂ4Ü`t∞◊W2´∆5ı4≥¿ üqê=⁄Oä†'Ã)…#»&æ$Sìç±„i.1±“FÿCπı84◊[´Å%€Éèà—B“éäZ∏…‘§öøUm’XÀkv◊∞ÀOÅDæ◊_g®–‚ v—∂HÓ| µÉÅˆèUŒv÷‘›«∂Ω¶UG	ZDEû·f6H
Ó;Õn–Ú#ÔU2Ö]Æ†Dë2K¿—WAlL´˚Î◊˝uF~˜{#›‚àÃ7˚ÁŒnÜ©Ÿ&Ø∞çÁ@„XÂñ5Ü Å‡;£∏»ºîgv9n’}¿%T∂·¥ÛOì…ç:˘™nqÓ§åY ≈≈Csµ'8%∂  ê§Ÿ—p"◊5≠q◊}„
Öﬂ[tô>*'d ,ê‘ÍÉe˚d4¡:üuØù¢U„Z˜©D+R’ûc- õ	$V5Æ ô?rΩã”ãÉ∑	 -*:aa#Ñmlqù…À˝üaë«áO§í∆ó6∏Æ∂6 ûUÜ:+h<%K¨ÉüáÇ÷ºÄ#∆UÁ„5ñÑÏpmì»<Ö"k:º<BH$€71ç”ƒ$«ñ÷Z"%H∞ŒËˆÚÉA&∑:H<éË≠Ë≠—`sHô·5øAŒAû¸"ºWÍ$ˆ¶{å<n É‹$õŸãZIák5s\‡5tp
meécÄjIOG®np±·Õh;K{|RWv´ú‚ÊìfÜ §¸UãöÊá?sö`F•5ˆW]l%·≠q¶éFµ“‡ÿ#sDû~‰N⁄ °€®$∏∏H;àÉÛRqh∑⁄◊c›˘™8ı?eçsã«3"Ωçñº5Ú5‹3ÊQ´*¥x⁄"t˚JzI4ê 	‹π‚«Y–p	ˆì
Œ∑“ys[Qh-oπø4ë”ÏZÌ∆÷∑’pÏ€˜¢X«{é›Ûi<È‚á}µ∞±•ÁqÊ€‡¨à÷7¥F∫ERúÊRÌÃˇ $ùÕ¯©Zd±õŒ„√Z›€ºß¡Ki™ó2∂π¿ùñ2Pns˝ç∫ΩmnÈ˛©Ïí∑?À˚[-ı4íZ5qñi‰°Xy%ÆmuÄ”¥3Ëˇ iLó¥Ì?Dè#ÒP∆eçy›W¶gêdï—V=6˛ìa·ÂÇAÚ¨l.c<cjE§3ù±˜"4K:√π	-%Ïv“– >3>hÖÅÃÄÁ1Ì	ÔÄÿ◊BôÃpkıq2ti˘"∂ıµ»~–2I‘¬≠v‡Ôsà·†√~%=[Ω26ñÿùƒ|SYYxsáì{˘í7fw“  ˛˜ﬁö†}C.s§˜ ¶÷ù¢tIŒ2$û¿$èPCL#éÈÜÌáÛèâ•ÛÛ—3Ip◊Êä¶ß_ îÃ¬m˚[‚Nö&Å∑àwÇHˇ◊Èk-0‡DÚ´ºEßÉ‡O(ò≈œ•Æ}{	?C¡@ΩÓ -5Äﬁ÷œíè£dnSìÌ<4À…;û◊=º"Hp∂ ƒûË8’À˙1X'FÛ™*9O,{@∞6yÛR.≥kà ¿ˆ˘®‹\€”VÛŸ˝öãf◊÷AAè‡ÖjûÅ+Ó}3s	w—iï"7_†–wÏ£Ö[j¶°w(}¥˛öY˛èº¢ö÷Tﬂs˝é ««Ñ™c\»“N≤É®+âh'«àE§hB8EiŸ°f3≠Õﬂmzµ“Ø=ŒkCF˛ûRk∆˜<∞∂¯œ¡*±ma›ˇ ;Tìv@+„µ∆ç•£S®Ï°mÕ≤∆‘Hi’ºëÏgß[kf∞%T√˜‰XÔK” Í„˘ﬁi(u=õªõµƒ:ÊjÉZ◊8∏ºŒ¯©d>ÍÍ>ñﬂPÍ∏)Ë‹it$¢íÇ˚ó#®“≤∞“A„…cd÷Ê8Ç"Í.⁄rGª˚´gb’∂À∂Ówp%°ûÿêçHGÇ›˚65˚OºËﬁÍÉllx(ıd6j ~!L@Q ¥ê{'Jå≥DÑæ•õXw±∆\ﬁƒéù®Å yM0í„IŸŸˆ ﬂ•
¶ÚNâ&“õUºπ⁄âVMüö“©VÒÙ#ûËÏacÉßO“ﬂÇ⁄√Ä˜Ω˚æãªÑ'eÅ°ÖS#)Œq0DJ–UØªqé˛*±Jdß%çŒ:ù–•¢e d®õö4‰ßØsﬁd{|=ÀFí•°’¨g#Ú£>© ˆ
x¯≠q.<wZ‚nŸ3C¶íLÒÆÖ$ãπÆÓ[0•∏'Ê¥ŸÖÌkˆÌ”ïmÿ-hlç9U‚:îi@U4qÒè¶ËOuaÃ⁄XLx¢‘F«êZc_ÓL‡¿Ì‚{tEi$ï\x˘°‘Õ≈ßë:¯#ÿ›‡â€Á êØkZ—¬ΩWS}c0t–¯"X–ZAœdÙ≤†ÕE€¶¥‰}ëvT_¥∏O vïö\«8{§ÚåXœt∏¥@‘®µÌ∏5¿ç ¯§´”OcΩfµŒñéTØ;}G1¬f"Tpı€Y"yÛæÙ[4ﬁÌÃh.Â√Oö*ÌlÀøC\û˙é“á[è®d∞€Ô…ÅacZ,–„tr)6Fˆ=Õü¢;qÓAU°cë{jeu7uá€Ì›*…sF÷@-ÌØ‹P^l¶¶∏mác`›ŸèüdîãvÇ-;ﬁÒ¨w¬<,gΩéﬂ`"eÄM4J”k¨6∏H/çß«OÇìú∆∏âè£Â‚íØU…ô%£kÄè?ä-mL{X÷‘ :L∑^e{Iÿû∆;(3µ»€∞>dNÈûN®¢◊≤K[∂÷÷ÿ‡ÄÁÇì§ñ8[∑oÊJ¨k)¨mC˜Àwƒx)Uc-©èfËü$$$•cW±Ó˝®œ.®_ÁMe¬∫É≠±îòÓ'_‰ü5V÷‰I©’óDæd;…Y∫ÉÈlmL∂;?è$∫(’ãÍΩm&¶Éﬂì‰£W•ˆüi~Ê 3≥T@Ê◊SfÇ;)KæëÅ⁄8EeÓ 	6IâC Ï0x=¥Rs«hF∫¯ÍTF¨v„º»íús\–<â’Lâs∑L¿ &€0ZŸéÂO_iòçR*wÏñ3ùÓ2ID:»Hóá	ìœ	€%«∑}QÓ∞.ÿGÂNHo$Îÿ%ƒè•>)mlÍ|ÇHeªY·3]π˝Ù”Tá–èäg9°¿I'√≤*f"v¡HØáäé†ê4ÛI¢$o‹„ﬂ¡$?ˇ–ËÎ÷¿⁄	·@≤ØZLÔÏ;+-`1¥…ÓU73/Ì_Hzøxü —∞ì≠$ ÿ)|ÿZÁÕK”4¥4í;8ÚTØﬁ⁄é–“ÓÕ<*åVŸ|~è’©sZrZw8vÿ>èƒ¢‰9˛õÉ˘–¯Ì˚Qæ∆ä˚>u)]Ìi%õƒÃ õ‘/K*nÁªπ‚T*`ıúÚû„îVôN?5U√Æ±e÷4ªsâô‡yU–±œ≠ñVﬂUé{A·ß_ö8!µ5≠˙#¡2uMıw~h◊z≤ÌÕiì¥¢IË∏Ø∂÷÷^#Ûû8¯%ïa¨z•û@}$LwŸq-sOƒ!eú£ub∂∞’#sè“jI˝&‹Å∏íchˆÑ<g[‹&è(Ø6	⁄@ò%3ÌA2#âIoD9^Å,≠ÕsÅ‡è‚èÈÅÈµçÌ'¿ ⁄Ø∂◊KÕL[[≠ªﬁI¨ XÉ‡í∫,≠Á(Ω¿ﬁJ◊KHisµ›G”µ’VœÂ}' ûE{ãhêuÂ©.ÍÑ–¯Ø›¨ó9Y•î∫˜∑πÌ>‡tkJﬂt<TÒÒÔ.{≠s\ÌhõÊP)åÙ$º˚€hç/tí·›R≥¿ç∫©£Àƒmn¨1Œﬂªﬂ…5Ω4¥2÷3‹F†öbÃ2˚º´´∞xî-ƒ<ï—ø¬◊3`<ÖR¸¥:ﬁ?™Ö.≤v.D¯%Í#‰“˜=áP`N@q–ûH	‚ï”6∏ì¢∫«ÿ=ïZÈ|LBûÀ~]îr¶Pt’wËt2J√˘∆<ª¢ÜÜjˇ óöX’Yëë¯4≈:"÷ tç∆∑^7ü%*±ﬁ\÷π∫«%l∑¶\+Fêuñ•XLhl¥H∏©DXe1π6Û¯Ω6«9ƒÒÚZ#ßV›@.µkSY¨∏&	º|“ @˛I	‘«Ók¢*Ò√∆ê∂4ÂN™Ω ˝§ù4.ÂπØ˚vç\9CK\jvD{§≤…Ec‡π§ë¨ õ´.q◊€¥T2Xeé˜ﬁcÉÒˇ §`‹Ës`)&ÙÍ•µ“Ë Å‡¢t∞?>
õ˚7ó5≠ «…1cç¿√Ñx˝‘€2˝Epyr`‚X ;õ:k+p›¿˛rã@cCd«P?Ç+lR
 s»⁄œ~Jç§á4;^@’6˚/-5mû˝úïé- n-›°Å ˘ ª™Byq0`ju
æ◊Áp&4-ﬂπÇgi‘4<5B†SúctÚﬁ
ECF%µ ﬁˆè†>íùª°„ÿt;@IÏS[[æ—[Ω0X˜ÉÓo˚—ü[Ω•°€ª¢*Ωê—]{_∑x<7Ëì‰§÷∆N‡Òo“”îı1¨≠Ã⁄ i®˘$“=`vÜÜù˙_ÇØuû„Èí\Ÿì©rß[O∑‡tÛJ∆ÿ›œ`kü<¢SÓ¥‘¿òp¯Î¢(Ë¬ß4ZZÁá∫tÅ®iÒOcöÍÅ u`ù'∫ç{}P¬[æuè§>*V Í=∑˙;	õ#˜yêÇ∫§ÄEs¿ù|T˜˙«ÙAénõπ‹3Ù≠≠Õyÿ◊hGká%E±ˆ≥Ìx-‹gb*≠’cÓeN?¢c‰Üóˇ 7 &3‹iıCı{x'Ö70∏ºX¿ˆœ—ùR•ªZÊmÄ>à’£…$)⁄—tÔq$hﬂÕ¯¢∏á¥¥∏Hù8Ïö«–w ;àùÄ3†÷>I!É¡Y4Gò¶Áó@˜:G	0r6Ìë¬g9≈£mÇ∞;¯¢é©`Ç{àâCc≠6º¥ˆæ	⁄∆ê◊bGﬁë˘†~$§ÜE§2>)ò¶D¿˜RRuì¿<&¨85¿˚IILã\@â)…25Å(óë\Ä\xòük$∆º$Ö¡%¿ü.«^<›°$˛
Q¿ÛEKí#üägá%¡¨ÓìNé3?ƒ∏¡yˆILΩ•¿ƒí wvè-ºÈéÌ„P‚íüˇ—Í$1ƒmqZÎu/µ≈≥πÜ<âH†Ìﬂ :î:∑zÜ^5Äöœ›Ü]5ﬂçµŒv◊rG)È≠å©çdµÉÄySΩ◊W[v4A˙@ˆoä#wâ◊N{$´5ıiQ∞Âºã\Á£<1O& Ÿ¥X˝§ù<¸ëi‚K||¸‘rN¬÷Aë=í]~•AŸ∫`FàX€ö«∏<û#@¨ºncö·⁄
Ögß¥≠4ëz4y;ΩJ‹÷5ƒI˙#∫.Isis´fÛGƒ¯!Ωç˚D¡‚#¥&ÃsÖáö„áèÕI=bèé8£’¨TÈ˛lB≤,ÀkdñÎ∫a∞U  Ùò“„∫y<∫ˆ¥˝9=öíA‘∞ ’>∑1œc¥%∫íÜ.=5b∂°Y€∏“uë‹ï.¢Z1å›Ët∞k¥ -õh¨Ó:…ÙâÑï~ëÊ◊yÃvkX67ù⁄ü‰´πµ’cú‡÷IÇ‚≥«ÿ›’w±Ø˚@A˙ÛW≤ÒIÙò‚LÉÙ\íà‘tGCÀqCùdõœüÇïµQm¡áys`ˇ %ﬂ5**∑“h∞ç”: P.∫~–`è—~~‰ï‘“wÅ∂¬∆óΩ∫m˘p±]i«.uFó£[µ#‚•êˇ Jªc» Ã@Ö
.Ø#{wö…„£ù™HÈıehxp˜6?;«‰âha≠ƒ$T.s∑¥˚OÁx%ªSÓÁπI]ê„÷÷µ¿KŸ n“r¥≥q!¢8›¸Äˆ;v≤~ê‚PãZmÄ”§jÇMíÂu\J£s!§Î wÛYl¨:∂µ⁄ÄO‚∂zõú$H⁄L,⁄™w2†À*l„˘l§´∏ÌcI¯j¶jh+X∂€é‚ÍÃHÉ:Ú†ÊÇI'û πílﬂÉPQΩÌ  ÷˚úO+Oßb1∂9Ãs]'∑?5Zù≠Orµj!—≠#˜;´xÎÑ1e'dÔ‹÷ ÷4˘8¡è=∞¡§ò‰°Ÿ˘ÆÅÌ‚yFÍ¡t9RµŒ¡!¿∏ñµ∫3>hWKÿ›üù˚√¡ç 8¿ÓB±Ø6ál–~tÒÚA#t∂nq—ù•ÜnaqsfπøG‰à˜5≠3y.„Ê£éMåv–”†€ÙHÚI]euov‚GÛO≈N–"ΩOtjã¥xhò<¬%¬wâ"4<$Æ»h∫»⁄cëœäw{û íNª{)R–⁄›RDâê
ò{À%ÁS˝È(ùKÛªq“{®≤π ŒÄ¸˛Hè∏}=yL¿·µ†pf{UËçïw'^„‰ïíX–” Éﬂ‚§-gØ¥9∆¡Æ√¿ ¶∫»`ÿ@$«ª∫I÷¬M£t@ç£C¬Ö,€[õ±¨1;AñÑπÇÌFÿ?Ët∑⁄ˆµõDdˇ ë—{âék	ó«…9sﬂπ∫8Û—B⁄CùSˆ∏ë˘√±é˛JÀ√ct-ŒI7≤*Z@àçÕÊ>
'è_i æ{y•S⁄÷5ÏcÑµßÈÛ2ôıáﬁ◊CÀÜÄÃ0¸êWS™cX.¥…Ï; MüKi A€ÃGiH7RËóç?z1^K„Q†íH≠ÊxÔÛEÿø∏^≠Ä•`0˝8¨Z›A‚·#_$+[û,,”®˘#Ì&÷DG¡%Öf)‘âlÕ‡¸î-y4õø@ÿêO≈ö⁄ÅÄÄGÒOÀD<7N|BH±jûA!‚~jR⁄⁄¿}“Hyô%3Vô DGe
¿ı\`Kæè¿$´–Æ˝˛õ@,owO9Ö!Õ!⁄êtÏSÏ•°†ÄbìHì”€ÑPÖég¨ÊÜ=§sùÙOıQvÅªP 2{®øÈá8∏˘vF!°⁄w%¬≤◊∞ñjæ)=§¡hrë í–È1¨vI≠ò§ë‚íN≠=°&èvÄÅ‚S IçxO≤ª_ôI_ßRGÚSÜùúLq)ü!§Œ¡‚k!’üqÚ∏E=zçŸ∏n˝ﬁÍQ£àObÖ∫œR=!ÏùUÄ=ﬁ3Ÿ$∂FÑFú”†è≈OPtákˆÄ·ª‡íó.ì<x$G∏ö∆ÜÌhS ißÕ%?ˇ“Í+4à>Ñ
X∆æ◊zF±¨æuqÒ
ËÇ–ò˘*î2Õˆ8øq$√O	¨‡Óá:‹qÈQiÈtalÀïñ  ÁcZ iÚB»6ó÷≤”.∑˙™√Å-ê$«)$Ï^ã){û*v˜7Èy(Â9û≠fÀ\—1µøú~Jxû±iıjm_…iR∑‘73ch˙D˛jJ˝/Ìgipc»v”˘øÌQ†í¿È‹{û…Ô%µΩÕn„Á›*ãΩ6ó∂	ù	#¢6õw∫6§jHK3’Ùb∞	qiûTiÿo{Ω71¿ù≈‹i˚™YûõCâƒ {í{ ü“€[ˆ≥Ç[©(,ué»qu{#@Ôﬂ!ZiÅßM8A§1Æ{§ù≤LÒ®ÿ_Y}P÷¥ÎÙ]®D•Øÿ…Ç·;è‰ïÓ¨R◊8{\FΩ‰§§O⁄í∫5™-9ªö\5 }(˛RlÊ2ÃmñZj$¿pÒû1=7‹˚)KúC‹|B±î€v∑cCµ÷uÅ˚…t\tê^ä´Æñ0Ië:ôÛUÍƒ®dæÌê˜ùI◊A‡≠1ØkYÓ∏¯¸Èæóﬁ˙Î%Œ`˜H0Ñ§ã:≥πñ9ßf›∆`;ÇÄœk .ƒÈiÿ"ZHc@ap<Î¬ÉâÜj]‰íÜÕ76´2dó3ÈW'dÛ(ñ<äw◊V‚u5ìß©Õs‹CÅb?äÕî8∏Ç?úné†…‘U∫ÁV¥1ªá¥Î
‹ñ∂¡6…nÆÆ5¯¢µõkku;H‰˝/äŒÀ‹Î]∏7à›Më°k¢-k≠qsù"IzÀv°÷4é›ëXﬂFr≥´cJ§çÉ®Q,÷{ˆSŸ"4ÛQ⁄‘UªﬂÆÄ-<6÷Áq„k)¿L˝·]√∞1Ü∂˘jOâVL|•fQ¶ç˜ l›†£<0Ç–“È‰*ÂÏ.€ÆÛÙ|≈«80ó ˙_eÆFÃÈ⁄ 6ü£0<~vÍá A‚{}…ÿIl¥˚	O1‚Ñ˜∑◊ΩCÙI˙%%©l=Å¡Ì#N*-™≤ ±¢!‹{˘ –iq>¬Hç8◊èöH}ã⁄‡,&I¸ﬁ≈„ÈÔvû—˚∞ôÌ|∆ÊÌQ˘‡˘&∏Ω∆@ [… sÚI]ña•¿÷[«∑í’ºG∏O>òÔΩ*CkßGòÅÓ~Æp'YP∞Xo¨g¶&]√«Ä	'©HKlêHí@jU¥∫†u8@>jvAiﬁNﬁxB¨˙µóWπ¨ë¥C‹y§ÆåÚÏ¢“dégH*Om˚Ëµ∂˜Ô“u‰)Üùºˆ˙R•}m:9˚OÊùRUÍÌ-kŸA?ΩØ8Ì®>∆÷◊∑˜ãß];#!ë¶§·¢X»uaœ.–∏;Äfîï–±vïV‡˜ñÅÆﬂŒÚ(ÊÅ”ßoÄÛAΩŒm`Wg§ìÂ=˛(Õ'€ªì#NQ€Ìj·=∑õΩ≈Æ ˙ö√∞ÚDÀk^÷kÍ â·—˘•ç˝9÷G;FõBô`‹\@òòIDÎjce≠sµ–âûTk®ûd» ôîCeM$¡ù£¬JyÚû‡§ã+∆¿‘rß:0ƒ¡ÇTL5ßqw=πÇô•Æh"@I˛)!y;∆‡ûD4Í– pÄK~—¸—qgdcÆÒµÆßÑïK…Ù¡ÜŒæj.kÀ√ã‹@‡vRÖD Ì	˝ﬂÇãÃ=≤Ú<˘§¢†œi⁄y3¬çsµ€·ßÀÖ9ÒÖvÍ›•†û˝“GE>$«hS hN¶!#º2#≈;xlùRSNÛÏoàÓß°ˆ…tx$C˝†È…*Ω◊äXÎ-ò›§™≤ô≈ﬁ÷¥YAmıõ˝9qp÷5⁄¶«◊emv◊I‘O?4¿‰˙∞Z—WÔ~rIR{µÿŸ3ﬂÖ(%¶` ù¬AQcK	ÒEj˚I">ÙÓ$:;BgD	&|ìêÈ)Öqºƒüä!–Ü”‘ì(∆H#ÑîX∞	‡¢@Ö
¡ôRòIˇ”Íö‡vóØ-˙<†”mn∂¡[”˘Ô#€> £VN—¡˜qîŒAiq'k[∆ﬂÕ’5üª™±M’æ◊√F7≥âVú ‡"r@-4µÆÉ®?öâ.-∂_~ú$£∞’§ˆΩ’ªp&ßëÒQµîú∂Ô±€¿ˆ÷	 ÎÙ¥E≈kΩ{=#?CîŒ†b#[;«Ç]~¢æQ>ãö,ô——!™T9Ø®l$çu*9F1ﬂ∂Ω‡L∑˜æ	Ë6:ñ∫∆?˜Aò˘§è—˙±®¥⁄·∫\ˆ˘)‹G“héA˛u9€ﬁ67_wr´ÁåwYK◊2»·«¿§ê._»∑Z›5”È “Ès€º9ÌÕ%45€£U\±ıΩÌ¨÷”'qÂ⁄¡Ibó"“–œ{@?H;∏˛J(" òˆ˝Í¶[ãn°≠£‘.'cœ¿Ó|’£ªq–F—ÛI$hcë∂√º;ë#∑˚ê≥æŒ"Á∏√”€˘Óö|í≠Ÿ?g∞äÿ€dÜ◊˘ºÚc≈O)ÓÇjk;“oıOÈ&Caº6[Â*æ+Óq±÷÷):√{ª¡«‚¨oisŸΩ§ÇZ>ì| ©Ñ⁄´9∂˙‰çl3·ÚIcÙaô∏πÉ◊5˛˚GÁ∂8ûŸí ‚áôøÌ∑“n•è<¥ˇ µœh&và ît[É˝W◊QcZ]3°.£ÿ,'s±±i◊Dÿ¢»y±¡ÓÙtl&ønˆL˝2óE˝R%å'ƒªÕUÙ}\á{H„é ·ÏNÅ¢$ˆî*ùg®wê@’ªO-ÛM"˜P5uŸ… áπùõ§¢±∫&{ö˚ˆkåÑFƒk°YÛ‹∂z/∞ò ƒ$ÌDQÁ«oˆÿ&-ΩZèa’ÒÌﬁLh<äE¶
T:ê'XÓe&3Íiñ±-◊˙ÜZX>ìG“ÚV,xppùáÄPX«}¢H⁄»˙~sÙQ›XsKX„3?Dï†¶¥UDzdNÚ5›ƒ¸oQÂ¿'ä„_å¯&a5VEÉ]5*eáw®6ÌÔ˚»°r–˝Ì"Lªo<rïAﬁãÀIÇ$ÍÔâD{àó∂uêÜ¬˝è˜zéâﬂÙA>	#ßÿ¬ lmÖºh^≠hÔkòÁ9¶4N™ä˝F=Ìqwpù≤{êH˚ˆÛŸ%≤
À≠®∫¬“¯âo—ô‡Jw≥Pvƒjï@ù¬`r∆öÀÀÉ§«—'¡$ı†ëÓwÊ»w˜(R˜zD˙õœÒå´Ëû‰!4÷ÌÕ§Å¿◊îñÙ˚∏\nl 4x?Å
w1ª$¥OÊÚ%L∞7¡.è•ŸI€û'o~I&ˆ`∞5ºNá˚‘«eŒê8—õÈÇtØbôÔo©#n˛ ¸‰ê/VEÜLÚxL£CÓ‹ìã¡q kƒË <{¿lÅ%2.q¥F»Ù“&∆áπÔlÀ∏≤≠p∏>∫€ Ay˙{O`éÌ∆x éÒI5≥πÆÆ^ZLà-˙%3Ï∞Y¥«'‚ûíÁ5¡·†è‹˙";)<¥àøäJÍ…¿ê}≈º˛‰Ãçé∑˘ûTÑπ⁄pLóop:hBKQº∑{8ì˛j1|©>*.#k}–#üÅ%¿ éR¡ßin»∑)ú,Ù∆›£«rU[V‚∆íHÊS∏5Õê“Ë<$û¨∑7€¨√IÙâ>ë@ˆÇDÎ˜'vÈ–à¢ãPÄŸ◊∫gn:°◊ÍÁ…„Ö*√É@à¬J•ΩYqÃ˜·C#Ì&Ü¥∏wùåπ∂eÅ¿ükb!Ìmç,3¡$ËÍ¬Ω∆πy›„ÑÂÉvÌÇUR ´Ù⁄4N©‹b<§é∫.fy–èöçdNß‚ß¥hTΩ—(°ìû÷\Rl<;$FÊùº˘¶©èÇd˘$Æåã_∫I‡â
$x©È	 ®D•°*0'E1¬Hˇ‘ÈË5>Ü>±ë,iˆü∏°b[C›i§í‡aƒÃ<j≠5≈Õix⁄Á9Ç™„í˚Ωj⁄ õ>ôI—‹è4ﬁÃ˝Òaö⁄Ωf:À˝#¿lÌ‹U∑a ∆ú˘™˘[%èÙ}G∑Ë·íj.è~—Ì?ë.™;E´”ZÒ[‹Ïè¥øw∏˛kOÄV⁄€∆Î Üw.A√≠Câ¨‘–Ë-vÑ¡NÁ<Â≤øCsyı§C¿•—'rÀ*~œ∞T]Ù]·'ÕÅ∂¶¥;xÉÔ:í3}!HTm¿h˝„¬±QX€0‘ê~QÊ◊†R2,k.ﬁ¯$≥tÏ…>C¨ad9Ä›œˆS“ÎZV¬uuüº|sô_ËiuÆkΩõyıÚI?§ﬁhw™Ä/ÿˇ £∏iR.§∆°†«í©Œ-c∏ûRZ?É+Éã€6∑Ûõ‚{)π°≠y{ΩΩ«Ç∂{+.'áv∫3€-xç∆5Ûí{4Yé(x≠∆∆ûl◊›Ød<÷≥Ì4˛ÆÎ^	Ù‹>ã|wJ≥å‹vÜ÷tØç¢xMí2=fm±¢ì"÷˛|ˆ⁄áE◊Í?^¨˝65Ô±å«4nåp
©å¸õqﬁ˜±µZOµùÜ±™æËÇ	“ÉÚ™¥6∫ËsÀãÿbê]¢(O±M’YSﬁCŒ°øæ·ExÓ]∏oî%ê÷z¨wß/ Ï=á≈=‚‚4$˘†ª≥[”n7µ•ç:4;ÈÛ›5Æk-h6ÜóHŸ‹ü$¯˚Hóop#{öLJÆl.Í"ØFlkd]ÿ1›í]‘∑ˇ Œ<˚∫*u±µ„XÍÿX—Æ˙Sƒ+üM∂	êÔ?ÖÍÏ∆.íÌ◊3‡õ-èíc˚CEå ¿"¥y&hó=fl∑l≥òO).™Zâ´VtÌ0òH'∆~h‡;∫êh<˜Óù”lõê√í¿7˙Ü}ß˘®ÊOöµköCÁâ:∑ëÊ©zÃ˚Kh.i””YÒûahYTµ˛ÔLùº»Âh«f	P!AŒ¨!Æà˙QÁÊôÓãæÑ˝NÑ|kèHÔ!¿	‚R-h:∏´%=mÍTIõ˜8Å¿•âÍ>Ø“÷Ë÷±√TˆçŒë†D´s}zghÇAvâ-'O±ï’íGøiÓﬂ$CXÅﬁÅEÂ–◊4ÚTó¥èo“˛	-÷Ék`ﬁ@,iíAÒÚR61’µÏp DèÔPÆ∆ŸcÖNqŸÌv·|îo´!Ìg§‡5€ª∑∫K´]My¶ﬁIh”f›GÁœ˜!Ìn◊◊`p'CÓ:Ú˝Ì$AûHêÒõSZ¯'lôûGí(“ïmÏc⁄«=¿∫  K]Â(Ö∂`√£ì®
Oôf›ûK‰ûLOñçI≤*ö\¬\@xëÙ~J{\ É˚zùÿ;¢c∂KΩõ9ˆû˛j7‘€‹—<∑D∫.øRG{€µ√sH·ïÜñ2≥PlçÖYFè/§°[“˝If{|[zcKöË◊πD-ó	Óﬁ|Tm°∑9ÒXÓΩJ˜◊Ç‡`G#≈$Í∆ä√7≥n‚IºOt˙¡$¯w
5m9¢√a&`˛h
ñ◊TùÓ ¡ŸÙíWT∆Cõ¶ÑCì≥WF›£Ú¶ik	…V≈mmµÌ≠œv∫áÃÑ¢™–¯6liÿ6œÚ∏	ÜÔo4J⁄⁄*’•˛-
lh⁄”ºGDmi{àÉ˜©Ôdò$s)ßÙc˘Jï∏á
µù…+vZG∂Hû¸®õÍÜ44Ê}ﬂrj¡sZK˜OÁx°1∏ﬂk;XE√óûI5øZMê?D‚Áñﬁjù,h≠∞‚·˚»éH#Eÿ>	"Ù¶%ç/›∑Q›H»ì=∏Ps$ÍI¸àΩÙ—$!¶Hq2~*E¿ NâöO®At˘)<”∑B<QOU˜H%Cmõ˚˛*mù∫ÍSòÑê !&˜O∑MS4 íse8I∆q®I$Óé»Å1
]íQˇ’Í*‹⁄X«;’ty”Ú*ÿUÊãn~CøFLTŸühÓçä˙_Mfπ#Ç5”≤b∑6«1œ7ºj\XÄ&vg˝·˚‰◊{û«VÌÄN˛ˇ S∏çvàöØ‘+Æ∆5ñ\*Ò3≤Gí≤÷èI†Ã⁄ <»E]CëÈn»⁄ÁÓ–3Äπ∑;)éEBw3ô%,V1çsZ˝∆DÎÙJÅ¶±ùÍπ«y†O∑D:'©ÚÏíÛ\ª±<rßXpkdÓpÁp£ê Ï§∂” ˜B#=6Üühz+z}Zµ£{ﬂcáß1Éóƒî≥FC€Y¶¡Aëº:µ>)´÷∞4πœŒ‡aæA©}óÏ„ÌŒf‡—&IK¢Ô“~±∫AÉH†P-;uÇ«œo¢5E`kX–”ÌZ{ÖGß_çe6ä™}l˜‹gêR@0€∂–€Å≤uoyÌ
n›µÂŒÌ?ªßt\—î∆
ã˜Ç}_Õhoä%≠ae√f˘ùÕ<;NUlµVWe$∂¿‚{NõÇV˙bÊË\Û0;DÚáÄZq∂üI∫m¨ˆ ©\2éC[DÀ…’”˚°%u#Õ#åz°¢^4◊é4C∆úplhcŒ•ÉÜüG≤«∂ÊXÌ¨qÜ˝&∂*∂Ω°≈Õ‹tÚRWO±‰z†4#˘øŒ¯àÏ•l48˝.‰yBOÊ4
ø7˘Œ€gË©‰∆9”±£øÇª5ÒÄ˚;CY±Ñç≠<«öØ≤„ô%√–Å∞•øº´,u~ìq-±¬?H˘!4úË¨ÇZ“˜ìÏ> íÎ›YøJÕÕ64ŒˆÚc¿!ù«≠`\–Ÿ˝‘L∂?“ÔI”;áÑ˜îJò¡Hí\KÜºÍöE§ ¯¥çd8˝È¢~(Ö∑ª,±√Ùq"œ?›NXF™ÜHYDëñ˘)¸—6ò	5∫«‡£•Z=º˘"WPxüÕÓ§Z–“Áh;ì¿¯¢cj›5üŒèiÛS‚≈dZŸKD—ï≠[^DÄÌ˚™—mç/ﬂÔi2ÄéwõáÈ<fûÓ?º≠\eéﬂ£x”· ∏Œ·h≤ù≠öZ ÜèkÑ7»xñÇO.“ZQ_∞ÜªvüO≈MﬁìHﬂ;ß⁄|J(ΩY
ùá1©Ô¢Ü7™wû€]®‹—HÏi3$jTÿyˆÌ3«Ôy¢∂Ù(Ækv¥ÌsãH 7«Ñ`@€›–TI~…¨ÌÌÓRÏÿ”Tî¬üQÆ˜êÈ>¬;4◊äÕc’."u-¯¢5õm0“]ÿ˘&p&∑
›±Õ$n"uIW≠≤kH⁄Ô	ÅŸ3]π∆H$4„Êú§ôÛL÷èPç°≥…ù¢H`ˆ¥Ì;Kú<
(Ïq©Cqkko“ q¸‘¡ 4nÇdÌÒIEç@4:\\5‘ÛOÀ&?ävüvé&`(ÁVŸ`sßQ‡|íWVAﬁˆ	ÒÜ¸j/ﬁÌŒi˚#√ÕH±ªö„»ë*≠VêÊ˙&°0ÁìÌÜ‘íÉ‰î>ˆQ/Ùö˘>LÚÑ@„:ﬂ∆|êr+Æ vŸYsXth‘¸B#+kÿ◊AL∂{häçU¯±k-m≈Ô-ÿ~à©^Î[ãÈ—«Ä´≤ÚÏ£I°Ã-‘ÿ~âJ’ﬁò≠≈ÏñZ5C¢é‚◊•ÆÙ€∏ÇÓ‰w* X-·∞pﬁÚùè¨sAk{ £˙?\ñ∞ÓÓÓ»£©I'ió	ûT‡ÊËÓ¸Ñü∏moª∞)Èkã%¿5›¿I]„aÃàv¯ô¸’f∆4∞Ç›ﬂ…NX·h26¯wSë$ííâ€…É‚#≤s”!&8Lœ≈'H!£‚RGU8Û…ÚQ®8¥»⁄|
.ÄÚ†à§Æå∑Cu)õ¿)HKX¢•µÏéç'íòê∆©»ûtIJlÌO¥O*-l'I§§©ª§9IKë*C¡ 	!yO**Q¢Hˇ÷Íkx⁄÷ºm$˚@¯*Ï»€MÇO™8’X®÷¿]Í;ªïqˆÛú–F(‚usì:3ä◊mòıãÈ1◊Po0ÿú≠5Õ,hl0O˜G…WÍ-Õu ·Àw w}ì™<X)óê€6çÔnÄz´†˛(pN=åq••≠'W8m. ˘©9ˇ Æ6øMƒÙ«—l&√9?•7πén·ÈÏÛEy»9--rÈ˙G»%—GÊ>]ÿeŸÈRÁ±Ç›ßVÒ›ß÷◊ñÌqDˆBÀ˚GŸ›ˆp=iˆœ—Áíã^Ò[C‡øoΩ√A>I#ÙGõO.ÀrﬂH«s+dá\NÖﬂ<ÁñT◊WO¨Ì√hAÒOC2C‹˚∑“D2∏|¬Y’ﬂe Sh«∞¿.Á€ﬁËªN û$4¯ÌŸW∆`YÎÜhO¶∆~Ï˜¯´-iŒ‹C}««ÕR¡e-v@eÓ∂–b¬‚NŒ„€Ÿ$äKÜKÆd<UTK∆ÑÓÏ3ã°„Üè¢ÈÚ¸≤}ckıw˝ËVµÕpÁH# W@áƒ“º9Ú78jAæÃqó[l>÷˜i)tÔ≥}ú≤Üê∆:	"$è à˜‰}®4VﬂL C˚˘Ñ∫'iØÇ[Z-5çœ2`Ò1¬ º—Y≤∂÷È`‘4GÂR∂¬ ¨781ívø¿GtR1Z÷^nŒÎ'q.ÓGË˝V{âÀÌÿ#Ù@ç˚º¬%˚]]ªÅµÑôdp<j™±‘,±¥m±¡°ˆˆpÌ
’“jqüH…áÇzè¢6óñUDªËüÕlhPòÿÀ/6ni¸Ø4vV“⁄›∏ò$œä´]ﬂØ€L?OU¸≥Ì#≈$éµŸ{l¶ÏB˝¶Ê>AkyÊ!Å¡ï∑Fì»hy$UIfÊ–\Hc£€Ò*4S[´•ÂÓ∞∞í?Iƒk>I'ß‘≥cXr`jÊî˚=íÒq O	ÿluŒkÉZŸ]˚„¡'ªÙ.ëÍ»⁄? Lî›VoÏ`+%Ä∑]`§⁄⁄mû?*ùmw¶»ˆ4è‰«a≠9ÖÌ| Ô›ƒy¶{1∞i6ud‡√Uõ˘sÉö~Ì©©≠≠∆hççCõ|îûO¶„h–}ºÅ‚üó◊π∫0¡i<êTÄØ™‘Xp™,çnÊ‡≠85ﬁ£Ù†}ƒ!9Ìıvwë;<Gä∞Êàq‰ò–"¢vÚCèP¢í¬ lñè-Q‹KÄ--&Ó†b±ÅÆ-4ÃóŒ‹ßk∂zmóµ⁄G—Û)tA÷I⁄‚!øõª¯!’mnµÏcãã8Õî@Gµºê	ü$=_]¡ÔköL÷Ù¢?=Ω79‚ß—kÁVÃN©ÁFv·†ÏH·F¡∫ßn&∞Iﬂ§<‘òj«O$$ÆüU‹aˇ JOÓüæ≤Ó¿¢ˇ Sv—∞~Á|ªgßfZﬁI¸RWeÎ1 ®˝”!6÷æ˜1Å¿¥√ßM<B|gPâµŒÂ·I¡¬Õto29¯$û§,MÅê«¥º.<BìZ\`8	ó˜ü€k«°Œ∂∑®fß^Ëå,⁄»$}ÚÓí∫Z,{Á∫)uDq?ú|ì[u-∆ı-ﬁ÷	‡¡*≈ÓkÚ=aÀXyg≈ˆ⁄Í∂‘ÊµƒÚÓËì\CËµ~ˇ MÌ$4L‹´UHfV∑5'cµâWk1≠:êaƒ!êÒt5Ä0Îøø¡%ª;C∂ø`ùúkv∫Zø M~¨;ôºO—HmkKKuÄ<[—…uç5é˘»∂ÔøkÉ]Ÿ«ÄÑYKr$0õÀª"⁄–‚ÊÓ⁄íN„¯-Hq¨opsªë¡)ã-›º~Ôu*^√\¥;'ÄH1'≈$^•ô]y
j§wÂ
,$Ãüπ$tccÜ ¸Q'ÑŒg∏˘'‹7G$§Ø%ò n§‰ô‰9N¿$ê!F¿‚ªRWTÅ¢ÿ◊áù—°†çe4 È£∫Œ$Î‰ùáM'|¯¬ã8ÒI]πÆ/tëL ë1IJ$ƒ &œ)¨œ…%*˜Jìa<$ã^4M	˚&JJ^%<¶)vIˇ◊Ë1[™°‘í∆I⁄◊ÚÔå¢¥ñ]Íœ∑J¥—y
IÉf¡‹˘÷ÛÍuî5¶¡Ii›1ÌùGÕYÙö¨ÍH^6í=Võ·eıôççKØm7˙é$Àˆ∞Ã˝n«„◊õW®‚-pÜ~ÎäÚDê/?1ªÿæ∑ò∞»}Ö≠'È∑ë°òıµè/lq;ãá≈xÚHıZ~_ãÍ∏üa˚mœ•ƒ›{u k™.eïQé◊ﬁ{dùNö‰©!—q˘Ü˝<ﬂeÑ˙ÄsD|>
Ω.÷öK$ò˜˝À»íE`ÿ˝VŒ}¨∂áSé.$˚I–≥«UvÕ¡Øs˙H(«x‚I$ÌÂ’ıÃëˆ}Ÿmvì;¿ïjπŸUø÷5“µç7ø¡y*ItWÈ∫æπûhn-Æ∏Q‘’¿zx®c∞UQc$ “ ù>íÚTíÍØ–ÎªÍåf[s`Ÿ˙ºÓgª≈§´Y6WM.s⁄\¿u¿+»RC∫NÒøïˆÁ÷«ÌçßëÊ©ä2Œ®oåq œÔº©$T7ïVœ¨eñ‚œ]íA`Áï,soß\∞3R6Ûpºï$∫ßÙ~Ø™TÏaôÌ|⁄tÙœÊ¸ì‰1ˆc<Q,±•€`ƒøÊº©$‘}7}g≠î0Z‚ÁL∏ù}ƒpùçµ∑KÑ3M§w=¡^JíH÷Õˇ /'◊_;∞>NáÑ‘Ç⁄@∑BH08K»“I>øW÷][Õ·˚DDo¸·Ø
ÃjË–È%xÍIKßìÏ-c∆ÌﬁÌ8	Æ‘¶tñ˛˜íÒÙíGWÿõøpÅ€Û¯ b”MVŸËµÕ6;uÑÒ'¡y"I+°˛_kÏ.ê◊ÏÇ·1ªèÇã,‹»0ÁÇ7«+»E]X¥Rr⁄MéÉOµ”ﬁØı}7˙PÎ;5‹%‰) ü›˝ØÆP\ko®– ñòäæ‘NÚl:˙}æ+…E]OÏ}{#÷5∏‘F˘”pëR©Æ5ÇÚø;„‰º}$ë˙=?kÎMÅî‡⁄∂∏˝+?xvó◊S™"…ùcêºÖ$ì‘WÉÏñzm-òÌ=–ç$dÔıå¢Û^HíHfº_d ÄL¸¸ëÌvÔºy$ê˙›¢Òê-®÷®˜‰¨ô ôè5„i$ì”gÿÎçdœòQ∞ù√›ŸxÚI#´Ïªyï¥ØI$>«øA!HËç$íü_°¢].’·≠lëπx‚I$Ó˚\ŸàL] ï„©"≠-ˆh	ö!x“I!ˆG)	+∆RIO≤ÅH∂Wå$ího	Ã/I$>“ò^.íJ}™≈RIOˇŸ
endstreamendobj23 0 obj<< /Type /Page /Parent 11 0 R /Resources 25 0 R /Contents 24 0 R /CropBox [ 28.8 55.44 566.2 801.67999 ] >> endobj24 0 obj<< /Length 8249 >> stream
BT
/F4 1 Tf
10 0 0 10 493.49 85.31 Tm
0 0 0 rg
/GS2 gs
0.006 Tc
(455)Tj
ET
0 0 0 RG
0 J 0 j 0.48 w 10 M []0 d
/GS1 gs
1 i 
28.61 53.87 m
28.61 -1.33 l
567.17 53.87 m
567.17 -1.93 l
-2.83 53.63 m
28.37 53.63 l
566.93 53.63 m
596.69 53.63 l
567.17 841.91 m
567.17 802.19 l
28.61 843.23 m
28.61 802.19 l
566.93 801.95 m
598.13 801.95 l
-2.23 801.95 m
28.37 801.95 l
S
BT
9.5 0 0 9.5 85.01 693.11 Tm
/GS2 gs
0.004 Tc
-0.053 Tw
(homem. O per\355odo de incuba\347\343o \351 de 2 a 5 dias,)Tj
0 -1.099 TD
-0.036 Tc
-0.07 Tw
(podendo variar de 1 a 10 dias. Os principais sintomas)Tj
0 -1.112 TD
-0.02 Tc
(incluem o corrimento uretral e a dis\372ria, geralmente)Tj
0 -1.099 TD
-0.001 Tc
(sem aumento da freq\374\352ncia ou urg\352ncia urin\341ria.)Tj
0 -1.112 TD
-0.006 Tc
(O corrimento pode ser inicialmente muc\363ide, mas)Tj
23.432 4.421 TD
0.004 Tc
-0.016 Tw
(em 1 a 2 dias, torna-se purulento. Comparada \340)Tj
0 -1.099 TD
-0.062 Tw
(uretrite n\343o-gonoc\363cica, o per\355odo de incuba\347\343o)Tj
0 -1.112 TD
0.003 Tc
0.023 Tw
[(da gonorr\351ia mostra-se menor)54(, a dis\372r)-22(ia re)28(v)23(ela-)]TJ
0 -1.099 TD
0.004 Tc
-0.025 Tw
(se mais comum e o corrimento, mais abundante)Tj
0 -1.112 TD
0.01 Tw
(e purulento)Tj
5.5 0 0 5.5 355.61 654.35 Tm
0.001 Tc
(52)Tj
9.5 0 0 9.5 361.73 651.11 Tm
0.004 Tc
0.012 Tw
[( \(Figuras 1 e 2\).)]TJ
7 0 0 7 255.77 759.71 Tm
0.009 Tc
0.049 Tw
[(Re)26(vista da Sociedade Br)9(asileir)-8(a de Medicina )44(T)123(ropical 33:451-464, set-out, 2000)]TJ
ET
0.24 w 1000 M 
/GS1 gs
85.17 631.43 203.86 -135.81 re
306.77 631.33 203.86 -135.81 re
S
BT
8 0 1.7 8 85.01 474.35 Tm
/GS2 gs
0.005 Tc
-0.058 Tw
[(Figura 1 - Corrimento uretral abundante em paciente com)]TJ
0.185 -0.87 TD
-0.001 Tc
(gonorr\351ia )Tj
8 0 0 8 120.41 467.39 Tm
-0.069 Tw
(\(Foto gentilmente cedida pelo Professor Sin\351sio)Tj
-4.425 -0.87 TD
0.009 Tc
[(T)110(alhar)-21(i\).)]TJ
8 0 1.7 8 307.13 474.35 Tm
0.005 Tc
-0.058 Tw
[(Figura 2 - Corrimento uretral abundante em paciente com)]TJ
0.188 -0.885 TD
-0.001 Tc
(gonorr\351ia )Tj
8 0 0 8 342.53 467.27 Tm
-0.069 Tw
(\(Foto gentilmente cedida pelo Professor Sin\351sio)Tj
-4.425 -0.87 TD
0.009 Tc
[(T)125(alhar)-36(i\).)]TJ
9.5 0 0 9.5 99.17 433.91 Tm
0.004 Tc
0.092 Tw
(A maioria dos casos de uretrite gonoc\363cica)Tj
-1.491 -1.086 TD
0.009 Tc
0.139 Tw
(n\343o tratados evolui para cura espont\342nea em)Tj
0 -1.074 TD
0.003 Tc
0.016 Tw
(algumas semanas. Uma pequena propor\347\343o de)Tj
0 -1.086 TD
0.103 Tc
-0.07 Tw
(homens permanece assintom\341tica e n\343o)Tj
T*
0.018 Tc
0.138 Tw
[(apresenta sinais de uretr)-33(ite)]TJ
5.5 0 0 5.5 208.61 395.87 Tm
0.017 Tc
0.136 Tw
(22 42)Tj
9.5 0 0 9.5 223.49 392.75 Tm
0.018 Tc
0.142 Tw
[(.)56( A epididimite)]TJ
-14.577 -1.086 TD
0.004 Tc
0.017 Tw
(aguda constitue a complica\347\343o mais comum da)Tj
T*
-0.05 Tw
(uretrite gonoc\363cica, sendo respons\341vel por 10%)Tj
0 -1.074 TD
-0.009 Tc
-0.069 Tw
(das epididimites agudas nos jovens. Dependendo)Tj
0 -1.086 TD
0.004 Tc
0.062 Tw
(da extens\343o do processo inflamat\363rio, poder\343o)Tj
T*
0.05 Tc
-0.07 Tw
(ocorrer complica\347\365es como edema peniano,)Tj
T*
-0.016 Tc
(balanopostite, cowperite, litrite, prostatite e orquite.)Tj
T*
-0.001 Tc
(Poder\341 tamb\351m evoluir para quadros sist\352micos,)Tj
T*
0.02 Tc
0.14 Tw
(caracterizando a gonococcemia em todas as)Tj
0 -1.074 TD
0.004 Tc
0.004 Tw
(suas manifesta\347\365es, como a artrite gonoc\363cica,)Tj
0 -1.086 TD
0.008 Tw
(a s\355ndrome de Fitz-Hugh-Curtis e complica\347\365es)Tj
T*
0.005 Tc
0.14 Tw
(card\355acas e nervosas. N\343o mais se observam)Tj
T*
-0.022 Tc
-0.069 Tw
(as estenoses uretrais em decorr\352ncia do abandono)Tj
T*
0.006 Tc
0.14 Tw
(das lavagens e instila\347\365es uretrais profil\341ticas)Tj
T*
0.004 Tc
0.016 Tw
(utilizadas no passado)Tj
5.5 0 0 5.5 177.53 251.75 Tm
0.003 Tc
0.018 Tw
(27 42)Tj
9.5 0 0 9.5 191.45 248.51 Tm
(.)Tj
/F6 1 Tf
9.5 0 2.019 9.5 99.17 235.43 Tm
0.004 Tc
-0.001 Tw
[(Gonorr\351ia na m)17(ulher)55(.)]TJ
/F4 1 Tf
10.105 0 TD
( )Tj
9.5 0 0 9.5 197.93 235.43 Tm
0.003 Tc
0 Tw
(Aqui o )Tj
9.5 0 2.019 9.5 227.81 235.43 Tm
0.004 Tc
(locus)Tj
9.5 0 0 9.5 250.13 235.43 Tm
0.003 Tw
[( pr)-21(im\341r)-9(io)]TJ
-17.381 -1.086 TD
0.041 Tw
(da infec\347\343o genital situa-se na endoc\351rvice)Tj
5.5 0 0 5.5 271.01 228.23 Tm
0.001 Tc
0.046 Tw
(12 13)Tj
9.5 0 0 9.5 285.05 225.11 Tm
(,)Tj
-21.057 -1.086 TD
-0.026 Tc
-0.069 Tw
(por\351m a )Tj
9.5 0 2.019 9.5 119.33 214.79 Tm
-0.027 Tc
-0.068 Tw
(N. gonorrhoeae)Tj
9.5 0 0 9.5 181.25 214.79 Tm
-0.026 Tc
-0.07 Tw
[( \351 tamb\351m freq\374entemente)]TJ
-10.131 -1.086 TD
0.004 Tc
0.053 Tw
(recuperada da uretra ou reto e ocasionalmente)Tj
T*
-0.002 Tc
-0.07 Tw
(das gl\342ndulas periuretrais de Skene e dos ductos)Tj
0 -1.074 TD
0.004 Tc
0.102 Tw
[(das gl\342ndulas de Bar)-47(tholin.)55( A e)29(v)24(olu\347\343o natur)17(al)]TJ
0 -1.086 TD
0.057 Tc
0.14 Tw
(da gonococcia na mulher continua menos)Tj
T*
-0.001 Tc
-0.07 Tw
(compreendida que no homem, parcialmente pela)Tj
T*
-0.005 Tc
(freq\374\352ncia de co-infec\347\343o com outros pat\363genos,)Tj
T*
0.027 Tc
(como )Tj
9.5 0 2.019 9.5 113.57 142.67 Tm
0.028 Tc
0.144 Tw
[(Chlam)15(ydia trachomatis )]TJ
9.5 0 0 9.5 221.33 142.67 Tm
0.034 Tc
(e )Tj
9.5 0 2.019 9.5 231.17 142.67 Tm
0.027 Tc
[(T)120(r)-19(ichomonas)]TJ
-15.149 -1.112 TD
0.003 Tc
(vaginalis)Tj
5.5 0 0 5.5 122.33 135.23 Tm
0.004 Tc
0.036 Tw
(15 22)Tj
9.5 0 2.019 9.5 136.37 132.11 Tm
(.)Tj
9.5 0 0 9.5 321.77 433.91 Tm
0.079 Tc
-0.07 Tw
(A maior parte das pacientes infectadas)Tj
-1.491 -1.086 TD
-0.005 Tc
(provavelmente desenvolve sintomas, mas muitas)Tj
0 -1.074 TD
0.016 Tc
0.14 Tw
(permanecem assintom\341ticas ou desenvolvem)Tj
0 -1.086 TD
0.004 Tc
0.006 Tw
(sintomatologia leve que n\343o incita preocupa\347\343o)Tj
T*
-0.051 Tw
(e busca de assist\352ncia m\351dica. Ent\343o, mulheres)Tj
T*
0.067 Tc
0.14 Tw
(com infec\347\343o subcl\355nica acumulam-se na)Tj
T*
0.004 Tc
0.041 Tw
(popula\347\343o, e em grupos nos quais identifica-se)Tj
0 -1.074 TD
0 Tc
-0.07 Tw
(a maioria das infec\347\365es por triagem ou por busca)Tj
0 -1.086 TD
0.004 Tc
0.057 Tw
(ativa, mais de 90% das mulheres permanecem)Tj
T*
0.012 Tc
0.139 Tw
(assintom\341ticas. H\341, ao que parece, cepas de)Tj
T*
0.038 Tc
(gonococo capazes de determinar infec\347\365es)Tj
T*
0.035 Tc
(assintom\341ticas. O per\355odo de incuba\347\343o da)Tj
T*
0.004 Tc
0.029 Tw
(gonorr\351ia \351 mais vari\341vel e menos definido nas)Tj
0 -1.074 TD
0.096 Tw
(mulheres que nos homens, mas a maioria das)Tj
0 -1.086 TD
-0.006 Tc
-0.07 Tw
(que se tornam sintom\341ticas fazem-no em 10 dias.)Tj
T*
0.004 Tc
-0.017 Tw
(Os sintomas predominantes incluem a cervicite,)Tj
T*
0.005 Tc
0.121 Tw
(\340s vezes uretrite, corrimento vaginal, dis\372ria e)Tj
T*
0.044 Tc
-0.02 Tw
(sangramento intermenstrual. Isso ocorre em)Tj
0 -1.099 TD
0.004 Tc
-0.029 Tw
(qualquer combina\347\343o e varia em gravidade. Dor)Tj
0 -1.124 TD
0.013 Tc
0.139 Tw
(abominal ou p\351lvica geralmente se associa \340)Tj
0 -1.112 TD
0.004 Tc
0.044 Tw
(salpingite, mas \340s vezes ocorrem em mulheres)Tj
T*
0.011 Tc
0.14 Tw
(cuja laparoscopia mostra trompas normais. O)Tj
0 -1.124 TD
0.066 Tc
-0.07 Tw
(exame f\355sico pode ou n\343o revelar exsudato)Tj
0 -1.112 TD
-0.022 Tc
(cervical purulento ou mucopurulento e outros sinais)Tj
T*
0.004 Tc
-0.025 Tw
(de cervicite purulenta, como edema em zona de)Tj
0 -1.099 TD
-0.068 Tw
[(ectopia cer)-34(vical ou sang)17(r)9(amento endocer)-34(vical.)55( A)]TJ
0 -1.086 TD
0.051 Tw
(contribui\347\343o espec\355fica do gonococo na origem)Tj
T*
0.02 Tc
0.14 Tw
(desses sinais, dados os altos \355ndices de co-)Tj
0 -1.074 TD
0.034 Tc
(infec\347\343o com outros pat\363genos, permanece)Tj
0 -1.112 TD
0.048 Tc
(desconhecida. Dor presente \340 mobiliza\347\343o)Tj
ET
/GS1 gs
q
202.65 0 0 135.8 85.05 495.3 cm
/Im1 Do
Q
q
202.65 0 0 136.35 307.6 495.2 cm
/Im2 Do
Q
endstreamendobj25 0 obj<< /ProcSet [ /PDF /Text /ImageC ] /Font << /F4 5 0 R /F6 6 0 R >> /XObject << /Im1 21 0 R /Im2 22 0 R >> /ExtGState << /GS1 9 0 R /GS2 10 0 R >> >> endobj26 0 obj<< /Type /Page /Parent 11 0 R /Resources 28 0 R /Contents 27 0 R /CropBox [ 28.8 55.44 566.2 801.67999 ] >> endobj27 0 obj<< /Length 11233 >> stream
BT
/F4 1 Tf
10 0 0 10 85.01 83.87 Tm
0 0 0 rg
/GS2 gs
0.006 Tc
(456)Tj
ET
0 0 0 RG
0 J 0 j 0.48 w 10 M []0 d
/GS1 gs
1 i 
28.61 53.87 m
28.61 -1.33 l
567.17 53.87 m
567.17 -0.01 l
-4.27 53.63 m
28.37 53.63 l
566.93 53.63 m
598.13 53.63 l
567.17 841.91 m
567.17 802.19 l
28.61 843.83 m
28.61 802.19 l
566.93 801.95 m
598.13 801.95 l
-2.23 801.95 m
28.37 801.95 l
S
BT
9.5 0 0 9.5 85.01 693.11 Tm
/GS2 gs
-0.001 Tc
-0.069 Tw
(uterina e \340 palpa\347\343o anexial geralmente associa-)Tj
0 -1.099 TD
0.006 Tc
0.14 Tw
[(se a inf)19(ec\347\343o ascendente)6(.)69( Alter)6(a\347\365es tub\341r)-19(ias)]TJ
0 -1.112 TD
0.004 Tc
(podem ocorrer como complica\347\343o da infec\347\343o)Tj
0 -1.099 TD
-0.006 Tc
-0.07 Tw
(pelo gonococo, levando aproximadamente a 10%)Tj
0 -1.112 TD
0.004 Tc
0.122 Tw
(dos casos de obstru\347\343o tub\341ria e infertilidade.)Tj
0 -1.099 TD
-0.004 Tc
-0.069 Tw
(Nos casos em que n\343o ocorre obstru\347\343o, h\341 risco)Tj
0 -1.112 TD
0.004 Tc
0.011 Tw
(de gravidez ect\363pica)Tj
5.5 0 0 5.5 173.21 633.35 Tm
0 Tc
0.018 Tw
(6 22)Tj
9.5 0 0 9.5 184.13 630.11 Tm
(.)Tj
/F6 1 Tf
9.5 0 2.019 9.5 99.17 616.79 Tm
-0.038 Tc
-0.069 Tw
(Gonorr\351ia anorretal)Tj
/F4 1 Tf
8.539 0 TD
-0.033 Tc
(. )Tj
9.5 0 0 9.5 184.25 616.79 Tm
-0.039 Tc
(Mais de 40% das mulheres)Tj
-10.446 -1.099 TD
0.004 Tc
-0.056 Tw
(com gonorr\351ia n\343o complicada e uma propor\347\343o)Tj
0 -1.112 TD
-0.023 Tc
-0.07 Tw
(semelhante de homens homossexuais apresentam)Tj
0 -1.099 TD
0.005 Tc
-0.016 Tw
(culturas retais positivas para )Tj
9.5 0 2.019 9.5 208.85 585.35 Tm
0.003 Tc
(N. gonorrhoeae)Tj
9.5 0 0 9.5 275.21 585.35 Tm
0.007 Tc
-0.021 Tw
(. O)Tj
-20.021 -1.112 TD
0.004 Tc
-0.069 Tw
(reto constitui o \372nico local infectado em 40% dos)Tj
0 -1.099 TD
0.104 Tw
(homossexuais masculinos e em 5% ou menos)Tj
0 -1.112 TD
0.061 Tc
-0.069 Tw
[(das mulheres com gonorr\351ia.)61( A maior)-27(ia das)]TJ
0 -1.099 TD
-0.003 Tc
(pessoas com culturas retais positivas permanece)Tj
0 -1.112 TD
(assintom\341tica, mas algumas apresentam proctite)Tj
0 -1.099 TD
0.051 Tc
[(aguda, com dor)51(, pr)-25(ur)-12(ido)38(, tenesmo)51(, descarga)]TJ
0 -1.112 TD
0.057 Tc
[(pur)-31(ulenta e sang)19(r)11(amento retal.)57( A anoscopia)]TJ
0 -1.099 TD
-0.001 Tc
(revela em alguns casos exsudato mucopurulento)Tj
0 -1.112 TD
0.004 Tc
0.015 Tw
(e altera\347\365es inflamat\363rias na mucosa retal)Tj
5.5 0 0 5.5 265.85 493.91 Tm
0.001 Tc
(33)Tj
9.5 0 0 9.5 272.09 490.79 Tm
(.)Tj
/F6 1 Tf
9.5 0 2.019 9.5 99.17 477.47 Tm
-0.022 Tc
-0.069 Tw
(Outras manifesta\347\365es locais.)Tj
/F4 1 Tf
13.086 0 TD
( )Tj
9.5 0 0 9.5 225.29 477.47 Tm
-0.068 Tw
(O principal fator)Tj
-14.766 -1.112 TD
-0.007 Tc
-0.07 Tw
(de risco para a faringite gonoc\363cica \351 a exposi\347\343o)Tj
0 -1.099 TD
-0.026 Tc
-0.007 Tw
(sexual orogenital. Esta pode ser encontrada em 10)Tj
0 -1.112 TD
-0.023 Tc
-0.069 Tw
(a 20% das mulheres heterossexuais com gonorr\351ia)Tj
0 -1.099 TD
0.004 Tc
0.044 Tw
(e em 10 a 25% dos homens homossexuais)Tj
5.5 0 0 5.5 271.01 438.59 Tm
0.001 Tc
0.046 Tw
(14 22)Tj
9.5 0 0 9.5 285.05 435.47 Tm
(.)Tj
-21.057 -1.112 TD
0.053 Tc
-0.069 Tw
(Raramente h\341 faringite aguda ou linfadenite)Tj
0 -1.099 TD
0.066 Tc
(cervical; a maioria das infec\347\365es far\355ngeas)Tj
0 -1.112 TD
0.004 Tc
0.052 Tw
(permanece assintom\341tica.)Tj
1.491 -1.402 TD
0.021 Tc
0.14 Tw
(A infec\347\343o ocular nos adultos geralmente)Tj
-1.491 -1.099 TD
0.004 Tc
-0.05 Tw
(resulta da autoinocula\347\343o da conjuntiva em uma)Tj
0 -1.112 TD
0.125 Tw
[(pessoa com gonorr\351ia genital.)55( A conjuntivite \351)]TJ
0 -1.099 TD
0.012 Tc
0.14 Tw
(geralmente grave, com exsudato purulento, e)Tj
0 -1.112 TD
0.005 Tc
(ulcera\347\343o corneana pode ocorrer rapidamente)Tj
0 -1.099 TD
0.004 Tc
0.021 Tw
(na aus\352ncia de antibioticoterapia imediata.)Tj
1.491 -1.415 TD
-0.007 Tc
-0.07 Tw
(Infec\347\343o gonoc\363cica cut\342nea prim\341ria )Tj
16.573 0 TD
-0.02 Tc
(mostra-)Tj
-18.063 -1.099 TD
-0.003 Tc
-0.048 Tw
[(se rara, sendo a maioria dos casos )-8(relacionada )-8(\340)]TJ
0 -1.112 TD
-0.069 Tw
(inocula\347\343o de les\343o pr\351-existente ou \340 exposi\347\343o)Tj
0 -1.099 TD
0.004 Tc
0.018 Tw
(simult\342nea com inj\372ria cut\342nea, havendo casos)Tj
0 -1.112 TD
0.052 Tc
0.14 Tw
(com manifesta\347\343o de les\365es ulceradas da)Tj
0 -1.099 TD
0.004 Tc
0.014 Tw
(genit\341lia, per\355neo ou dedos)Tj
5.5 0 0 5.5 201.05 275.39 Tm
0.003 Tc
0.018 Tw
(13 15 22)Tj
9.5 0 0 9.5 222.89 272.27 Tm
(.)Tj
/F6 1 Tf
9.5 0 2.019 9.5 99.17 258.95 Tm
-0.004 Tc
[(P)31(erihepatite)-29(.)]TJ
9.5 0 0 9.5 155.69 258.95 Tm
( )Tj
/F4 1 Tf
0.202 0 TD
-0.005 Tc
-0.07 Tw
[(A per)-30(ihepatite aguda \(s\355ndrome)]TJ
-7.642 -1.112 TD
0.004 Tc
-0.021 Tw
(de Fitz-Hugh e Curtis\) ocorre primariamente por)Tj
0 -1.099 TD
0.121 Tw
(extens\343o direta da)Tj
9.5 0 2.019 9.5 166.25 237.95 Tm
[( Neisseria gonorrohoeae )]TJ
9.5 0 0 9.5 277.13 237.95 Tm
0 Tc
(ou)Tj
-20.223 -1.112 TD
(da)Tj
9.5 0 2.019 9.5 95.69 227.39 Tm
0.004 Tc
-0.019 Tw
[( Chlamydia trachomatis)]TJ
9.5 0 0 9.5 195.41 227.39 Tm
-0.02 Tw
[( da trompa de Fal\363pio)]TJ
-11.621 -1.099 TD
0.022 Tc
0.139 Tw
(\340 c\341psula hep\341tica e ao perit\364nio adjacente.)Tj
0 -1.112 TD
0.004 Tc
0.098 Tw
(Alguns casos podem resultar de dissemina\347\343o)Tj
0 -1.099 TD
-0.043 Tw
(linfang\355tica ou bacteri\352mica, explicando os raros)Tj
0 -1.112 TD
0.001 Tc
-0.068 Tw
[(casos de per)-12(ihepatite em homens)14(.)52( A per)-12(ihepatite)]TJ
0 -1.099 TD
0.004 Tc
-0.07 Tw
(resulta em dor abdominal, hipersensibilidade em)Tj
0 -1.112 TD
0.013 Tc
0.14 Tw
(topografia hep\341tica, e sinais de peritonite em)Tj
0 -1.099 TD
0.004 Tc
0.061 Tw
[(hipoc\364ndr)-21(io direito)42(.)55( A maior)-21(ia dos casos ocorre)]TJ
0 -1.112 TD
0.073 Tc
-0.071 Tw
(simultaneamente com doen\347a inflamat\363ria)Tj
0 -1.099 TD
0.076 Tc
-0.07 Tw
(p\351lvica, mas muitas mulheres n\343o relatam)Tj
23.432 58.964 TD
0.004 Tc
0.113 Tw
[(sintomatologia p\351lvica.)67( A per)-21(ihepatite de)42(v)24(e)1( ser)]TJ
0 -1.099 TD
-0.001 Tc
-0.069 Tw
(considerada no diagn\363stico diferencial de dor em)Tj
0 -1.112 TD
0.088 Tc
(quadrante superior direito do abdome em)Tj
0 -1.099 TD
0.004 Tc
0.016 Tw
(pacientes jovens sexualmente ativas)Tj
5.5 0 0 5.5 464.21 664.79 Tm
0.003 Tc
0.018 Tw
(18 26 44)Tj
9.5 0 0 9.5 485.93 661.67 Tm
(.)Tj
/F6 1 Tf
9.5 0 2.019 9.5 321.77 648.35 Tm
-0.03 Tc
-0.069 Tw
[(Inf)8(ec\347\343o gonoc\363cica disseminada)]TJ
/F4 1 Tf
15.145 0 TD
-0.076 Tc
(. )Tj
9.5 0 0 9.5 469.25 648.35 Tm
-0.029 Tc
-0.068 Tw
[(A inf)22(ec\347\343o)]TJ
-17.015 -1.112 TD
0.086 Tc
-0.07 Tw
(gonoc\363cica disseminada \(IGD\) resulta de)Tj
0 -1.099 TD
0.004 Tc
0.117 Tw
(bacteriemia gonoc\363cica e ocorre em 0,5 a 3%)Tj
0 -1.112 TD
0.074 Tw
[(dos pacientes inf)29(ectados)17(.)55( Ar)-47(tr)-9(ite s\351ptica e uma)]TJ
0 -1.099 TD
-0.067 Tw
(s\355ndrome caracter\355stica de poliartrite e dermatite)Tj
0 -1.112 TD
0.065 Tw
(constituem as manifesta\347\365es predominantes, e)Tj
0 -1.099 TD
0.015 Tc
0.14 Tw
(a IGD representa a principal causa de artrite)Tj
0 -1.112 TD
-0.025 Tc
-0.069 Tw
[(inf)38(ecciosa em adultos jov)33(ens)]TJ
5.5 0 0 5.5 419.81 577.91 Tm
(23 36 48)Tj
9.5 0 0 9.5 439.37 574.79 Tm
-0.071 Tw
[(.)51( As complica\347\365es)]TJ
-13.869 -1.099 TD
0.054 Tc
-0.018 Tw
(raras incluem a endocardite, a meningite, a)Tj
0 -1.112 TD
0.119 Tc
-0.069 Tw
(osteomielite, a sepse com s\355ndrome de)Tj
0 -1.099 TD
0.073 Tc
-0.031 Tw
[(W)44(aterhouse-F)60(r)-23(ider)-15(ichsen e a s\355ndrome da)]TJ
0 -1.112 TD
0.004 Tc
-0.013 Tw
[(ang\372stia respirat\363r)-21(ia do adulto)42(.)55( As propr)-9(iedades)]TJ
0 -1.099 TD
0.013 Tc
(da )Tj
9.5 0 2.019 9.5 322.49 522.35 Tm
0.012 Tc
0.142 Tw
(N. gonorrhoeae)Tj
9.5 0 0 9.5 391.49 522.35 Tm
0.014 Tc
[( classicamente associadas)]TJ
-8.829 -1.112 TD
0.004 Tc
-0.003 Tw
(com a dissemina\347\343o incluem resist\352ncia \340 a\347\343o)Tj
0 -1.099 TD
0.039 Tw
(bactericida do soro humano, especificidade por)Tj
0 -1.112 TD
0.106 Tw
(sorotipos por IA e susceptibilidade marcante \340)Tj
0 -1.099 TD
0.006 Tc
(penicilina.)Tj
1.491 -1.427 TD
-0.002 Tc
-0.07 Tw
(A defici\352ncia de complemento pode predispor)Tj
-1.491 -1.124 TD
0.044 Tc
0.003 Tw
(\340 bacteriemia gonoc\363cica. Mais de 13% dos)Tj
T*
0.004 Tc
0.14 Tw
(pacientes com IGD apresentam defici\352ncia de)Tj
T*
0.05 Tc
-0.069 Tw
(complemento, e os pacientes com epis\363dios)Tj
0 -1.137 TD
0.005 Tc
0.14 Tw
(repetidos de bacteriemia por )Tj
9.5 0 2.019 9.5 437.45 423.95 Tm
(Neisseria )Tj
9.5 0 0 9.5 481.49 423.95 Tm
0.004 Tc
(devem)Tj
-18.303 -1.124 TD
0.061 Tc
-0.069 Tw
(ser estudados quanto aos n\355veis s\351ricos de)Tj
T*
-0.006 Tc
(complemento. Outros fatores de risco associados)Tj
T*
0.004 Tc
0.008 Tw
(ao risco aumentado de dissemina\347\343o incluem o)Tj
T*
-0.014 Tc
-0.069 Tw
(sexo feminino, a menstrua\347\343o, a infec\347\343o far\355ngea)Tj
T*
0.004 Tc
-0.034 Tw
(gonoc\363cica e a gravidez. Em 50% das mulheres)Tj
0 -1.137 TD
-0.007 Tw
(afetadas, os sintomas iniciam-se dentro de sete)Tj
0 -1.124 TD
0.013 Tw
(dias ap\363s o in\355cio da menstrua\347\343o.)Tj
1.491 -1.427 TD
0.079 Tc
-0.069 Tw
(As manifesta\347\365es mais comuns da IGD)Tj
-1.491 -1.124 TD
0.001 Tc
(constituem a s\355ndrome artrite-dermatite. Durante)Tj
T*
0.075 Tc
(os primeiros dias, a maioria dos pacientes)Tj
T*
-0.003 Tc
(queixa-se de sintomas constitucionais e \340s vezes)Tj
T*
0.042 Tc
0.14 Tw
(de poliartralgias migrat\363rias envolvendo os)Tj
T*
0.055 Tc
-0.07 Tw
[(j)62(oelhos, os cotovelos e as articula\347\365es mais)]TJ
0 -1.137 TD
0 Tc
(distais. Nesse est\341gio, o exame f\355sico demonstra)Tj
0 -1.124 TD
-0.008 Tc
(tenossinovite, artrite e outros sinais de inflama\347\343o)Tj
T*
0.034 Tc
-0.038 Tw
(periarticular em duas ou mais articula\347\365es. O)Tj
T*
0.004 Tc
-0.035 Tw
(envolvimento assim\351trico oligoarticular ajuda na)Tj
0 -1.112 TD
0.064 Tc
-0.013 Tw
(distin\347\343o entre IGD e a poliartrite devido \340)Tj
0 -1.124 TD
0.024 Tc
0.139 Tw
(s\355ndrome de deposi\347\343o de imunocomplexos.)Tj
0 -1.112 TD
-0.019 Tc
-0.069 Tw
(Uma dermatite caracter\355stica encontra-se presente)Tj
T*
0.008 Tc
0.14 Tw
(em 75% dos casos, consistindo de p\341pulas e)Tj
0 -1.137 TD
-0.007 Tc
-0.07 Tw
[(p\372stulas \340s vezes com componente hemorr\341gi)6(co.)]TJ
0 -1.124 TD
0.004 Tc
0.11 Tw
(As les\365es apresentam-se em n\372mero vari\341vel,)Tj
T*
0.005 Tc
0.14 Tw
(de 5 a 40, ocorrendo predominantemente nas)Tj
T*
-0.036 Tc
-0.07 Tw
(extremidades. Bolhas hemorr\341gicas ocasionalmente)Tj
T*
0.004 Tc
0.079 Tw
(s\343o vistas, como tamb\351m as les\365es necr\363ticas)Tj
0 -1.112 TD
-0.002 Tw
(mimetizando ectima gangrenoso e as les\365es da)Tj
7 0 0 7 85.01 759.71 Tm
0.01 Tc
0.012 Tw
[(Penna GO  et al)]TJ
ET
endstreamendobj28 0 obj<< /ProcSet [ /PDF /Text ] /Font << /F4 5 0 R /F6 6 0 R >> /ExtGState << /GS1 9 0 R /GS2 10 0 R >> >> endobj29 0 obj<< /Type /Page /Parent 11 0 R /Resources 31 0 R /Contents 30 0 R /CropBox [ 28.8 55.44 566.2 801.67999 ] >> endobj30 0 obj<< /Length 10420 >> stream
BT
/F4 1 Tf
10 0 0 10 493.49 85.31 Tm
0 0 0 rg
/GS2 gs
0.006 Tc
(457)Tj
ET
0 0 0 RG
0 J 0 j 0.48 w 10 M []0 d
/GS1 gs
1 i 
28.61 53.87 m
28.61 -1.33 l
567.17 53.87 m
567.17 -1.93 l
-2.83 53.63 m
28.37 53.63 l
566.93 53.63 m
596.69 53.63 l
567.17 841.91 m
567.17 802.19 l
28.61 843.23 m
28.61 802.19 l
566.93 801.95 m
598.13 801.95 l
-2.23 801.95 m
28.37 801.95 l
S
BT
9.5 0 0 9.5 85.01 693.35 Tm
/GS2 gs
0.004 Tc
-0.043 Tw
(S\355ndrome de Sweet. Se n\343o tratada, a dermatite)Tj
0 -1.086 TD
-0.025 Tc
-0.07 Tw
(e a artropatia na maioria das articula\347\365es melhoram)Tj
T*
-0.035 Tc
(espontaneamente, mas a artrite tipicamente progride)Tj
T*
0.036 Tc
(em alguns locais, mais comumente no joelho,)Tj
T*
-0.036 Tc
(tornozelo, cotovelo e punho. Nesse est\341gio, o quadro)Tj
T*
-0.024 Tc
(cl\355nico e os achados do fluido sinovial assemelham-)Tj
0 -1.074 TD
0.004 Tc
0.089 Tw
[(s)24(e)4( \340queles da ar)-34(tr)-21(ite s\351ptica.)67( A IGD resulta da)]TJ
0 -1.086 TD
-0.014 Tw
(dissemina\347\343o bacteri\352mica da )Tj
9.5 0 2.019 9.5 216.17 621.23 Tm
0.003 Tc
-0.016 Tw
(N. gonorrohoeae)Tj
9.5 0 0 9.5 85.01 610.91 Tm
-0.005 Tc
-0.069 Tw
(para a pele, articula\347\365es e tecidos periarticulares,)Tj
T*
0.008 Tc
0.14 Tw
(embora em alguns casos imunocomplexos ou)Tj
T*
0.023 Tc
(outros mecanismos imunol\363gicos contribuam)Tj
T*
0.003 Tc
0.021 Tw
(para a patog\352nese.)Tj
1.491 -1.377 TD
0.004 Tc
0.075 Tw
(Durante o est\341gio de dermatite-poliartrite, o)Tj
-1.491 -1.086 TD
-0.024 Tw
(gonococo pode ser recuperado na hemocultura,)Tj
T*
-0.017 Tc
-0.069 Tw
(entretanto, o l\355quido sinovial, se obtido, geralmente)Tj
T*
-0.023 Tc
-0.068 Tw
(cont\351m menos de 20.000 leuc\363citos/mm)Tj
5.5 0 0 5.5 245.33 539.15 Tm
(3)Tj
9.5 0 0 9.5 248.21 535.91 Tm
-0.071 Tw
[( e mostra-)]TJ
-17.179 -1.086 TD
0.004 Tc
0.019 Tw
[(s)22(e)22( )7(est\351ril. O gonococo pode ser visualizado por)]TJ
0 -1.074 TD
0.021 Tc
0.139 Tw
(m\351todos imunohistoqu\355micos em bi\363psias de)Tj
0 -1.086 TD
0.004 Tc
0.053 Tw
(les\365es cut\342neas, mas as culturas permanecem)Tj
T*
0.005 Tc
0.064 Tw
(est\351reis. Na artrite s\351ptica gonoc\363cica, o fluido)Tj
T*
0.019 Tc
0.14 Tw
(sinovial geralmente cont\351m mais que 50.000)Tj
T*
0.046 Tc
(c\351lulas/mm)Tj
5.5 0 0 5.5 137.45 477.35 Tm
(3)Tj
9.5 0 0 9.5 140.81 474.11 Tm
-0.07 Tw
[( e a cultura pode ser positiva em)]TJ
-5.874 -1.086 TD
0.005 Tc
0.01 Tw
(parte dos casos.)Tj
1.491 -1.377 TD
0.004 Tc
0.058 Tw
(De maneira geral, s\363 metade dos pacientes)Tj
-1.491 -1.086 TD
-0.069 Tw
(com IDG apresenta culturas positivas no sangue)Tj
T*
0.005 Tc
0.028 Tw
(ou fluido sinovial, mas a )Tj
9.5 0 2.019 9.5 191.45 430.07 Tm
0.003 Tc
0.027 Tw
(N. gonorrohoeae)Tj
9.5 0 0 9.5 263.45 430.07 Tm
0.005 Tc
0.031 Tw
[( pode)]TJ
-18.783 -1.086 TD
-0.007 Tc
-0.069 Tw
(ser recuperada de uma mucosa em cerca de 80%)Tj
0 -1.074 TD
0.004 Tc
0.016 Tw
(dos pacientes. Quando suspeita-se de infec\347\343o)Tj
0 -1.086 TD
0.021 Tc
0.14 Tw
(gonoc\363cica disseminada, um m\355nimo de tr\352s)Tj
T*
-0.008 Tc
-0.069 Tw
(hemoculturas devem ser obtidas; o fluido sinovial,)Tj
T*
0.005 Tc
-0.044 Tw
(se dispon\355vel, deve ser cultivado; todos os s\355tios)Tj
T*
-0.001 Tc
-0.07 Tw
(de mucosa potencialmente infectados devem ser)Tj
T*
(cultivados \(uretra ou endoc\351rvice, reto e faringe\),)Tj
0 -1.074 TD
0.054 Tc
0.14 Tw
(independente da hist\363ria dos sintomas ou)Tj
0 -1.086 TD
-0.02 Tc
-0.07 Tw
(exposi\347\343o; e o parceiro sexual deve ser examinado)Tj
T*
0.008 Tc
0.14 Tw
(e seus l\355quidos cultivados. Embora raramente)Tj
T*
-0.01 Tc
-0.07 Tw
(positivas, a colora\347\343o pelo Gram e as culturas das)Tj
T*
-0.025 Tc
-0.015 Tw
(les\365es cut\342neas pustulares s\343o de f\341cil obten\347\343o e)Tj
T*
0.004 Tc
0.019 Tw
(devem ser realizadas.)Tj
1.491 -1.377 TD
0.025 Tc
0.14 Tw
(O diagn\363stico diferencial da s\355ndrome de)Tj
-1.491 -1.086 TD
0.004 Tc
-0.047 Tw
(artrite-dermatite inclui meningococcemia, outras)Tj
T*
0.005 Tc
0.015 Tw
(artrites infecciosas e o vasto n\372mero de artrites)Tj
T*
0.023 Tc
0.14 Tw
[(inflamat\363r)-15(ias)10(.)61( A s\355ndrome de Reiter e outras)]TJ
0 -1.074 TD
0.021 Tc
(artrites reativas s\343o comumente confundidas)Tj
0 -1.086 TD
-0.001 Tc
-0.07 Tw
(com a IGD, por serem comuns em adultos jovens)Tj
T*
0.004 Tc
0.086 Tw
(sexualmente ativos e se associarem a uretrite,)Tj
T*
0.005 Tc
0.009 Tw
(cervicite e a les\365es cut\342neas.)Tj
1.491 -1.389 TD
0.023 Tc
0.139 Tw
(A endocardite infecciosa, que geralmente)Tj
-1.491 -1.074 TD
-0.017 Tc
-0.069 Tw
(envolve a v\341lvula a\363rtica, representa manifesta\347\343o)Tj
0 -1.086 TD
0.004 Tc
-0.016 Tw
(grave da doen\347a, por\351m rara, ocorrendo em 1 a)Tj
T*
0.069 Tc
0.14 Tw
(2% dos casos de IGD. Embora \340s vezes)Tj
0 -1.099 TD
0.005 Tc
(associada com a s\355ndrome artrite-dermatite, a)Tj
0 -1.112 TD
0.004 Tc
0.108 Tw
(endocardite pode ser a \372nica manifesta\347\343o da)Tj
0 -1.099 TD
-0.001 Tc
-0.069 Tw
[(IGD)62(.)50( A meningite gonoc\363cica, a sepse fulminante)]TJ
23.432 58.724 TD
0.07 Tc
0.139 Tw
[(mimetizando a s\355ndrome de )32(W)54(aterhouse-)]TJ
0 -1.086 TD
0.047 Tc
-0.069 Tw
(Friderichsen, a osteomielite e a s\355ndrome de)Tj
T*
0.054 Tc
0.139 Tw
(ang\372stia respirat\363ria do adulto constituem)Tj
T*
0.004 Tc
0.014 Tw
(manifesta\347\365es raras da IGD)Tj
5.5 0 0 5.5 427.25 665.51 Tm
0.003 Tc
0.018 Tw
(16 18 44)Tj
9.5 0 0 9.5 448.97 662.39 Tm
(.)Tj
/F6 1 Tf
9.5 0 2.019 9.5 321.77 649.19 Tm
0.027 Tc
0.139 Tw
[(Gonorr\351ia na gra)27(videz.)]TJ
/F4 1 Tf
11.672 0 TD
( )Tj
9.5 0 0 9.5 436.97 649.19 Tm
0.142 Tw
(A gonorr\351ia nas)Tj
-13.617 -1.074 TD
0.004 Tc
0.108 Tw
(gestantes associa-se com risco aumentado de)Tj
0 -1.086 TD
0.045 Tc
-0.07 Tw
(aborto espont\342neo, parto prematuro, ruptura)Tj
T*
0.015 Tc
0.14 Tw
(prematura de membranas e mortalidade fetal)Tj
T*
0.009 Tc
(perinatal, por\351m n\343o est\341 claro se a infec\347\343o)Tj
T*
0.092 Tc
(gonoc\363cica responsabiliza-se por estas)Tj
T*
0.004 Tc
-0.06 Tw
(conseq\374\352ncias ou se constitui simplesmente um)Tj
0 -1.074 TD
0.084 Tc
0.028 Tw
(marcador para alto risco devido a outros)Tj
0 -1.086 TD
0.032 Tc
0.141 Tw
[(mecanismos patog\352nicos)7(.)57( As manif)19(esta\347\365es)]TJ
T*
0.08 Tc
-0.07 Tw
(cl\355nicas da gonocorr\351ia n\343o se alteram na)Tj
T*
0.038 Tc
0.14 Tw
(gravidez, exceto que a doen\347a inflamat\363ria)Tj
T*
0.004 Tc
-0.029 Tw
(p\351lvica e a perihepatite revelam-se raras ap\363s o)Tj
T*
0.032 Tw
(primeiro trimestre, quando o concepto obstrui a)Tj
0 -1.074 TD
0.04 Tc
0.14 Tw
(cavidade uterina. H\341 controv\351rsias sobre a)Tj
0 -1.086 TD
0.004 Tc
-0.04 Tw
(possibilidade de a gravidez ser um fator de risco)Tj
T*
0.003 Tc
0.024 Tw
(para infec\347\343o disseminada)Tj
5.5 0 0 5.5 421.97 497.87 Tm
0 Tc
0.028 Tw
(22 27)Tj
9.5 0 0 9.5 435.89 494.75 Tm
(.)Tj
/F6 1 Tf
9.5 0 2.019 9.5 321.77 481.55 Tm
0.009 Tc
0.14 Tw
(Infec\347\365es neonatais e pedi\341tricas.)Tj
/F4 1 Tf
16.939 0 TD
( )Tj
9.5 0 0 9.5 486.89 481.55 Tm
0.006 Tc
(M\343es)Tj
-18.872 -1.074 TD
0.031 Tc
-0.068 Tw
(infectadas podem transmitir a )Tj
9.5 0 2.019 9.5 441.29 471.35 Tm
0.03 Tc
-0.074 Tw
(N. gonorrhoeae)Tj
9.5 0 0 9.5 307.61 461.03 Tm
0.024 Tc
-0.065 Tw
(para o concepto intra\372tero, durante o parto, ou)Tj
0 -1.086 TD
0.004 Tc
0.014 Tw
[(no per\355odo p\363s-par)-47(to)29(.)55( A conjuntivite gonoc\363cica)]TJ
T*
0.042 Tw
(do neonato \(oftalmia neonatorum\) representa a)Tj
T*
-0.057 Tw
(manifesta\347\343o mais comumente reconhecida e j\341)Tj
T*
0.005 Tc
0.14 Tw
(foi a principal causa de cegueira nos Estados)Tj
0 -1.074 TD
0.004 Tc
0.053 Tw
(Unidos, sendo ainda em alguns pa\355ses pobres.)Tj
0 -1.086 TD
0.068 Tc
-0.069 Tw
(A profilaxia pela instila\347\343o de uma solu\347\343o)Tj
T*
-0.021 Tc
(aquosa de nitrato de prata a 1% no saco conjuntival)Tj
T*
0.004 Tc
0.106 Tw
(logo ap\363s o parto revelou-se altamente eficaz,)Tj
T*
-0.052 Tw
[(embor)17(a f)29(al\352ncias ocasionais possam ocorrer)42(.)55( As)]TJ
T*
-0.003 Tc
-0.07 Tw
(principais medidas preventivas incluem a triagem)Tj
0 -1.074 TD
0.004 Tc
-0.012 Tw
(de rotina e o tratamento pr\351-parto das mulheres)Tj
0 -1.086 TD
0.084 Tc
-0.069 Tw
(gr\341vidas infectadas. Foi Karl Cred\351 quem)Tj
T*
0.004 Tc
-0.033 Tw
(estabeleceu as bases dessa profilaxia em 1884.)Tj
1.491 -1.402 TD
0.123 Tw
(O diagn\363stico da oftalmia gonoc\363cica deve)Tj
-1.491 -1.099 TD
-0.022 Tw
(ser suspeitado clinicamente quando conjuntivite)Tj
0 -1.112 TD
0.053 Tw
(aguda, geralmente com exsudato purulento, se)Tj
0 -1.099 TD
0.042 Tc
-0.07 Tw
(desenvolve dentro de 1 semana \(usualmente)Tj
0 -1.112 TD
0.074 Tc
(2 a 3 dias\) do parto. Ela \351 confirmada pela)Tj
0 -1.099 TD
0.088 Tc
(identifica\347\343o do gonococo nas secre\347\365es)Tj
0 -1.112 TD
0.08 Tc
(conjuntivais, obtida pelo Gram ou cultura.)Tj
0 -1.099 TD
0.004 Tc
0.058 Tw
(Rec\351m-nascidos expostos \340 gonorr\351ia tamb\351m)Tj
0 -1.112 TD
-0.01 Tc
-0.069 Tw
(podem desenvolver doen\347a sist\352mica, com sepse)Tj
0 -1.099 TD
0.005 Tc
0.029 Tw
(e artrite. Entretanto, vaginite purulenta constitui)Tj
0 -1.112 TD
0.059 Tc
0.14 Tw
(a principal manifesta\347\343o da gonorr\351ia em)Tj
0 -1.099 TD
0.004 Tc
0.084 Tw
(crian\347as pr\351-p\372beres ap\363s o per\355odo neonatal.)Tj
0 -1.112 TD
0.009 Tw
(Ap\363s o per\355odo neonatal at\351 1 ano de idade, as)Tj
0 -1.099 TD
0.025 Tw
(crian\347as adquirem a doen\347a por via n\343o-sexual)Tj
0 -1.112 TD
-0.002 Tc
-0.069 Tw
(de um parente infectado, usualmente na vig\352ncia)Tj
0 -1.099 TD
0.005 Tc
0.139 Tw
[(de maus h\341bitos de higiene)18(.)56( Ap\363s um ano de)]TJ
0 -1.112 TD
0.022 Tc
(idade, as crian\347as adquirem a gonorr\351ia por)Tj
0 -1.099 TD
0.004 Tc
0.011 Tw
(abuso sexual)Tj
5.5 0 0 5.5 364.13 138.47 Tm
0.003 Tc
0.018 Tw
(14 22 42)Tj
9.5 0 0 9.5 385.85 135.35 Tm
(.)Tj
7 0 0 7 255.77 759.71 Tm
0.009 Tc
0.049 Tw
[(Re)26(vista da Sociedade Br)9(asileir)-8(a de Medicina )44(T)123(ropical 33:451-464, set-out, 2000)]TJ
ET
endstreamendobj31 0 obj<< /ProcSet [ /PDF /Text ] /Font << /F4 5 0 R /F6 6 0 R >> /ExtGState << /GS1 9 0 R /GS2 10 0 R >> >> endobj32 0 obj<< /Type /Page /Parent 11 0 R /Resources 34 0 R /Contents 33 0 R /CropBox [ 28.8 55.44 566.2 801.67999 ] >> endobj33 0 obj<< /Length 10509 >> stream
BT
/F4 1 Tf
10 0 0 10 85.01 83.87 Tm
0 0 0 rg
/GS2 gs
0.006 Tc
(458)Tj
ET
0 0 0 RG
0 J 0 j 0.48 w 10 M []0 d
/GS1 gs
1 i 
28.61 53.87 m
28.61 -1.33 l
567.17 53.87 m
567.17 -0.01 l
-4.27 53.63 m
28.37 53.63 l
566.93 53.63 m
598.13 53.63 l
567.17 841.91 m
567.17 802.19 l
28.61 843.83 m
28.61 802.19 l
566.93 801.95 m
598.13 801.95 l
-2.23 801.95 m
28.37 801.95 l
S
BT
9.5 0 0 9.5 152.81 691.79 Tm
/GS2 gs
(DIAGN\323STICO)Tj
-5.646 -1.768 TD
0.054 Tc
0.14 Tw
(O diagn\363stico laboratorial da gonorr\351ia)Tj
-1.491 -1.099 TD
0.004 Tc
-0.038 Tw
(depende da identifica\347\343o da )Tj
9.5 0 2.019 9.5 206.21 664.55 Tm
-0.04 Tw
(N. gonorrhoeae )Tj
9.5 0 0 9.5 274.61 664.55 Tm
0.001 Tc
(em)Tj
-19.958 -1.112 TD
0.052 Tc
-0.069 Tw
(um local infectado. O isolamento por cultura)Tj
0 -1.099 TD
0.074 Tc
-0.065 Tw
(representa o m\351todo diagn\363stico padr\343o e)Tj
0 -1.112 TD
0.037 Tc
0.139 Tw
(sempre deve ser utilizado)Tj
5.5 0 0 5.5 205.97 636.11 Tm
0.033 Tc
0.136 Tw
(5 49)Tj
9.5 0 0 9.5 218.21 632.99 Tm
0.038 Tc
0.142 Tw
(. Outros testes)Tj
-14.021 -1.099 TD
0.004 Tc
-0.032 Tw
(diagn\363sticos mostram-se inferiores, mas podem)Tj
0 -1.112 TD
-0.053 Tw
(ser \372teis quando o isolamento n\343o \351 pr\341tico pela)Tj
0 -1.099 TD
0.003 Tc
-0.07 Tw
(aus\352ncia de acesso a laborat\363rio ou dificuldades)Tj
0 -1.112 TD
0.006 Tc
0.138 Tw
[(no transpor)-45(te do esp\351cime)19(.)57( A amplifica\347\343o do)]TJ
0 -1.099 TD
-0.007 Tc
-0.07 Tw
(DNA pela rea\347\343o em cadeia da polimerase \(PCR\))Tj
0 -1.112 TD
0.004 Tc
-0.058 Tw
(oferece sensibilidade compar\341vel ou at\351 mesmo)Tj
0 -1.099 TD
0.114 Tw
(superior a cultura, por\351m a experi\352ncia cl\355nica)Tj
0 -1.112 TD
0.036 Tw
(revela-se limitada)Tj
5.5 0 0 5.5 160.49 552.11 Tm
0.001 Tc
(25)Tj
9.5 0 0 9.5 166.61 548.99 Tm
(.)Tj
-7.099 -1.402 TD
0.002 Tc
-0.069 Tw
(Uma simples cultura em meio seletivo mostra)Tj
-1.491 -1.112 TD
0.015 Tc
0.139 Tw
(sensibilidade de 95% ou mais para amostras)Tj
0 -1.099 TD
0.053 Tc
-0.069 Tw
(uretrais de homens com uretrite sintom\341tica)Tj
0 -1.112 TD
0.088 Tc
(e 80-90% para infec\347\343o endocervical nas)Tj
0 -1.099 TD
0.004 Tc
0.047 Tw
(mulheres, dependendo da qualidade do meio e)Tj
0 -1.112 TD
0.021 Tc
0.139 Tw
(da adequa\347\343o da amostra)Tj
5.5 0 0 5.5 204.05 486.35 Tm
0.02 Tc
0.136 Tw
(24 25 31 45)Tj
9.5 0 0 9.5 236.69 483.11 Tm
0.021 Tc
0.143 Tw
(. Embora a)Tj
-15.966 -1.099 TD
0.004 Tc
0.134 Tw
(uretra seja comumente infectada, a cultura de)Tj
0 -1.112 TD
0.022 Tc
0.14 Tw
(material uretral n\343o aumenta a sensibilidade)Tj
0 -1.099 TD
0.004 Tc
0.118 Tw
(diagn\363stica, exceto em mulheres que n\343o t\352m)Tj
0 -1.112 TD
0.018 Tc
0.14 Tw
(c\351rvice por histerectomia. Culturas de outros)Tj
0 -1.099 TD
0.017 Tc
(locais, por exemplo de gl\342ndulas, devem ser)Tj
0 -1.112 TD
0.008 Tc
(obtidas quando indicadas pelo quadro cl\355nico.)Tj
0 -1.099 TD
0 Tc
-0.069 Tw
(Amostras de fluidos normalmente est\351reis, como)Tj
0 -1.112 TD
0.004 Tc
0.126 Tw
(sangue e fluido sinovial devem ser inoculadas)Tj
0 -1.099 TD
0.016 Tw
(em meio n\343o seletivo como \341gar-chocolate)Tj
5.5 0 0 5.5 268.37 391.79 Tm
0 Tc
0.018 Tw
(5 49)Tj
9.5 0 0 9.5 279.29 388.67 Tm
(.)Tj
-18.96 -1.415 TD
0.128 Tc
-0.069 Tw
(Material da uretra masculina \351 mais)Tj
-1.491 -1.112 TD
0.029 Tc
0.14 Tw
(adequadamente obtido pela inser\347\343o de um)Tj
T*
0.004 Tc
(swab de 2-3cm na uretra, embora o exsudato)Tj
0 -1.124 TD
0.033 Tc
(purulento possa ser adequado para exame.)Tj
0 -1.112 TD
0.004 Tc
0.092 Tw
(Quando a obten\347\343o do material uretral n\343o for)Tj
T*
0.062 Tw
(poss\355vel, os primeiros 20-30ml de urina podem)Tj
0 -1.124 TD
0.014 Tw
[(ser centr)-21(ifugados e o sedimento cultiv)29(ado)42(.)55( )43(T)122(e)6(m)6(-)]TJ
0 -1.112 TD
-0.001 Tc
-0.069 Tw
(se o material endocervical utilizando-se um )Tj
9.5 0 2.019 9.5 265.61 301.07 Tm
-0.003 Tc
(swab)Tj
9.5 0 0 9.5 85.01 290.51 Tm
0.031 Tc
0.139 Tw
(no orif\355cio externo, com cuidado para evitar)Tj
0 -1.124 TD
-0.008 Tc
-0.07 Tw
(contato com a mucosa vaginal ou com secre\347\365es.)Tj
0 -1.112 TD
0.054 Tc
0.129 Tw
(Amostras retais s\343o obtidas com )Tj
9.5 0 2.019 9.5 248.09 269.27 Tm
(swab )Tj
9.5 0 0 9.5 276.65 269.27 Tm
0.05 Tc
(de)Tj
-20.173 -1.112 TD
0.011 Tc
-0.07 Tw
(2-4cm no canal anal. Em pacientes com proctite)Tj
0 -1.124 TD
0.039 Tc
0.14 Tw
(sintom\341tica, aumenta-se a sensibilidade da)Tj
0 -1.112 TD
0.004 Tc
-0.005 Tw
(bacterioscopia e da cultura com a realiza\347\343o da)Tj
T*
-0.004 Tw
[(anoscopia e an\341lise de secre\347\365es pur)-21(ulentas.)55( A)]TJ
0 -1.124 TD
-0.003 Tw
(escolha dos pontos anat\364micos de obten\347\343o de)Tj
0 -1.112 TD
-0.007 Tc
-0.069 Tw
(material para estudo depende dos s\355tios expostos)Tj
T*
0.004 Tc
0.011 Tw
(e das manifesta\347\365es cl\355nicas)Tj
5.5 0 0 5.5 208.01 198.23 Tm
0.003 Tc
(5 9 16 17)Tj
9.5 0 0 9.5 231.29 195.11 Tm
(.)Tj
-8.109 -2.147 TD
0.018 Tc
[(TRA)119(T)124(AMENT)31(O)]TJ
-5.798 -1.768 TD
0.106 Tc
0.139 Tw
(Os medicamentos aceit\341veis para o)Tj
-1.491 -1.112 TD
0.038 Tc
(tratamento da gonorr\351ia devem ter efic\341cia)Tj
0 -1.099 TD
0.005 Tc
(pr\363xima de 100%. Deve-se considerar que os)Tj
23.432 58.547 TD
0.042 Tc
0.141 Tw
(padr\365es de susceptibilidade antimicrobiana)Tj
0 -1.099 TD
0.004 Tc
-0.043 Tw
(variam de acordo com a \341rea geogr\341fica ou com)Tj
0 -1.112 TD
0.015 Tc
0.14 Tw
(a popula\347\343o estudada e flutuam ao longo do)Tj
0 -1.099 TD
0.003 Tc
-0.07 Tw
(tempo, devendo o tratamento ser individualizado)Tj
0 -1.112 TD
0.004 Tc
-0.02 Tw
(de acordo com os dados epidemiol\363gicos. Deve)Tj
0 -1.099 TD
-0.008 Tc
-0.07 Tw
(ser ressaltado que quando se comparam as taxas)Tj
0 -1.112 TD
0.005 Tc
0.059 Tw
(de resposta da )Tj
9.5 0 2.019 9.5 375.41 630.11 Tm
0.003 Tc
0.063 Tw
(N. gonnorhoeae)Tj
9.5 0 0 9.5 444.53 630.11 Tm
0.004 Tc
0.061 Tw
[( \340 penicilina h\341)]TJ
-14.413 -1.099 TD
0.022 Tc
0.14 Tw
(algumas d\351cadas \340s respostas hoje obtidas,)Tj
0 -1.112 TD
0.004 Tc
-0.049 Tw
[(obser)-34(v)24(am-se crescentes n\355v)29(eis de resist\352ncia.)55( A)]TJ
0 -1.099 TD
0.102 Tw
(fal\352ncia na cura de um caso de gonorr\351ia tem)Tj
0 -1.112 TD
0.022 Tc
0.14 Tw
(implica\347\365es em n\355vel de sa\372de p\372blica, pelo)Tj
0 -1.099 TD
0.012 Tc
(potencial para transmiss\343o continuada e pela)Tj
0 -1.112 TD
0.004 Tc
0.023 Tw
(r\341pida emerg\352ncia de resist\352ncia.)Tj
1.491 -1.415 TD
0.143 Tc
-0.07 Tw
(Uma variedade de fatores, al\351m da)Tj
-1.491 -1.124 TD
0.004 Tc
0.102 Tw
(susceptibilidade antimicrobiana, influenciam as)Tj
0 -1.137 TD
0.032 Tc
0.14 Tw
(decis\365es terap\352uticas na gonococcia. Estes)Tj
0 -1.124 TD
0.037 Tc
0.141 Tw
(incluem caracter\355sticas farmacocin\351ticas do)Tj
T*
0.044 Tc
-0.017 Tw
(agente, efic\341cia nas infec\347\365es complicada e)Tj
T*
0.039 Tc
-0.07 Tw
(n\343o-complicada, toxicidade, conveni\352ncia da)Tj
T*
0.004 Tc
-0.05 Tw
(administra\347\343o e custo. Uma considera\347\343o inicial)Tj
T*
0.042 Tw
(\351 a efic\341cia potencial do agente para infec\347\365es)Tj
0 -1.137 TD
-0.022 Tc
-0.07 Tw
(concomitantes. Historicamente, essa considera\347\343o)Tj
0 -1.124 TD
-0.014 Tc
(se refere \340 s\355filis, e permanece um fator importante)Tj
T*
-0.031 Tc
(ainda nos dias atuais. Mas, a )Tj
9.5 0 2.019 9.5 420.53 446.63 Tm
-0.032 Tc
-0.074 Tw
(Chlamydia trachomatis)Tj
9.5 0 0 9.5 307.61 435.95 Tm
-0.001 Tc
-0.07 Tw
(constitui o agente concomitante mais encontrado)Tj
T*
0.004 Tc
0.046 Tw
(em associa\347\343o com a gonorr\351ia, ocorrendo em)Tj
T*
-0.057 Tw
(15 a 25% dos homens heterossexuais e em 35 a)Tj
T*
0.031 Tc
-0.068 Tw
[(50% das m)6(ulheres)6(.)56( Altas taxas de co-inf)31(ec\347\343o)]TJ
0 -1.137 TD
0.003 Tc
0.028 Tw
(t\352m sido menos comumente documentadas em)Tj
0 -1.124 TD
0.004 Tc
0.022 Tw
[(pa\355ses em desen)29(v)24(olvimento que na Am\351r)-21(ica do)]TJ
T*
0.014 Tw
(Norte e na Europa.)Tj
1.491 -1.415 TD
0.105 Tw
(Recomenda-se como terapia inicial um dos)Tj
-1.491 -1.112 TD
0.002 Tc
-0.069 Tw
(quatro esquemas terap\352uticos alinhados abaixo:)Tj
0 -1.124 TD
0.037 Tc
0.14 Tw
(ceftriaxona 250mg IM, cefixime 400mg VO,)Tj
0 -1.112 TD
-0.021 Tc
-0.069 Tw
[(ciprofloxacina 500mg VO ou ofloxacina 400mg )-14(V)-19(O)-19(,)]TJ
T*
-0.016 Tc
-0.001 Tw
(sendo todos administrados em dose \372nica)Tj
5.5 0 0 5.5 479.57 319.07 Tm
-0.017 Tc
-0.003 Tw
(22 29 35 41)Tj
9.5 0 0 9.5 507.65 315.95 Tm
(.)Tj
-21.057 -1.124 TD
0.004 Tc
0.05 Tw
(Ciprofloxacina e ofloxacina devem ser evitadas)Tj
0 -1.112 TD
-0.009 Tc
-0.07 Tw
(em gestantes e n\343o apresentam atividades contra)Tj
T*
0.035 Tc
(a s\355filis, n\343o abortando a s\355filis em incuba\347\343o.)Tj
0 -1.124 TD
0.021 Tc
0.14 Tw
(Esquemas em dose \372nica com v\341rias outras)Tj
0 -1.112 TD
0.001 Tc
-0.07 Tw
(cefalosporinas, quinolonas ou outros antibi\363ticos)Tj
T*
-0.019 Tc
(podem ser utilizados, mas n\343o mostram vantagens)Tj
0 -1.124 TD
0.006 Tc
0.14 Tw
[(sobre esses quatro regimes recomendados)19(.)57( )-8(A)]TJ
0 -1.112 TD
0.004 Tc
0.038 Tw
(espectinomicina 2g IM em dose \372nica pode ser)Tj
T*
0.002 Tw
(utilizada em gestantes com hist\363ria de alergia \340)Tj
0 -1.124 TD
0 Tc
-0.069 Tw
(penicilina ou \340s cefalosporinas. Independente do)Tj
0 -1.112 TD
0.002 Tc
(antibi\363tico de \372nica dose escolhido, o tratamento)Tj
T*
-0.007 Tc
(inicial deve ser seguido de um terapia ativa contra)Tj
9.5 0 2.019 9.5 307.61 178.07 Tm
-0.022 Tc
-0.068 Tw
[(Chlam)16(ydia trachomatis)]TJ
5.5 0 0 5.5 398.93 181.31 Tm
-0.024 Tc
-0.063 Tw
(1 51)Tj
9.5 0 0 9.5 408.89 178.07 Tm
-0.022 Tc
-0.069 Tw
[(.)67( Al\351m de tratar a inf)29(ec\347\343o)]TJ
-10.661 -1.112 TD
0.028 Tc
(pela )Tj
9.5 0 2.019 9.5 328.97 167.51 Tm
(Chlamydia,)Tj
9.5 0 0 9.5 379.25 167.51 Tm
0.029 Tc
[( dar uma segunda droga pode)]TJ
-7.541 -1.112 TD
0.047 Tc
(reduzir o potencial de sele\347\343o de gonococos)Tj
0 -1.124 TD
0.004 Tc
-0.003 Tw
(resistentes. Os esquemas recomendados s\343o a)Tj
0 -1.112 TD
0.017 Tw
(doxiciclina 100mg 12/12h VO diariamente por 7)Tj
7 0 0 7 85.01 759.71 Tm
0.01 Tc
0.012 Tw
[(Penna GO  et al)]TJ
ET
endstreamendobj34 0 obj<< /ProcSet [ /PDF /Text ] /Font << /F4 5 0 R >> /ExtGState << /GS1 9 0 R /GS2 10 0 R >> >> endobj35 0 obj<< /Type /Page /Parent 11 0 R /Resources 37 0 R /Contents 36 0 R /CropBox [ 28.8 55.44 566.2 801.67999 ] >> endobj36 0 obj<< /Length 9639 >> stream
BT
/F4 1 Tf
10 0 0 10 493.49 85.31 Tm
0 0 0 rg
/GS2 gs
0.006 Tc
(459)Tj
ET
0 0 0 RG
0 J 0 j 0.48 w 10 M []0 d
/GS1 gs
1 i 
28.61 53.87 m
28.61 -1.33 l
567.17 53.87 m
567.17 -1.93 l
-2.83 53.63 m
28.37 53.63 l
566.93 53.63 m
596.69 53.63 l
567.17 841.91 m
567.17 802.19 l
28.61 843.23 m
28.61 802.19 l
566.93 801.95 m
598.13 801.95 l
-2.23 801.95 m
28.37 801.95 l
S
BT
9.5 0 0 9.5 85.01 693.11 Tm
/GS2 gs
0.004 Tc
0.092 Tw
(dias, ou dose \372nica de azitromicina 1g VO)Tj
5.5 0 0 5.5 270.65 696.35 Tm
0.001 Tc
0.091 Tw
(19 32)Tj
9.5 0 0 9.5 285.05 693.11 Tm
(.)Tj
-21.057 -1.099 TD
-0.01 Tc
-0.069 Tw
(Mulheres gr\341vidas com gonorr\351ia n\343o complicada)Tj
0 -1.112 TD
0.012 Tc
0.139 Tw
(devem ser tratadas com ceftriaxona em dose)Tj
0 -1.099 TD
0.002 Tc
-0.069 Tw
[(\372nica de 250mg IM.)53( A do)27(xiciclina e as quinolonas)]TJ
0 -1.112 TD
0 Tc
(mostram-se contra-indicadas na gravidez, sendo)Tj
0 -1.099 TD
0.004 Tc
0.131 Tw
(se \351 recomenda realizar novos testes para se)Tj
0 -1.112 TD
0.001 Tc
-0.069 Tw
(documentar cura, exceto quando h\341 persist\352ncia)Tj
0 -1.099 TD
0.004 Tc
0.011 Tw
(dos sintomas)Tj
5.5 0 0 5.5 141.65 622.79 Tm
0.003 Tc
0.013 Tw
(2 10 12 20 22 29)Tj
9.5 0 0 9.5 183.53 619.67 Tm
(.)Tj
-8.88 -1.402 TD
0.056 Tc
0.139 Tw
(Os pacientes com infec\347\343o gonoc\363cica)Tj
-1.491 -1.112 TD
0.018 Tc
(disseminada devem ser tratados inicialmente)Tj
0 -1.099 TD
-0.029 Tc
-0.07 Tw
(com ceftriaxona 1g IV ou IM diariamente por 14 dias.)Tj
1.491 -1.415 TD
0.015 Tc
0.14 Tw
(Infec\347\365es n\343o complicadas em crian\347as e)Tj
-1.491 -1.099 TD
0.014 Tc
0.091 Tw
(neonatos devem ser tratadas com ceftriaxona)Tj
0 -1.112 TD
-0.016 Tc
-0.069 Tw
[(25-50mg/kg, n\343o e)22(xcedendo 125mg.)60( A conjuntivite)]TJ
0 -1.099 TD
0 Tc
(e a doen\347a disseminada devem ser tratadas com)Tj
0 -1.112 TD
0.004 Tc
0.007 Tw
(essa dose por 7 a 10 dias.)Tj
2.804 -2.135 TD
0.002 Tc
0.068 Tw
[(MANEJO DO P)128(ARCEIR)15(O SEXU)40(AL)]TJ
-1.314 -1.768 TD
0.004 Tc
(O manejo dos parceiros sexuais representa)Tj
-1.491 -1.112 TD
0.086 Tc
-0.069 Tw
(parte integral do tratamento de pacientes)Tj
0 -1.099 TD
0.008 Tc
0.14 Tw
(com gonorr\351ia e outras doen\347as sexualmente)Tj
0 -1.112 TD
-0.031 Tc
-0.07 Tw
(transmiss\355veis. Os parceiros devem ser examinados)Tj
0 -1.099 TD
0.004 Tc
-0.011 Tw
(e tratados com uma das drogas recomendadas,)Tj
0 -1.112 TD
0.019 Tw
(independente da presen\347a de sintomas.)Tj
1.705 -2.135 TD
0.002 Tc
-0.016 Tw
(A GONORR\311IA COMO PROBLEMA DE)Tj
4.408 -1.314 TD
0.053 Tw
(SA\332DE P\332BLICA)Tj
5.5 0 0 5.5 219.89 410.63 Tm
0.001 Tc
(39)Tj
9.5 0 0 9.5 226.01 407.51 Tm
(*)Tj
-13.352 -1.768 TD
0.086 Tc
-0.07 Tw
[(T)116(endo em vista n)10(umerosos f)23(atores que)]TJ
-1.491 -1.112 TD
0.112 Tc
(correlacionam as doen\347as sexualmente)Tj
0 -1.099 TD
0.004 Tc
-0.062 Tw
[(transmiss\355v)29(eis \(DST\) entre si e essas com o HIV)130(,)]TJ
0 -1.112 TD
0.066 Tw
(na \363ptica da sa\372de p\372blica \351 necess\341rio que a)Tj
0 -1.099 TD
0.005 Tc
0.051 Tw
(gonorr\351ia seja vista no contexto da )Tj
9.5 0 2.019 9.5 239.45 348.71 Tm
0.002 Tc
(abordagem)Tj
-16.021 -1.112 TD
0.059 Tc
(sindr\364mica)Tj
9.5 0 0 9.5 136.61 338.15 Tm
0.061 Tc
0.14 Tw
(. Dentre outros objetivos, essa)Tj
-5.432 -1.099 TD
0.004 Tc
0.133 Tw
(abordagem busca melhorar a sensibilidade do)Tj
0 -1.112 TD
-0.022 Tw
(diagn\363stico e do tratamento dos pacientes, e ao)Tj
0 -1.099 TD
-0.055 Tw
(abord\341-lo lembrando de todas as DSTs e n\343o de)Tj
0 -1.112 TD
0.003 Tc
0.019 Tw
(uma s\363 patologia.)Tj
1.491 -1.402 TD
0.007 Tc
0.14 Tw
(A abordagem sindr\364mica agrupa a maioria)Tj
-1.491 -1.112 TD
-0.024 Tc
-0.069 Tw
[(das DSTs nas categor)-24(ias:)39( \372lcer)14(a genital, corr)-24(imento)]TJ
0 -1.099 TD
(uretral no homem, corrimento cervical e dor p\351lvica.)Tj
1.491 -1.402 TD
-0.034 Tc
(O texto a seguir enfoca a abordagem sindr\364mica,)Tj
-1.491 -1.112 TD
0.004 Tc
(enfatizando o paciente com corrimento, situa\347\343o)Tj
0 -1.099 TD
0.013 Tw
(na qual o diagn\363stico de gonorr\351ia se imp\365e.)Tj
1.491 -1.415 TD
0.014 Tc
0.139 Tw
(Embora os poucos dados epidemiol\363gicos)Tj
-1.491 -1.099 TD
0.009 Tc
(existentes n\343o se prestem a fazer infer\352ncias)Tj
0 -1.112 TD
0.004 Tc
-0.015 Tw
(para o pa\355s como um todo, ao menos permitem,)Tj
0 -1.099 TD
-0.034 Tw
(quando conjugados \340s informa\347\365es geradas em)Tj
0 -1.112 TD
0.095 Tw
(outros pa\355ses, a realiza\347\343o de estimativas que)Tj
23.432 54.846 TD
0.028 Tw
(concluem pela elevada freq\374\352ncia das DST em)Tj
0 -1.099 TD
0.015 Tc
0.14 Tw
(nosso pa\355s. Isto, associado ao alto \355ndice de)Tj
0 -1.112 TD
-0.006 Tc
-0.004 Tw
[(automedica\347\343o)32(, tor)-19(na o prob)32(lema ainda maior)45(, j\341)]TJ
0 -1.099 TD
0.004 Tc
-0.059 Tw
(que muitos dos casos n\343o recebem a orienta\347\343o)Tj
0 -1.112 TD
-0.024 Tc
-0.07 Tw
(e tratamento adequados, permanecem subcl\355nicos,)Tj
0 -1.099 TD
0.06 Tc
(transmissores e mantendo-se como os elos)Tj
0 -1.112 TD
0.053 Tc
(fundamentais na cadeia de transmiss\343o das)Tj
0 -1.099 TD
0.007 Tc
(doen\347as.)Tj
1.491 -1.402 TD
0.044 Tc
-0.058 Tw
(As DST s\343o o principal fator facilitador da)Tj
-1.491 -1.112 TD
0.004 Tc
0.025 Tw
[(tr)17(ansmiss\343o se)29(xual do HIV)130(, sendo que algumas)]TJ
0 -1.099 TD
-0.069 Tw
(delas, quando n\343o diagnosticadas e tratadas em)Tj
0 -1.112 TD
(tempo, podem evoluir para complica\347\365es graves)Tj
0 -1.099 TD
-0.018 Tw
[(e at\351 o \363bito;)55( algumas DST)118(, dur)17(ante a gesta\347\343o)29(,)]TJ
0 -1.112 TD
0.032 Tc
-0.069 Tw
(podem ser transmitidas ao feto, causando-lhe)Tj
0 -1.099 TD
0.025 Tc
0.14 Tw
(importantes les\365es ou mesmo provocando a)Tj
0 -1.112 TD
0.045 Tc
-0.07 Tw
(interrup\347\343o espont\342nea da gravidez; as DST)Tj
0 -1.099 TD
-0.023 Tc
(podem causar grande impacto psicol\363gico em seus)Tj
0 -1.112 TD
0.051 Tc
(portadores; as DST causam tamb\351m grande)Tj
0 -1.099 TD
0 Tc
(impacto social, que se traduz em custos indiretos)Tj
0 -1.112 TD
0.036 Tc
(para a economia do Pa\355s e que, somados aos)Tj
0 -1.099 TD
-0.032 Tc
(enormes custos diretos decorrentes das interna\347\365es)Tj
0 -1.112 TD
0.004 Tc
-0.004 Tw
(e procedimentos necess\341rios para o tratamento)Tj
0 -1.099 TD
0.026 Tw
(de suas complica\347\365es, elevam dramaticamente)Tj
0 -1.112 TD
0.005 Tc
0.008 Tw
(esses custos totais.)Tj
1.491 -1.402 TD
0.183 Tc
-0.07 Tw
[(As DST)120(, por suas car)6(acter\355sticas)]TJ
-1.491 -1.112 TD
0.035 Tc
0.139 Tw
(epidemiol\363gicas, s\343o agravos vulner\341veis a)Tj
0 -1.099 TD
0.002 Tc
-0.07 Tw
(a\347\365es de preven\347\343o prim\341ria, como por exemplo)Tj
0 -1.112 TD
-0.008 Tc
(a utiliza\347\343o de preservativos, de forma adequada,)Tj
0 -1.099 TD
0.004 Tc
0.032 Tw
[(em todas as rela\347\365es se)29(xuais)17(.)55( Al\351m disso)42(, com)]TJ
0 -1.112 TD
0.015 Tw
[(e)29(xce\347\343o das DSTs causadas por v\355r)-9(us)17(, e)29(xistem)]TJ
0 -1.099 TD
0.057 Tw
(tratamentos eficazes para todas elas; portanto,)Tj
0 -1.112 TD
-0.026 Tc
-0.07 Tw
(\340 medida que se consiga conscientizar os pacientes)Tj
0 -1.099 TD
0.018 Tc
0.14 Tw
(da necessidade de procurar rapidamente um)Tj
0 -1.112 TD
0.004 Tc
-0.037 Tw
(servi\347o de sa\372de para tratar-se adequadamente)Tj
0 -1.099 TD
0.005 Tc
0.083 Tw
(e a seus parceiros sexuais, se lograr\341, a curto)Tj
0 -1.112 TD
0.004 Tc
0.062 Tw
(prazo, romper a cadeia de transmiss\343o dessas)Tj
0 -1.099 TD
0.042 Tw
(doen\347as e consequentemente da infec\347\343o pelo)Tj
0 -1.112 TD
0.013 Tc
[(HIV)114(.)]TJ
1.491 -1.402 TD
0.04 Tc
-0.07 Tw
(O controle das DST \351 poss\355vel, desde que)Tj
-1.491 -1.099 TD
0.002 Tc
(existam bons programas preventivos e uma rede)Tj
0 -1.112 TD
-0.009 Tc
(de servi\347os b\341sicos resolutivos, ou seja, unidades)Tj
0 -1.099 TD
0.004 Tc
0.129 Tw
(de sa\372de acess\355veis para pronto atendimento,)Tj
0 -1.112 TD
0.044 Tc
-0.04 Tw
(com profissionais preparados, n\343o s\363 para o)Tj
0 -1.099 TD
0.004 Tc
0.128 Tw
(diagn\363stico e tratamento, mas tamb\351m para o)Tj
0 -1.112 TD
0.008 Tc
0.14 Tw
(adequado acolhimento e aconselhamento dos)Tj
0 -1.099 TD
0.004 Tc
-0.036 Tw
(portadores de DST e de seus parceiros sexuais,)Tj
0 -1.112 TD
0.095 Tw
(e que tenham a garantia de um fluxo cont\355nuo)Tj
0 -1.099 TD
0.021 Tw
(de medicamentos e preservativos.)Tj
1.491 -1.415 TD
0.017 Tc
0.139 Tw
(Os princ\355pios b\341sicos para o controle das)Tj
-1.491 -1.099 TD
0.006 Tc
[(D)8(S)8(T)120(, como em qualquer processo de controle)]TJ
0 -1.112 TD
0.004 Tc
0.014 Tw
(de epidemias, s\343o os seguintes:)Tj
/F6 1 Tf
9 0 0 9 307.61 143.39 Tm
(\267)Tj
/F4 1 Tf
1.573 0 TD
0.007 Tc
0.049 Tw
(interromper a cadeia de transmiss\343o, atuando)Tj
0 -1.16 TD
-0.023 Tc
-0.069 Tw
(objetivamente nos )Tj
9 0 1.913 9 392.33 132.95 Tm
-0.025 Tc
(elos)Tj
9 0 0 9 407.93 132.95 Tm
-0.024 Tc
[( que formam essa corrente,)]TJ
7 0 0 7 255.77 759.71 Tm
0.009 Tc
0.049 Tw
[(Re)26(vista da Sociedade Br)9(asileir)-8(a de Medicina )44(T)123(ropical 33:451-464, set-out, 2000)]TJ
4.1 0 0 4.1 84.65 146.63 Tm
(*)Tj
7 0 0 7 86.33 144.35 Tm
-0.04 Tw
(Adaptado do Manual de Controle das DST - Minist\351rio da Sa\372de)Tj
-0.24 -1.2 TD
0.022 Tw
(- 3\252 edi\347\343o, 1999.)Tj
ET
0.24 w 
/GS1 gs
84.65 151.79 m
141.29 151.79 l
S
endstreamendobj37 0 obj<< /ProcSet [ /PDF /Text ] /Font << /F4 5 0 R /F6 6 0 R >> /ExtGState << /GS1 9 0 R /GS2 10 0 R >> >> endobj38 0 obj<< /Type /Page /Parent 11 0 R /Resources 40 0 R /Contents 39 0 R /CropBox [ 28.8 55.44 566.2 801.67999 ] >> endobj39 0 obj<< /Length 7220 >> stream
BT
/F4 1 Tf
10 0 0 10 85.01 83.87 Tm
0 0 0 rg
/GS2 gs
0.006 Tc
(460)Tj
ET
0 0 0 RG
0 J 0 j 0.48 w 10 M []0 d
/GS1 gs
1 i 
28.61 53.87 m
28.61 -1.33 l
567.17 53.87 m
567.17 -0.01 l
-4.27 53.63 m
28.37 53.63 l
566.93 53.63 m
598.13 53.63 l
567.17 841.91 m
567.17 802.19 l
28.61 843.83 m
28.61 802.19 l
566.93 801.95 m
598.13 801.95 l
-2.23 801.95 m
28.37 801.95 l
S
BT
9 0 0 9 99.17 693.11 Tm
/GS2 gs
0.035 Tc
-0.069 Tw
(ou seja, detectando precocemente os casos,)Tj
0 -1.16 TD
0.037 Tc
-0.038 Tw
(tratando-os, e a seus parceiros, adequada e)Tj
0 -1.173 TD
0.008 Tc
(oportunamente;)Tj
/F6 1 Tf
-1.573 -1.48 TD
(\267)Tj
/F4 1 Tf
1.573 0 TD
0.091 Tc
-0.069 Tw
(prevenir novas ocorr\352ncias, por meio de)Tj
0 -1.16 TD
0.007 Tc
0.05 Tw
(aconselhamento espec\355fico, durante o qual as)Tj
0 -1.173 TD
0.014 Tc
0.139 Tw
(orienta\347\365es sejam discutidas conjuntamente,)Tj
0 -1.16 TD
-0.007 Tc
-0.07 Tw
(favorecendo a compreens\343o e o seguimento das)Tj
0 -1.173 TD
0.008 Tc
0.139 Tw
(prescri\347\365es m\351dicas e contribuindo de forma)Tj
0 -1.16 TD
0.007 Tc
-0.028 Tw
(mais efetiva para a ado\347\343o de pr\341ticas sexuais)Tj
0 -1.173 TD
0.006 Tc
0.027 Tw
(mais seguras.)Tj
9.5 0 0 9.5 99.17 582.47 Tm
-0.009 Tc
-0.07 Tw
(A preven\347\343o, estrat\351gia b\341sica para o controle)Tj
-1.491 -1.112 TD
0.004 Tc
0.062 Tw
[(da transmiss\343o das DST e do HIV)130(, se dar\341 por)]TJ
0 -1.099 TD
-0.04 Tw
(meio da constante informa\347\343o para a popula\347\343o)Tj
0 -1.112 TD
-0.044 Tw
(geral e das atividades educativas que priorizem:)Tj
0 -1.099 TD
0.131 Tc
-0.07 Tw
(a percep\347\343o de risco, as mudan\347as no)Tj
0 -1.112 TD
0.004 Tc
0.047 Tw
(comportamento sexual e a promo\347\343o e ado\347\343o)Tj
0 -1.099 TD
-0.002 Tc
-0.069 Tw
(de medidas preventivas com \352nfase na utiliza\347\343o)Tj
0 -1.112 TD
0.032 Tc
0.139 Tw
[(adequada do preser)-44(v)27(ativ)32(o)45(.)57( As atividades de)]TJ
0 -1.099 TD
0.004 Tc
0.047 Tw
(aconselhamento das pessoas com DST e seus)Tj
0 -1.112 TD
-0.024 Tc
-0.07 Tw
(parceiros durante o atendimento s\343o fundamentais,)Tj
0 -1.099 TD
-0.005 Tc
(no sentido de buscar que os indiv\355duos percebam)Tj
23.432 22.699 TD
-0.034 Tw
(a necessidade de maior cuidado, protegendo a si)Tj
0 -1.099 TD
-0.011 Tc
-0.07 Tw
(e a seus parceiros, prevenindo assim a ocorr\352ncia)Tj
0 -1.112 TD
0.004 Tc
-0.042 Tw
(de novos epis\363dios. Deve-se sempre enfatizar a)Tj
0 -1.099 TD
0.075 Tw
(associa\347\343o existente entre as DST e a infe\347\343o)Tj
0 -1.112 TD
-0.014 Tw
[(pelo HIV)130(.)55( De)17(v)24(e-se)17(, ainda, estimular a ades\343o ao)]TJ
0 -1.099 TD
0.136 Tw
(tratamento, explicitando a exist\352ncia de casos)Tj
0 -1.112 TD
0.037 Tw
(assintom\341ticos ou pouco sintom\341ticos, tamb\351m)Tj
0 -1.099 TD
-0.006 Tw
[(suscet\355v)17(eis a g)17(r)9(a)29(v)24(es complica\347\365es)17(.)55( A promo\347\343o)]TJ
0 -1.112 TD
0.039 Tw
(e distribui\347\343o de preservativos deve ser fun\347\343o)Tj
0 -1.099 TD
0.065 Tw
[(de todos os servi\347os que prestam esse tipo de)]TJ
0 -1.112 TD
0.005 Tc
0 Tw
(assist\352ncia. Desta forma, a assist\352ncia pode se)Tj
0 -1.099 TD
0.081 Tc
-0.069 Tw
(constituir em um momento privilegiado de)Tj
0 -1.112 TD
0.006 Tc
(preven\347\343o.)Tj
1.491 -1.402 TD
0.098 Tc
(Os portadores de DST devem receber)Tj
-1.491 -1.099 TD
0.003 Tc
-0.066 Tw
[(atendimento e tratamento imediato)41(.)54( A espera em)]TJ
0 -1.112 TD
0.004 Tc
0.108 Tw
(longas filas e a possibilidade de agendamento)Tj
0 -1.099 TD
-0.027 Tc
-0.07 Tw
(para outro dia, associadas \340 falta de medicamentos,)Tj
0 -1.112 TD
0.004 Tc
0.09 Tw
(s\343o talvez os principais fatores que induzem \340)Tj
0 -1.099 TD
-0.013 Tw
(busca de aten\347\343o diretamente com o balconista)Tj
0 -1.112 TD
0.077 Tw
(da farm\341cia. Em si, o atendimento imediato de)Tj
0 -1.099 TD
-0.013 Tc
-0.069 Tw
(uma DST n\343o constitui apenas uma a\347\343o curativa,)Tj
7 0 0 7 85.01 759.71 Tm
0.01 Tc
0.012 Tw
[(Penna GO  et al)]TJ
/F6 1 Tf
9.5 0 0 9.5 193.85 449.63 Tm
0.003 Tc
0.022 Tw
(Fluxograma para casos de corrimento uretral)Tj
ET
0.24 w 1000 M 
/GS1 gs
179.37 440.83 226.56 -18.76 re
S
BT
/F4 1 Tf
9.5 0 0 9.5 201.77 429.59 Tm
/GS2 gs
0.004 Tc
0.017 Tw
(paciente com queixa de corrimento uretral)Tj
4.004 -3.625 TD
0.015 Tw
(anamnese e exame f\355sico)Tj
ET
/GS1 gs
219.37 406.48 148.86 -18.01 re
S
BT
9.5 0 0 9.5 184.61 358.91 Tm
/GS2 gs
0.02 Tw
(bacterioscopia dispon\355vel no momento da consulta?)Tj
ET
/GS1 gs
172.37 370.48 243.46 -18.76 re
S
BT
9.5 0 0 9.5 219.65 321.59 Tm
/GS2 gs
0.006 Tc
[(n\343o)-11426(sim)]TJ
2.943 -3.688 TD
0.004 Tc
0.026 Tw
(diplococos gram negativos intracelulares)Tj
6.657 -1.099 TD
0.006 Tc
(presentes?)Tj
-8.994 -7.528 TD
0.004 Tc
0.017 Tw
(tratar clam\355dia e gonorr\351ia)Tj
16.838 0.215 TD
0.011 Tw
(tratar s\363)Tj
-0.025 -1.112 TD
0.006 Tc
(clam\355dia)Tj
-17.975 -3.309 TD
0.004 Tc
0.038 Tw
[(aconselhar)55(,)-5( o)-5(f)29(erecer anti-HIV e )56(VDRL,)]TJ
-0.998 -1.112 TD
0.03 Tw
[(enf)29(atizar a ades\343o ao tratamento)42(, notificar)55(,)]TJ
1.175 -1.099 TD
0.017 Tw
(convocar parceiros e agendar retorno)Tj
ET
/GS1 gs
208.37 334.48 35.81 -18.76 re
334.37 333.48 35.81 -18.76 re
S
BT
9.5 0 0 9.5 394.61 238.55 Tm
/GS2 gs
0.006 Tc
(n\343o)Tj
-11.091 0 TD
(sim)Tj
ET
/GS1 gs
383.37 251.48 35.81 -18.76 re
279.37 250.48 35.81 -18.76 re
241.52 299.48 185.46 -32.26 re
S
3.96 w 10 M 
296.87 422.63 m
296.87 412.91 l
S
3 w 1000 M 
294.793 411.994 m
297.415 407.23 l
300.036 411.994 l
b*
3.96 w 10 M 
297.95 388.55 m
297.95 378.83 l
S
3 w 1000 M 
295.943 377.995 m
298.565 373.231 l
301.186 377.995 l
b*
3.96 w 10 M 
227.87 351.59 m
227.87 341.87 l
S
3 w 1000 M 
225.795 340.996 m
228.417 336.232 l
231.038 340.996 l
b*
3.96 w 10 M 
351.83 351.59 m
351.83 341.87 l
S
3 w 1000 M 
349.792 340.996 m
352.414 336.232 l
355.035 340.996 l
b*
3.96 w 10 M 
352.79 315.59 m
352.79 305.87 l
S
3 w 1000 M 
350.792 304.997 m
353.414 300.233 l
356.035 304.997 l
b*
3.96 w 10 M 
296.87 268.55 m
296.87 258.83 l
S
3 w 1000 M 
294.793 257.998 m
297.415 253.234 l
300.036 257.998 l
b*
3.96 w 10 M 
401.87 268.55 m
401.87 258.83 l
S
3 w 1000 M 
399.791 257.998 m
402.412 253.234 l
405.034 257.998 l
b*
0.24 w 
379.37 216.48 48.61 -26.81 re
S
3.96 w 10 M 
401.87 233.63 m
401.87 223.91 l
S
3 w 1000 M 
399.791 222.999 m
402.412 218.235 l
405.034 222.999 l
b*
0.24 w 
205.37 216.48 148.86 -18.01 re
S
3.96 w 10 M 
296.87 232.55 m
296.87 222.83 l
S
3 w 1000 M 
294.793 221.999 m
297.415 217.235 l
300.036 221.999 l
b*
3.96 w 10 M 
226.91 314.51 m
226.91 223.79 l
S
3 w 1000 M 
224.795 222.949 m
227.417 218.185 l
230.038 222.949 l
b*
0.24 w 
174.37 174.98 243.46 -41.46 re
S
3.96 w 10 M 
276.83 194.15 m
276.83 184.31 l
S
3 w 1000 M 
274.794 183.5 m
277.415 178.736 l
280.037 183.5 l
b*
3.96 w 10 M 
403.79 191.15 m
403.79 181.31 l
S
3 w 1000 M 
401.791 180.5 m
404.412 175.736 l
407.034 180.5 l
b*
endstreamendobj40 0 obj<< /ProcSet [ /PDF /Text ] /Font << /F4 5 0 R /F6 6 0 R >> /ExtGState << /GS1 9 0 R /GS2 10 0 R >> >> endobj41 0 obj<< /Type /Page /Parent 45 0 R /Resources 43 0 R /Contents 42 0 R /CropBox [ 28.8 55.44 566.2 801.67999 ] >> endobj42 0 obj<< /Length 8126 >> stream
BT
/F4 1 Tf
10 0 0 10 493.49 85.31 Tm
0 0 0 rg
/GS2 gs
0.006 Tc
(461)Tj
ET
0 0 0 RG
0 J 0 j 0.48 w 10 M []0 d
/GS1 gs
1 i 
28.61 53.87 m
28.61 -1.33 l
567.17 53.87 m
567.17 -1.93 l
-2.83 53.63 m
28.37 53.63 l
566.93 53.63 m
596.69 53.63 l
567.17 841.91 m
567.17 802.19 l
28.61 843.23 m
28.61 802.19 l
566.93 801.95 m
598.13 801.95 l
-2.23 801.95 m
28.37 801.95 l
S
BT
9.5 0 0 9.5 85.01 692.99 Tm
/GS2 gs
0.055 Tc
0.14 Tw
(mas tamb\351m, e principalmente, uma a\347\343o)Tj
0 -1.137 TD
-0.013 Tc
-0.07 Tw
(preventiva da transmiss\343o do HIV e do surgimento)Tj
T*
0.004 Tc
0.021 Tw
(de outras complica\347\365es.)Tj
1.491 -1.44 TD
0.066 Tc
0.14 Tw
(O atendimento de pacientes com DST)Tj
-1.491 -1.137 TD
0.04 Tc
-0.07 Tw
(apresenta algumas particularidades. Ele visa)Tj
T*
0.004 Tc
0.118 Tw
(interromper a cadeia de transmiss\343o da forma)Tj
T*
-0.012 Tc
-0.07 Tw
[(mais ef)26(etiv)26(a e imediata poss\355v)13(el.)64( )44(Visa, ainda, e)26(vitar)]TJ
T*
(as complica\347\365es advindas da\(s\) DST em quest\343o,)Tj
T*
0.004 Tc
0.012 Tw
(e a cessa\347\343o imediata dos sintomas.)Tj
1.491 -1.44 TD
0.002 Tc
-0.069 Tw
[(O objetiv)15(o desse atendimento \351 tentar pro)27(v)22(e)7(r)40(,)]TJ
-1.491 -1.137 TD
0.004 Tc
-0.017 Tw
(em uma \372nica consulta: diagn\363stico, tratamento)Tj
T*
-0.033 Tc
-0.07 Tw
(e aconselhamento adequados. N\343o h\341 impedimento)Tj
T*
0 Tc
(para que exames laboratoriais sejam colhidos ou)Tj
T*
0.003 Tc
0.14 Tw
[(of)16(erecidos)16(.)54( A conduta, no entanto)41(, n\343o de)16(v)23(er\341)]TJ
T*
-0.006 Tc
-0.07 Tw
(depender de demorados processos de realiza\347\343o)Tj
T*
-0.008 Tc
[(e/ou interpreta\347\343o dos exames. N\343o se quer dizer)]TJ
T*
0.004 Tc
0.042 Tw
(com isto que o laborat\363rio seja dispens\341vel, ao)Tj
T*
-0.023 Tc
-0.07 Tw
(contr\341rio, tem seu papel aumentado principalmente)Tj
T*
0.004 Tc
0.028 Tw
(em unidades de sa\372de de maior complexidade,)Tj
T*
-0.011 Tc
-0.07 Tw
(que servir\343o como fontes para a defini\347\343o do perfil)Tj
T*
0.021 Tc
0.14 Tw
(epidemiol\363gico das diferentes DST e de sua)Tj
T*
0.004 Tc
0.032 Tw
(sensibilidade aos medicamentos preconizados.)Tj
1.491 -1.44 TD
-0.044 Tw
(Fluxogramas espec\355ficos, j\341 desenvolvidos e)Tj
-1.491 -1.137 TD
0.021 Tc
0.14 Tw
(validados, s\343o instrumentos que auxiliar\343o o)Tj
T*
-0.002 Tc
-0.069 Tw
(profissional que realiza o atendimento na tomada)Tj
T*
-0.022 Tc
(de decis\365es. Seguindo os passos dos fluxogramas,)Tj
T*
0.003 Tc
(o profissional, ainda que n\343o especialista, estar\341)Tj
T*
-0.023 Tc
(habilitado a: determinar um diagn\363stico sindr\364mico,)Tj
T*
0.044 Tc
0.054 Tw
(implementar o tratamento imediato, realizar)Tj
T*
0.023 Tc
0.14 Tw
(aconselhamento para estimular a ades\343o ao)Tj
T*
0.044 Tc
-0.042 Tw
(tratamento, para a redu\347\343o de riscos, para a)Tj
T*
-0.017 Tc
-0.07 Tw
(convoca\347\343o, orienta\347\343o e tratamento de parceiros,)Tj
T*
0.004 Tc
-0.015 Tw
(promo\347\343o de incentivo ao uso de preservativos,)Tj
T*
0.019 Tw
(dentre outros aspectos.)Tj
3.966 -2.147 TD
0.002 Tc
0.007 Tw
(PACIENTE COM QUEIXA DE)Tj
0.796 -1.314 TD
0.073 Tw
[(CORRIMENT)53(O URETRAL)]TJ
-3.272 -1.781 TD
0.004 Tc
0.096 Tw
(Este \351 o quadro de entrada do fluxograma.)Tj
-1.491 -1.112 TD
-0.004 Tc
-0.069 Tw
[(Nele encontra-se representada a principal queixa)]TJ
0 -1.099 TD
-0.012 Tc
(do paciente ao se apresentar ao servi\347o de sa\372de.)Tj
27.057 45.752 TD
0.003 Tc
0.026 Tw
(ANAMNESE E EXAME F\315SICO)Tj
-2.135 -1.743 TD
0.004 Tc
-0.049 Tw
(Este quadro de a\347\343o indica que \351 necess\341rio)Tj
-1.491 -1.061 TD
0.034 Tc
-0.07 Tw
(fazer a anamnese e examinar o paciente para)Tj
T*
0.002 Tc
(determinar se ele tem corrimento uretral ou outro)Tj
T*
0.031 Tc
[(sinal de DST)119(.)56( Ao e)18(xame f\355sico)44(, com o prep\372cio)]TJ
0 -1.074 TD
-0.025 Tc
(retra\355do, verificar se o corrimento prov\351m realmente)Tj
0 -1.061 TD
0.051 Tc
(do meato uretral. Se n\343o houver corrimento,)Tj
T*
0.072 Tc
(solicitar ao paciente que ordenhe a uretra,)Tj
T*
0.073 Tc
(comprimindo o p\352nis da base \340 glande. Se)Tj
T*
-0.02 Tc
(mesmo assim n\343o se observar o corrimento, sendo)Tj
T*
0.004 Tc
0.015 Tw
(a hist\363ria consistente, mantenha a conduta.)Tj
2.16 -2.135 TD
0.002 Tc
0 Tw
(BACTERIOSCOPIA DISPON\315VEL NO)Tj
1.971 -1.314 TD
0.001 Tc
0.092 Tw
[(MOMENT)39(O D)39(A)-1( CONSUL)102(T)119(A)-1(?)]TJ
-2.64 -1.743 TD
-0.001 Tc
-0.066 Tw
(Este quadro de decis\343o indica a possibilidade)Tj
-1.491 -1.061 TD
-0.006 Tc
0.029 Tw
[(de se fazer a bacterioscopia durante )-6(a)-11( )]TJ
17.296 0 TD
0.005 Tc
(consulta,)Tj
-17.296 -1.061 TD
0.074 Tc
-0.069 Tw
(o que poderia auxiliar na decis\343o sobre os)Tj
T*
0.004 Tc
0.022 Tw
(procedimentos a serem seguidos.)Tj
2.602 -2.135 TD
0.002 Tc
0.092 Tw
[(DIPLOCOCOS GRAM NEGA)116(TIV)40(O)7(S)]TJ
0.076 -1.314 TD
0.001 Tc
0.111 Tw
(INTRACELULARES PRESENTES?)Tj
-1.187 -1.731 TD
-0.006 Tc
0.011 Tw
(Este quadro de decis\343o indica que se houver)Tj
-1.491 -1.048 TD
0.031 Tc
0.139 Tw
(exame bacteriosc\363pico dispon\355vel durante a)Tj
0 -1.061 TD
-0.006 Tc
0.051 Tw
(consulta, deve-se questionar o paciente sobre a)Tj
0 -1.048 TD
0.006 Tc
0.139 Tw
(utiliza\347\343o pr\351via de antibi\363ticos ou sobre uma)Tj
T*
-0.006 Tc
0.02 Tw
(eventual mic\347\343o imediatamente anterior \340 coleta)Tj
T*
0.02 Tc
0.14 Tw
(do material, o que poderia comprometer sua)Tj
0 -1.061 TD
0.009 Tc
(qualidade; se nenhuma dessas possibilidades)Tj
0 -1.048 TD
-0.004 Tc
(ocorreu, e estando presentes diplococos Gram)Tj
T*
-0.005 Tc
0.05 Tw
(negativos intracelulares, se faz o diagn\363stico de)Tj
0 -1.061 TD
0.128 Tw
(gonorr\351ia, n\343o podendo-se, por\351m, descartar a)Tj
0 -1.048 TD
0.097 Tw
(possibilidade de co-infec\347\343o pela clam\355dia, cujo)Tj
T*
-0.012 Tc
-0.069 Tw
(diagn\363stico laboratorial exige t\351cnicas demoradas)Tj
0 -1.061 TD
(e raramente dispon\355veis. Recomenda-se, sempre,)Tj
0 -1.048 TD
0.064 Tc
0.215 Tw
(o tratamento concomitante para as duas)Tj
0 -1.074 TD
-0.003 Tc
(infec\347\365es.)Tj
2.514 -2.135 TD
0.002 Tc
0.048 Tw
[(TRA)116(T)120(AR CLAM\315DIA E GONORR\311IA)]TJ
-1.023 -1.756 TD
0.074 Tc
0.289 Tw
(Este quadro de a\347\343o orienta para o)Tj
-1.491 -1.086 TD
0.07 Tc
0.139 Tw
(tratamento concomitante para clam\355dia e)Tj
0 -1.099 TD
0.006 Tc
(gonorr\351ia:)Tj
/F6 1 Tf
7 0 0 7 150.05 214.55 Tm
0.013 Tc
[(Clam\355dia)-28633(Gonorr\351ia)]TJ
/F4 1 Tf
-8.4 -1.543 TD
0.01 Tc
0.017 Tw
(Azitromicina 1g, VO, em dose \372nica; )Tj
/F6 1 Tf
16.937 0 TD
0.012 Tc
(ou)Tj
/F4 1 Tf
11.006 0 TD
0.009 Tc
0.027 Tw
[(Ofloxacina 400 mg, VO, dose \372nica \(contra-indicado em menores)]TJ
-27.943 -1.543 TD
0.01 Tc
0.007 Tw
[(Doxiciclina )-17(100mg, )-17(VO, )-17(de )-17(12/12 )-17(horas,)-9830(    de 8 anos\); )]TJ
/F6 1 Tf
34.56 0 TD
0.012 Tc
(ou)Tj
/F4 1 Tf
-34.56 -1.56 TD
0.009 Tc
0.018 Tw
[(    )20(durante )8(7 )8(dias; )]TJ
/F6 1 Tf
8.28 0 TD
0.01 Tc
0.013 Tw
[(ou)-11956( mais)]TJ
/F4 1 Tf
19.663 0 TD
0.02 Tw
(Cefixima 400mg, VO, dose \372nica; )Tj
/F6 1 Tf
15.6 0 TD
0.012 Tc
(ou)Tj
/F4 1 Tf
-43.543 -1.543 TD
0.009 Tc
0.033 Tw
[(Eritromicina \(estearato\) 500mg, VO, de)-10054(Ciprofloxacina 500mg, VO, dose \372nica \(contra-indicado em menores)]TJ
0 -1.56 TD
0.01 Tc
0.008 Tw
[(    6/6 horas, durante 7 dias)-15401(    de 8 anos\); )]TJ
/F6 1 Tf
34.56 0 TD
0.012 Tc
(ou)Tj
/F4 1 Tf
-6.617 -1.543 TD
0.01 Tc
0.019 Tw
(Ceftriaxona 250 mg, IM, dose \372nica; )Tj
/F6 1 Tf
16.817 0 TD
0.012 Tc
(ou)Tj
/F4 1 Tf
-16.817 -1.543 TD
0.01 Tc
0.056 Tw
[(Tianf)27(enicol 2,5g, )45(V)43(O)51(, dose \372nica.)]TJ
-4.44 88.714 TD
0.009 Tc
0.049 Tw
[(Re)26(vista da Sociedade Br)9(asileir)-8(a de Medicina )44(T)123(ropical 33:451-464, set-out, 2000)]TJ
ET
0.24 w 1000 M 
/GS1 gs
85.17 225.23 424.96 -91.86 re
S
endstreamendobj43 0 obj<< /ProcSet [ /PDF /Text ] /Font << /F4 5 0 R /F6 6 0 R >> /ExtGState << /GS1 9 0 R /GS2 10 0 R >> >> endobj44 0 obj<< /Type /Pages /Kids [ 11 0 R 45 0 R ] /Count 14 /MediaBox [ 0 0 595 842 ] >> endobj45 0 obj<< /Type /Pages /Kids [ 41 0 R 46 0 R 49 0 R 52 0 R ] /Count 4 /Parent 44 0 R >> endobj46 0 obj<< /Type /Page /Parent 45 0 R /Resources 48 0 R /Contents 47 0 R /CropBox [ 28.8 55.44 566.2 801.67999 ] >> endobj47 0 obj<< /Length 9964 >> stream
BT
/F4 1 Tf
10 0 0 10 85.01 83.87 Tm
0 0 0 rg
/GS2 gs
0.006 Tc
(462)Tj
ET
0 0 0 RG
0 J 0 j 0.48 w 10 M []0 d
/GS1 gs
1 i 
28.61 53.87 m
28.61 -1.33 l
567.17 53.87 m
567.17 -0.01 l
-4.27 53.63 m
28.37 53.63 l
566.93 53.63 m
598.13 53.63 l
567.17 841.91 m
567.17 802.19 l
28.61 843.83 m
28.61 802.19 l
566.93 801.95 m
598.13 801.95 l
-2.23 801.95 m
28.37 801.95 l
S
BT
9.5 0 0 9.5 135.65 691.79 Tm
/GS2 gs
0.002 Tc
0.082 Tw
[(TRA)116(T)120(AR S\323 CLAM\315DIA)]TJ
-3.84 -1.731 TD
0.004 Tc
-0.048 Tw
(Este quadro de a\347\343o indica que se estiverem)Tj
-1.491 -1.048 TD
0.103 Tw
(ausentes os diplococos intracelulares, deve-se)Tj
0 -1.061 TD
0.017 Tc
0.139 Tw
(tratar o paciente apenas para clam\355dia como)Tj
0 -1.048 TD
0.004 Tc
0.01 Tw
[(indicado no quadro anter)-21(ior)42(.)]TJ
1.491 -1.352 TD
-0.02 Tc
-0.069 Tw
[(Aconselhar)43(, of)31(erecer anti-HIV e )44(VDRL, enf)31(atizar)]TJ
-1.491 -1.048 TD
-0.033 Tc
[(a ades\343o ao tratamento)43(, notificar)43(, con)18(v)25(ocar parceiros)]TJ
0 -1.061 TD
0.004 Tc
0.014 Tw
(e agendar retorno. Neste quadro de a\347\343o:)Tj
/F6 1 Tf
9 0 0 9 85.01 599.63 Tm
(.)Tj
/F4 1 Tf
1.573 0 TD
0.022 Tc
0.138 Tw
[(consider)9(ar a associa\347\343o entre as DSTs e a)]TJ
0 -1.107 TD
0.029 Tc
[(inf)29(ec\347\343o pelo HIV)109(.)54( Aconselhar o paciente e)]TJ
0 -1.12 TD
0.007 Tc
-0.042 Tw
[(of)20(erecer-lhe a realiza\347\343o de sorologia anti-HIV)34(;)]TJ
/F6 1 Tf
-1.573 -1.427 TD
(.)Tj
/F4 1 Tf
1.573 0 TD
0.02 Tc
0.139 Tw
(a associa\347\343o de mais de uma DST \351 muito)Tj
0 -1.107 TD
0.075 Tc
(freq\374ente. Explicar ao paciente sobre a)Tj
T*
0.007 Tc
0.008 Tw
(import\342ncia de realizar a sorologia para s\355filis;)Tj
/F6 1 Tf
-1.573 -1.427 TD
(.)Tj
/F4 1 Tf
1.573 0 TD
0.01 Tw
(como orienta\347\343o m\355nima para o paciente:)Tj
/F6 1 Tf
0 -1.427 TD
(.)Tj
/F4 1 Tf
1.587 0 TD
-0.001 Tc
-0.07 Tw
(concluir o tratamento mesmo se os sintomas)Tj
-0.013 -1.12 TD
0.007 Tc
0.014 Tw
(ou sinais tiverem desaparecido;)Tj
/F6 1 Tf
-1.573 -1.427 TD
(.)Tj
/F4 1 Tf
1.587 0 TD
0.056 Tc
0.139 Tw
(interromper as rela\347\365es sexuais at\351 a)Tj
-0.013 -1.147 TD
-0.02 Tc
-0.069 Tw
(conclus\343o do tratamento e o desaparecimento)Tj
0 -1.173 TD
0.006 Tc
0.028 Tw
(dos sintomas;)Tj
9.5 0 0 9.5 222.05 379.55 Tm
0.002 Tc
0.095 Tw
(REFER\312NCIAS BIBLIOGR\301FICAS)Tj
3.133 8.211 TD
0.01 Tc
[(A)20(GRADECIMENT)48(OS)]TJ
-16.105 -1.768 TD
0.004 Tc
0.125 Tw
[(V)77(anize de Oliv)29(eira Macedo)42(, Prof)17(essor)17(a Doutora da Univ)29(ersidade de Br)17(as\355lia pela or)-21(ienta\347\343o e)]TJ
-1.491 -1.099 TD
-0.046 Tw
[(r)9(e)29(vis\343o gera)-5(l)-5(.)67( )-17(F)59(abio Moherdaui, M\351dico Sanitar)-9(ista, assessor em DST do Progr)9(ama de DST e Aids do)]TJ
0 -1.112 TD
0.121 Tw
[(Minist\351r)-21(io da Sa\372de)17(, pela re)29(vis\343o do t\363pico )28(\223A gonorr\351ia como prob)17(lema de Sa\372de P\372b)17(lica\224.)55( Ana)]TJ
0 -1.099 TD
-0.067 Tw
(Maria Costa Pinheiro, Professora de Dermatologia \226 UNB/HUB pela leitura cr\355tica final. Edite Dam\341sio)Tj
0 -1.112 TD
0.017 Tw
(da Silva, pela editora\347\343o e diagrama\347\343o.)Tj
7.5 0 0 7.5 321.77 363.23 Tm
0.007 Tc
0.106 Tw
[(Brooks OF)135(, Ootschlich EC)23(, Holmes KK, Xao L, Chiang)]TJ
0 -1.344 TD
0.032 Tc
0.137 Tw
(RO \(eds\) Immunobiology of )Tj
7.5 0 1.594 7.5 426.05 353.15 Tm
0.14 Tw
(Neisseria gonorrhoeoe.)Tj
7.5 0 0 7.5 321.77 342.95 Tm
0.007 Tc
-0.058 Tw
[(W)39(ashington, DC)7(.)61( Amer)-9(ican Society f)7(or Microbiology 145-)]TJ
T*
0.008 Tc
0.033 Tw
(154, 1978.)Tj
-1.888 -1.728 TD
0.002 Tc
-0.068 Tw
[(8)-12(.)-1038(Cannon JG, Spar)-30(ling PP)178(.)56( )52(The genetics of the gonococcus.)]TJ
1.888 -1.344 TD
0.008 Tc
0.013 Tw
[(Ann)8(ual Re)24(v)7(i)7(e)8(w of Microbiology 38:111-133, 1984.)]TJ
-1.888 -1.728 TD
0.007 Tc
0.024 Tw
[(9)-7(.)-1033(Carballo M, Dillon JR, Lussier M, Milthor)-41(p P)167(,)11( )39(Winston S)23(,)]TJ
1.888 -1.344 TD
0.009 Tc
0.137 Tw
(Brodeur B. Evaluation of a urease-based confirmatory)Tj
T*
0.016 Tc
(enzyme linked immunosorbent assay for diagnosis of)Tj
7.5 0 1.594 7.5 321.77 266.63 Tm
0.009 Tc
0.05 Tw
(Neisseria gonorrhoeae. )Tj
7.5 0 0 7.5 403.97 266.63 Tm
0.008 Tc
0.051 Tw
(Journal of Clinical Microbiology)Tj
-10.96 -1.344 TD
0.053 Tw
(30:2181-2183, 1992.)Tj
-1.888 -1.744 TD
0.007 Tc
0.093 Tw
[(10.)-473(Centers f)23(or Disease Control and Pre)7(v)43(ention:)23( Antibiotic-)]TJ
1.888 -1.36 TD
0.054 Tc
0.136 Tw
(resistant strains of )Tj
7.5 0 1.594 7.5 396.41 233.27 Tm
0.056 Tc
0.14 Tw
(Neisseria gonorrhoeae: )Tj
7.5 0 0 7.5 488.21 233.27 Tm
(Policy)Tj
-22.192 -1.36 TD
-0.013 Tc
-0.068 Tw
(guideline for detection, management, and control. Morbidity)Tj
T*
0.007 Tc
0.035 Tw
[(and Mor)-57(tality )54(W)23(eekly Repor)-57(t 36\(Suppl\):)39( lS-18S)23(, 1987.)]TJ
-1.888 -1.744 TD
0.098 Tw
[(1)30(1)30(.)-537(Centers for Disease Control and Prevention: Summary)]TJ
1.888 -1.376 TD
-0.069 Tw
(of notifiable diseases, United States, 1995. Morbidity and)Tj
T*
0.006 Tc
0.024 Tw
[(Mor)-58(tality )39(W)22(eekly Repor)-42(t 44:4-5, 1996.)]TJ
-1.888 -1.728 TD
0.013 Tc
0.136 Tw
[(12.)-467(Centers for Disease Control and Prevention: Sexually)]TJ
1.888 -1.344 TD
0.066 Tc
(transmitted diseases treatment guidelines, 1998.)Tj
0 -1.36 TD
-0.001 Tc
-0.067 Tw
[(Morbidity and Mor)-49(tality )48(W)31(eekly Repor)-49(t Recommendations)]TJ
0 -1.328 TD
0.008 Tc
0.037 Tw
(and Reports 47\(RR-1\):1998.)Tj
-31.568 30.32 TD
0.004 Tc
-0.068 Tw
[(1)-10(.)-1036(Batteiger BE, Jones RB. Chlamydial infections. Infectious)]TJ
1.888 -1.344 TD
0.008 Tc
0.009 Tw
[(Diseases Clinical of Nor)-40(th Amer)-24(ica 1:55-81, 1987.)]TJ
-1.888 -1.712 TD
0.019 Tc
0.136 Tw
[(2.)-1021(Bignell C)19(.)57( Antibiotic treatment of gonorrhoea:)35( Clinical)]TJ
1.888 -1.328 TD
0.008 Tc
-0.068 Tw
(evidence for choice. Genitourinary Medicine 72:315-320,)Tj
T*
0.01 Tc
(1996.)Tj
-1.888 -1.728 TD
0.006 Tc
0.104 Tw
[(3)-8(.)-1034(Bis)6(w)8(as GD)70(, Blac)6(kman EY)134(, Spar)-26(ling PF)150(.)44( High-frequency)]TJ
1.888 -1.328 TD
0.007 Tc
0.055 Tw
(conjugal transfer of a gonococcal penicillinase plasmid.)Tj
T*
0.008 Tc
0.036 Tw
(Journal of Bacteriology 143:1318-1324, 1980.)Tj
-1.888 -1.712 TD
0.006 Tc
-0.031 Tw
[(4)-8(.)-1034(Bohnhoff M, Morello JA, Ler)-26(ner SA.)54( )8(A)22(uxotypes)-10(, penicillin)]TJ
1.888 -1.344 TD
0.007 Tc
0.065 Tw
[(susceptibility and serogroups of )]TJ
7.5 0 1.594 7.5 210.05 264.71 Tm
0.009 Tc
(Neisseria gonorrhoeoe)Tj
7.5 0 0 7.5 99.17 254.75 Tm
0.006 Tc
-0.068 Tw
(from disseminated and uncomplicated infections. Journal)Tj
0 -1.328 TD
0.007 Tc
0.037 Tw
(of Infectious Diseases 154:225-230, 1986.)Tj
-1.888 -1.712 TD
-0.021 Tw
[(5)-7(.)-1033(Bonin P)167(,)13( )40(T)122(anino )40(TT)119(, Handsfield HH.)55( Isolation of )]TJ
7.5 0 1.594 7.5 255.89 231.95 Tm
0.008 Tc
[(Neisser)-8(ia)]TJ
-20.61 -1.344 TD
(gonorrhoeae )Tj
7.5 0 0 7.5 145.49 221.87 Tm
0.007 Tc
0.121 Tw
(on selective and nonselective media in a)Tj
-6.176 -1.328 TD
0.015 Tc
0.136 Tw
(sexually transmitted disease clinic. Journal of Clinical)Tj
T*
0.008 Tc
0.046 Tw
(Microbiology 19:218-220, 1984.)Tj
-1.888 -1.712 TD
0.058 Tc
0.136 Tw
[(6)44(.)-982(Br)-22(itigan BE, Cohen MS)10(, Spar)-22(ling PF)138(.)64( Gonococcal)]TJ
1.888 -1.344 TD
0.03 Tc
0.137 Tw
(infections: a model of molecular pathogenesis. New)Tj
0 -1.328 TD
0.008 Tc
0.032 Tw
(England Journal of Medicine 312:1683-1694, 1985.)Tj
-1.888 -1.712 TD
0.007 Tc
0.085 Tw
[(7)-7(.)-1033(Buchanan )23(TM, Chen KCS)23(, Jones RB)23(.)61( Pili and pr)-9(incipal)]TJ
1.888 -1.344 TD
0.042 Tc
0.137 Tw
(outer membrane protein of )Tj
7.5 0 1.594 7.5 202.01 146.15 Tm
0.14 Tw
(Neisseria gonorrhoeoe)Tj
7.5 0 0 7.5 285.65 146.15 Tm
(:)Tj
-24.864 -1.328 TD
0.007 Tc
-0.051 Tw
(Immunochemical, structural, and pathogenic aspects. )Tj
7.5 0 1.594 7.5 279.29 136.19 Tm
0.004 Tc
(In:)Tj
7 0 0 7 85.01 759.71 Tm
0.01 Tc
0.012 Tw
[(Penna GO  et al)]TJ
/F6 1 Tf
9 0 0 9 321.77 692.75 Tm
(.)Tj
/F4 1 Tf
1.573 0 TD
0.006 Tc
-0.011 Tw
(ap\363s a cura, usar preservativo em todas as)Tj
0 -1.213 TD
0.001 Tc
-0.069 Tw
(rela\347\365es sexuais ou adotar outras formas de)Tj
0 -1.227 TD
0.006 Tc
0.016 Tw
(sexo mais seguro;)Tj
/F6 1 Tf
-1.573 -1.533 TD
(.)Tj
/F4 1 Tf
1.573 0 TD
-0.022 Tc
-0.069 Tw
(oferecer preservativos ao paciente, orientando)Tj
0 -1.227 TD
0.007 Tc
0.008 Tw
[(sobre as t\351cnicas de uso; e)]TJ
/F6 1 Tf
-1.573 -1.533 TD
(.)Tj
/F4 1 Tf
1.573 0 TD
0.042 Tw
(recomendar o retorno ao servi\347o de sa\372de)Tj
0 -1.227 TD
0.007 Tw
(se voltar a ter problemas genitais;)Tj
/F6 1 Tf
-3.147 -1.547 TD
(.)Tj
/F4 1 Tf
1.573 0 TD
0.139 Tw
(encorajar o paciente a comunicar a todos os)Tj
0 -1.213 TD
0.006 Tc
-0.049 Tw
(seus parceiros\(as\) sexuais do \372ltimo m\352s, para)Tj
0 -1.227 TD
0.007 Tc
-0.06 Tw
(que possam ser atendidos e tratados. Fornecer)Tj
T*
0.061 Tc
0.138 Tw
(ao paciente cart\365es de convoca\347\343o para)Tj
0 -1.213 TD
0.01 Tc
0.139 Tw
(parceiros\(as\) devidamente preenchidos. Esta)Tj
0 -1.227 TD
-0.005 Tc
-0.069 Tw
(atividade \351 fundamental para se romper a )Tj
18.08 0 TD
-0.016 Tc
(cadeia)Tj
-18.08 -1.227 TD
-0.003 Tc
0.036 Tw
[(de transmiss\343o e para evitar que o paciente )10(se)]TJ
0 -1.213 TD
0.008 Tc
(reinfecte;)Tj
/F6 1 Tf
-1.573 -1.547 TD
(.)Tj
/F4 1 Tf
1.573 0 TD
0.007 Tc
0.007 Tw
(notificar o caso no formul\341rio apropriado;)Tj
/F6 1 Tf
-1.573 -1.533 TD
(.)Tj
/F4 1 Tf
1.573 0 TD
0.087 Tc
-0.069 Tw
(marcar o retorno para conhecimento dos)Tj
0 -1.227 TD
0.046 Tc
-0.021 Tw
(resultados dos exames solicitados e para o)Tj
0 -1.213 TD
-0.003 Tc
0.008 Tw
(controle de cura.)Tj
ET
endstreamendobj48 0 obj<< /ProcSet [ /PDF /Text ] /Font << /F4 5 0 R /F6 6 0 R >> /ExtGState << /GS1 9 0 R /GS2 10 0 R >> >> endobj49 0 obj<< /Type /Page /Parent 45 0 R /Resources 51 0 R /Contents 50 0 R /CropBox [ 28.8 55.44 566.2 801.67999 ] >> endobj50 0 obj<< /Length 12398 >> stream
BT
/F4 1 Tf
10 0 0 10 493.49 85.31 Tm
0 0 0 rg
/GS2 gs
0.006 Tc
(463)Tj
ET
0 0 0 RG
0 J 0 j 0.48 w 10 M []0 d
/GS1 gs
1 i 
28.61 53.87 m
28.61 -1.33 l
567.17 53.87 m
567.17 -1.93 l
-2.83 53.63 m
28.37 53.63 l
566.93 53.63 m
596.69 53.63 l
567.17 841.91 m
567.17 802.19 l
28.61 843.23 m
28.61 802.19 l
566.93 801.95 m
598.13 801.95 l
-2.23 801.95 m
28.37 801.95 l
S
BT
7.5 0 0 7.5 85.01 693.59 Tm
/GS2 gs
0.014 Tc
0.137 Tw
[(13.)-466(Communicable Disease Surveillance Centre: Sexually)]TJ
1.888 -1.312 TD
0.035 Tc
0.138 Tw
(transmitted disease quarterly report: Gonorrhoea in)Tj
0 -1.296 TD
0.007 Tc
0.085 Tw
[(England and )22(W)55(ales)7(.)61( Comm)7(unity Diseases Repor)-57(t CDR)]TJ
0 -1.312 TD
0.033 Tw
(Wkly 7:225, 1997.)Tj
-1.888 -1.68 TD
-0.031 Tw
[(14.)-473(Corman LC, Levison ME, Knight R, Carrington ER, Kaye)]TJ
1.888 -1.312 TD
0.004 Tc
-0.067 Tw
[(D)54(.)58( )55(The high frequency of phar)-28(yngeal gonococcal inf)20(ection)]TJ
T*
0.036 Tc
0.137 Tw
[(in a prenatal clinic population.)52( Jour)-28(nal of Amer)-12(ican)]TJ
0 -1.296 TD
0.007 Tc
0.027 Tw
(Medical Association 230:568-570, 1984.)Tj
-1.888 -1.696 TD
0.047 Tc
0.137 Tw
[(1)38(5)38(.)-433(Dallabetta G, Hook EW III. Gonococcal infections.)]TJ
1.888 -1.296 TD
0.013 Tc
0.136 Tw
[(Inf)29(ectious Diseases Clinics of Nor)-35(th Amer)-19(ica 1:25-54,)]TJ
0 -1.312 TD
0.01 Tc
(1987.)Tj
-1.888 -1.696 TD
0.012 Tc
0.137 Tw
[(16.)-468(Dolter J, Bryant L, Janda JM. Evaluation of five rapid)]TJ
1.888 -1.296 TD
0.007 Tc
0.054 Tw
(systems for the identification of )Tj
7.5 0 1.594 7.5 208.01 567.47 Tm
0.008 Tc
0.06 Tw
(Neisseria gonorrhoeae.)Tj
7.5 0 0 7.5 99.17 557.63 Tm
0.005 Tc
-0.068 Tw
(Diagnostic Microbiology Infectious Diseases 13:265-267,)Tj
0 -1.312 TD
0.011 Tc
(1990)Tj
7.5 0 1.594 7.5 116.21 547.79 Tm
(.)Tj
7.5 0 0 7.5 85.01 535.19 Tm
0.027 Tc
0.136 Tw
[(1)18(7)18(.)-453(F)46(aur )74(Y)8(C)27(, )42(W)27(eisb)11(urd MH, )26(Wilson ME, Ma)27(y PS)11(.)49( A ne)27(w)]TJ
1.888 -1.312 TD
0.007 Tc
0.097 Tw
(medium for the isolation of pathogenic )Tj
7.5 0 1.594 7.5 234.53 525.35 Tm
(Neisseria )Tj
7.5 0 0 7.5 269.21 525.35 Tm
(\(NYC)Tj
-22.672 -1.296 TD
-0.068 Tw
(medium\): I. Formulations and comparisons with standard)Tj
0 -1.312 TD
0.034 Tw
(media. Health Laboratory Science 10:44-54, 1973.)Tj
-1.888 -1.68 TD
0.04 Tc
0.137 Tw
[(1)31(8)31(.)-440(Handsfield HH. Disseminated gonococcal infection.)]TJ
1.888 -1.312 TD
0.007 Tc
0.038 Tw
(Clinical Obstetrical and Gynecology 18:131-142, 1975.)Tj
-1.888 -1.68 TD
0.024 Tc
0.137 Tw
[(1)15(9)15(.)-456(Handsfield HH, Dalu ZA, Martin DH, Douglas Jr JM,)]TJ
1.888 -1.312 TD
0.007 Tc
0.065 Tw
(McCarty MC, Schlossberg D. Multicenter trial of single-)Tj
T*
0.02 Tc
0.137 Tw
(dose azithromycin vs. ceftriaxone in the treatment of)Tj
0 -1.296 TD
0.002 Tc
-0.068 Tw
[(uncomplicated gonorrhea.)50( )7(S)6(e)34(xually )50(T)117(r)-1(ansmitted Diseases)]TJ
0 -1.312 TD
0.006 Tc
-0.067 Tw
(21:107-111, 1994.)Tj
-1.888 -1.696 TD
0.019 Tc
0.137 Tw
[(2)10(0)10(.)-461(Handsfield HH, MeCutchan JA, Corey L, Ronald AR.)]TJ
1.888 -1.344 TD
0.007 Tc
0.079 Tw
(Evaluation of new anti-infective drugs for the treatment)Tj
0 -1.328 TD
0.086 Tw
(of uncomplicated gonorrhea in adults and adolescents.)Tj
T*
0.006 Tc
0.116 Tw
[(Inf)22(ectious Diseases Society of Amer)-42(ican and the F)22(ood)]TJ
0 -1.344 TD
0.021 Tc
0.137 Tw
[(and Dr)-27(ug Administr)21(ation.)69( Clinical Inf)21(ectious Diseases)]TJ
0 -1.328 TD
0.008 Tc
0.04 Tw
(l5\(Suppl 1\):123-130, 1992.)Tj
-1.888 -1.696 TD
0.043 Tc
0.137 Tw
[(2)34(1)34(.)-437(Handsfield HH, Rice RJ, Roberts MC, Holmes KK.)]TJ
1.888 -1.312 TD
0.008 Tc
0.08 Tw
(Localized outbreak of penicillinase-producing )Tj
7.5 0 1.594 7.5 256.01 346.19 Tm
0.007 Tc
(Neisseria)Tj
-20.633 -1.312 TD
0.01 Tc
(gonorrhoeae: )Tj
7.5 0 0 7.5 147.89 336.35 Tm
0.139 Tw
(Paradigm for introduction and spread of)Tj
-6.496 -1.296 TD
0.007 Tc
0.02 Tw
[(gonorrhea in a comm)-9(unity)103(.)61( Jour)-41(nal of Amer)-25(ican Medical)]TJ
0 -1.312 TD
0.057 Tw
(Association 261:2357-2360, 1989.)Tj
-1.888 -1.68 TD
0.008 Tc
0.029 Tw
[(22.)-472(Handsfield HH, Spar)-24(ling PF)152(.)62( )]TJ
7.5 0 1.594 7.5 196.13 304.19 Tm
0.034 Tw
[(Neisser)-8(ia Gonnorrhoea)]TJ
7.5 0 0 7.5 275.21 304.19 Tm
-0.054 Tc
(. )Tj
7.5 0 1.594 7.5 279.29 304.19 Tm
0.004 Tc
(In:)Tj
7.5 0 0 7.5 99.17 294.35 Tm
0.007 Tc
0.017 Tw
(Mandell GL, Bennett JE, Dolin R. Mandell, Douglas and)Tj
0 -1.312 TD
0.095 Tw
(Bennett. Principles and practice of infectious diseases,)Tj
0 -1.296 TD
(4)Tj
4.4 0 0 4.4 103.49 277.31 Tm
0.012 Tc
(th)Tj
7.5 0 0 7.5 107.21 274.79 Tm
0.008 Tc
0.027 Tw
[( edition, Churchill Livingstone, p 1909-1927, 1995.)]TJ
-2.96 -1.696 TD
0.011 Tc
0.137 Tw
[(23.)-469(Handsfield HH, )27(Wiesner PJ)27(, Holmes KK.)59( )58(T)110(reatment of)]TJ
1.888 -1.296 TD
0.007 Tc
0.076 Tw
[(the gonococcal ar)-57(thr)-9(itis-der)-25(matitis syndrome)7(.)61( Annals of)]TJ
0 -1.312 TD
0.008 Tc
0.037 Tw
(Internal Medicine 84:661-667, 1976.)Tj
-1.888 -1.68 TD
0.009 Tc
0.137 Tw
[(24.)-471(Heckels JE. Molecular studies on the pathogenesis of)]TJ
1.888 -1.312 TD
0.011 Tc
(gonorrhoeae. Journal of Medical Microbiology 18:293-)Tj
T*
0.008 Tc
0.033 Tw
(307, 1984.)Tj
-1.888 -1.68 TD
0.007 Tc
0.046 Tw
[(25.)-473(Ho BS, Feng WG, Bong BK, Beckmann LI. Polymerase)]TJ
1.888 -1.312 TD
0.008 Tc
-0.067 Tw
(chain reaction for the detection of )Tj
7.5 0 1.594 7.5 211.25 187.79 Tm
-0.074 Tw
(Neisseria gonorrhoeae)Tj
7.5 0 0 7.5 99.17 177.95 Tm
0.007 Tc
-0.026 Tw
(in clinical samples. Journal of Clinical Pathology 45:439-)Tj
0 -1.296 TD
0.008 Tc
0.033 Tw
(442, 1992.)Tj
-1.888 -1.696 TD
0.053 Tc
0.136 Tw
[(2)44(6)44(.)-427(Holmes KK, Counts GW)69(, Beaty HN.)37( Disseminated)]TJ
1.888 -1.296 TD
0.005 Tc
-0.068 Tw
[(gonococcal inf)21(ection.)53( Annals of Inter)-27(nal Medicine 74:979-)]TJ
0 -1.328 TD
0.008 Tc
0.033 Tw
(993, 1971.)Tj
27.792 74.384 TD
0.009 Tc
0.137 Tw
[(27.)-471(Hook EW III, Handsfield HH. Gonococcal infections in)]TJ
1.888 -1.296 TD
0.002 Tc
-0.067 Tw
[(the adult.)50( )]TJ
7.5 0 1.594 7.5 353.45 683.99 Tm
-0.004 Tc
(In:)Tj
7.5 0 0 7.5 361.85 683.99 Tm
0.001 Tc
-0.068 Tw
[( Holmes KK, Mardh P)129(A, Spar)-15(ling PF:)33( Se)17(xually)]TJ
-5.344 -1.296 TD
0.017 Tc
0.137 Tw
[(T)132(r)-2(ansmitted Diseases.)71( Ne)17(w )81(Y)140(o)-6(r)-15(k, McGra)13(w-Hill, p 149,)]TJ
T*
0.011 Tc
(1990.)Tj
-1.888 -1.664 TD
0.032 Tc
[(2)23(8)23(.)-448(Hook EW III, J)16(udson FN, Handsfield HH.)48( )-6(A)32(uxotype/)]TJ
1.888 -1.296 TD
0.001 Tc
-0.068 Tw
(serovar diversity and antimicrobial resistance of )Tj
7.5 0 1.594 7.5 478.97 642.35 Tm
-0.001 Tc
(Neisseria)Tj
-20.685 -1.296 TD
0.009 Tc
(gonorrhoeae )Tj
7.5 0 0 7.5 367.49 632.63 Tm
0.007 Tc
0.056 Tw
[(in tw)-9(o mid-siz)23(ed Amer)-25(ican cities)7(.)61( Se)23(xually)]TJ
-6.096 -1.296 TD
0.074 Tw
[(T)122(r)4(ansmitted Diseases 14:141-146, 1987.)]TJ
-1.888 -1.664 TD
0.076 Tc
0.224 Tw
[(2)67(9)67(.)-404(Ison CA.)60( Antimicrobial agents and gonorrhoea:)]TJ
1.888 -1.296 TD
0.067 Tc
0.136 Tw
[(therapeutic choice, resistance and susceptibility)83(.)]TJ
T*
0.008 Tc
0.042 Tw
(Genitourinary Medicine 72:253-260, 1996.)Tj
-1.888 -1.68 TD
0.007 Tc
0.045 Tw
[(30.)-473(J)27(a)7(c)7(kman JD Jr)39(, Glamann DB)23(.)61( Gonococcal endocarditis:)]TJ
1.888 -1.28 TD
0.004 Tc
-0.066 Tw
[(t)12(w)-12(enty-fiv)20(e y)20(ear e)36(xper)-28(ience.)42( Amer)-12(ican Jour)-28(nal of Medical)]TJ
0 -1.296 TD
0.007 Tc
0.047 Tw
(Science 301:221-230, 1991.)Tj
-1.888 -1.68 TD
0.013 Tc
0.136 Tw
[(31.)-467(Jephcott AE.)61( Microbiological diagnosis of gonorrhoea.)]TJ
1.888 -1.296 TD
0.008 Tc
0.042 Tw
(Genitourinary Medicine 73:245-252, 1997.)Tj
-1.888 -1.664 TD
0.052 Tw
[(32.)-472(J)28(udson FN.)56( )50(T)123(reatment of uncomplicated gonorrhea with)]TJ
1.888 -1.296 TD
0.026 Tc
0.138 Tw
[(ceftr)-22(iaxone:)58( a re)10(vie)26(w)44(.)64( )6(Se)10(xually )43(T)109(r)7(ansmitted Diseases)]TJ
T*
0.007 Tc
0.054 Tw
(13:199-202, 1986.)Tj
-1.888 -1.664 TD
0.081 Tw
[(33.)-473(J)27(udson FN, Ehret JM, Eic)23(khoff )39(TC)39(.)61( Anogenital inf)7(ection)]TJ
1.888 -1.296 TD
(with )Tj
7.5 0 1.594 7.5 337.61 482.63 Tm
0.008 Tc
0.03 Tw
(Neisseria meningitidis )Tj
7.5 0 0 7.5 414.41 482.63 Tm
0.007 Tc
0.029 Tw
(in homosexual men. Journal)Tj
-12.352 -1.296 TD
0.037 Tw
(of Infectious Diseases 137:458-463, 1978.)Tj
-1.888 -1.68 TD
0.011 Tc
0.136 Tw
[(34.)-469(K)54(ellogg DS Jr)27(,)11( )10(P)43(eacoc)11(k)14( )26(WL, Deacon )42(WE, Cheng D)27(W)75(.)]TJ
7.5 0 1.594 7.5 321.77 450.59 Tm
[(Neisser)-21(i)6(a)6( )]TJ
7.5 0 0 7.5 357.17 450.59 Tm
0.139 Tw
[(gonorrhoeae:)44( )45(Vir)-20(ulence genetically link)12(ed to)]TJ
-4.72 -1.28 TD
0.008 Tc
0.118 Tw
(clonal variation. Journal of Bacteriology 85:1274-1279,)Tj
0 -1.296 TD
0.011 Tc
(1963.)Tj
-1.888 -1.68 TD
0.076 Tc
0.214 Tw
[(3)67(5)67(.)-404(Luciano AA, Gr)-20(ubin L.)60( Gonorroheae screening:)]TJ
1.888 -1.296 TD
0.018 Tc
0.137 Tw
[(compar)-14(ison of three techniques)18(.)56( Jour)-30(nal of Amer)-30(ican)]TJ
0 -1.28 TD
0.007 Tc
0.054 Tw
(Association 243:680-68l, 1980.)Tj
-1.888 -1.68 TD
0.112 Tw
[(36.)-473(Maincour)-41(t DH, Or)-9(loff S)23(.)45( Gonococcal ar)-41(thr)-9(itis-der)-41(matitis)]TJ
1.888 -1.296 TD
0.018 Tc
0.137 Tw
(syndrome: study of serum and synovial fluid immune)Tj
T*
0.012 Tc
[(comple)28(x le)28(v)32(els)12(.)66( Ar)-36(th)-5(r)-20(itis and Rheumatism 25:574-578,)]TJ
0 -1.28 TD
(1982.)Tj
-1.888 -1.68 TD
0.006 Tc
0.029 Tw
[(37.)-474(Mar)-42(tin DH, Mroczko)18(wski )38(TF)150(, Dalu ZA, McCar)-42(ty J)22(,)2( Jones)]TJ
1.888 -1.296 TD
0.007 Tc
-0.007 Tw
[(R, Hopkins SJ)23(, Johnson RB)23(.)61( A controlled tr)-25(ial of a single)]TJ
T*
0.025 Tc
0.137 Tw
(dose of azithromycin for the treatment of chlamydial)Tj
T*
0.005 Tc
-0.069 Tw
(urethritis and cervicitis. New England Journal of Medicine)Tj
0 -1.28 TD
0.008 Tc
0.053 Tw
(327:921-925, 1992.)Tj
-1.888 -1.68 TD
0.007 Tc
0.023 Tw
[(38.)-473(McGee ZA, Johnson AP)183(, )38(T)122(a)35(ylor-Robinson D)55(.)61( )15(P)23(athogenic)]TJ
1.888 -1.296 TD
0.006 Tc
0.003 Tw
(mechanisms of )Tj
7.5 0 1.594 7.5 375.05 284.03 Tm
0.007 Tc
(Neisseria )Tj
7.5 0 0 7.5 408.89 284.03 Tm
0.008 Tc
0.006 Tw
(gonorrhoeae: observations on)Tj
-11.616 -1.296 TD
0.015 Tc
0.137 Tw
(damage to human fallopian tubes in organ culture by)Tj
0 -1.28 TD
0.006 Tc
-0.068 Tw
(gonococci of colony type 1 or type 4. Journal of Infectious)Tj
0 -1.296 TD
0.008 Tc
0.046 Tw
(Diseases 143:413-422, 1981.)Tj
-1.888 -1.68 TD
0.007 Tc
0.132 Tw
[(39.)-473(Minist\351rio da Sa\372de. Manual de controle das doen\347as)]TJ
1.888 -1.296 TD
0.043 Tw
(sexualmente transmiss\355veis. 3\252 edi\347\343o, Bras\355lia, 1999.)Tj
-1.888 -1.664 TD
0.041 Tw
[(40.)-473(Minnett S, Reller LB, Knapp JS. )]TJ
7.5 0 1.594 7.5 432.77 220.19 Tm
0.008 Tc
0.047 Tw
(Neisseria gonorrhoeae)Tj
7.5 0 0 7.5 321.77 210.47 Tm
0.007 Tc
0.107 Tw
(strains inhibited by vancomycin in selective media and)Tj
0 -1.296 TD
0.003 Tc
-0.068 Tw
(correlation with auxotype. Journal of Clinical Microbiology)Tj
T*
0.007 Tc
0.047 Tw
(14:94-99, 1981.)Tj
-1.888 -1.664 TD
0.072 Tc
0.136 Tw
[(4)63(1)63(.)-408(Mor)8(an IS)24(, Zenilman JM.)56( )54(Ther)-8(ap)24(y)12( )12(f)8(or gonococcal)]TJ
1.888 -1.296 TD
0.01 Tc
0.138 Tw
(infections: options in 1989. Review of Infect Diseases)Tj
T*
0.008 Tc
0.043 Tw
(12\(Suppl 6\):5656-5664, 1990.)Tj
-1.888 -1.68 TD
0.056 Tc
0.136 Tw
[(4)47(2)47(.)-424(Morello JM, J)8(anda )39(WM, Doer)-24(n GV)120(.)62( )]TJ
7.5 0 1.594 7.5 458.09 146.51 Tm
0.057 Tc
[(Neisser)-23(ia )]TJ
7.5 0 0 7.5 496.85 146.51 Tm
0.054 Tc
(and)Tj
7.5 0 1.594 7.5 321.77 136.67 Tm
0.007 Tc
[(Br)7(anhamella)]TJ
7.5 0 0 7.5 364.49 136.67 Tm
-0.07 Tc
(. )Tj
7.5 0 1.594 7.5 368.93 136.67 Tm
0.004 Tc
(In:)Tj
7.5 0 0 7.5 377.45 136.67 Tm
0.007 Tc
0.094 Tw
[( Balo)7(ws A, Hausler )39(W)11(J)7(, Herr)-9(mann KL,)]TJ
7 0 0 7 255.77 759.71 Tm
0.009 Tc
0.049 Tw
[(Re)26(vista da Sociedade Br)9(asileir)-8(a de Medicina )44(T)123(ropical 33:451-464, set-out, 2000)]TJ
ET
endstreamendobj51 0 obj<< /ProcSet [ /PDF /Text ] /Font << /F4 5 0 R >> /ExtGState << /GS1 9 0 R /GS2 10 0 R >> >> endobj52 0 obj<< /Type /Page /Parent 45 0 R /Resources 54 0 R /Contents 53 0 R /CropBox [ 28.8 55.44 566.2 801.67999 ] >> endobj53 0 obj<< /Length 5920 >> stream
BT
/F4 1 Tf
10 0 0 10 85.01 83.87 Tm
0 0 0 rg
/GS2 gs
0.006 Tc
(464)Tj
ET
0 0 0 RG
0 J 0 j 0.48 w 10 M []0 d
/GS1 gs
1 i 
28.61 53.87 m
28.61 -1.33 l
567.17 53.87 m
567.17 -0.01 l
-4.27 53.63 m
28.37 53.63 l
566.93 53.63 m
598.13 53.63 l
567.17 841.91 m
567.17 802.19 l
28.61 843.83 m
28.61 802.19 l
566.93 801.95 m
598.13 801.95 l
-2.23 801.95 m
28.37 801.95 l
S
BT
7.5 0 0 7.5 99.17 693.47 Tm
/GS2 gs
0.008 Tc
0.129 Tw
[(Hagmann ZL \(eds\) Man)-8(ual of Clinical Microbiology)104(.)62( )11(5)]TJ
4.4 0 0 4.4 283.97 695.99 Tm
0.012 Tc
(th)Tj
7.5 0 0 7.5 99.17 683.51 Tm
0.075 Tc
0.296 Tw
[(edition.)59( )41(W)27(ashington, DC)27(.)65( Amer)-21(ican Society f)11(o)4(r)]TJ
0 -1.328 TD
0.008 Tc
0.031 Tw
(Microbiology p. 258-276, 1991.)Tj
-1.888 -1.728 TD
0.007 Tc
0.036 Tw
[(43.)-473(No)7(winski RC)23(,)9( )37(T)122(am MR, Goldstein LC)23(, K)7(uo CC)39(, K)39(o)1(re)7(y L,)]TJ
1.888 -1.328 TD
0.032 Tc
0.137 Tw
(Stamm WE, Handsfield HH, Knapp JS, Holmes KK.)Tj
T*
0.061 Tc
0.138 Tw
(Monoclonal antibodies for diagnosis of infectious)Tj
0 -1.344 TD
0.007 Tc
0.035 Tw
(diseases in humans. Science 219:637-644, 1983.)Tj
-1.888 -1.712 TD
0.033 Tc
0.137 Tw
[(4)24(4)24(.)-447(O\222Br)-31(ien J)17(A, Goldenberg DL, Rice P)97(A)2(.)65( Disseminated)]TJ
1.888 -1.328 TD
-0.002 Tc
-0.069 Tw
(gonococcal infection: a prospective analysis of 49 patients)Tj
T*
-0.012 Tc
-0.068 Tw
(and a review of pathophysiology and immune mechanisms.)Tj
0 -1.344 TD
0.008 Tc
0.043 Tw
(Medicine 62:395-406, 1983.)Tj
-1.888 -1.712 TD
0.007 Tc
0.131 Tw
[(45.)-473(O)7(f)23(ek I, Beach)23(y EH, Bisno AL.)55( Resistance of )]TJ
7.5 0 1.594 7.5 255.89 574.91 Tm
0.008 Tc
[(Neisser)-8(ia)]TJ
7.5 0 0 7.5 99.17 564.95 Tm
0.014 Tc
0.137 Tw
(gonorrhoeae to phagocytosis: Relationship to colonial)Tj
0 -1.328 TD
0.053 Tc
0.136 Tw
(morphology and surface pili. Journal of Infectious)Tj
0 -1.344 TD
0.008 Tc
0.046 Tw
(Diseases 129:310-316, 1974.)Tj
-1.888 -1.712 TD
0.022 Tc
0.136 Tw
[(4)13(6)13(.)-458(Rinaldi RZ, Harr)-26(ison )37(W)22(O)32(,)10( )9(F)38(an PT)118(.)60( )15(P)38(enicillin resistant)]TJ
1.888 -1.328 TD
0.007 Tc
-0.041 Tw
[(gonococcal ar)-41(thr)-25(itis.)61( Annals of Inter)-41(n Medicine 97:43-45,)]TJ
T*
0.01 Tc
(1982.)Tj
-1.888 -1.728 TD
0.006 Tc
0.018 Tw
[(47.)-474(Rober)-58(ts M, Piot P)182(,)-2( F)54(alk)6(ow S)22(.)60( )46(The ecology of gonococcal)]TJ
1.888 -1.328 TD
0.01 Tc
0.138 Tw
(plasmids. Journal of Clinical Microbiology 14:491-494,)Tj
T*
-0.01 Tc
(1979.)Tj
-1.888 -1.712 TD
0.021 Tc
0.136 Tw
[(4)12(8)12(.)-459(Rompalo AM, Hook EW Ill, Rober)-43(ts PL, Ransey PG,)]TJ
1.888 -1.344 TD
0.007 Tc
0.127 Tw
[(Handfield H, Holmes KK.)55( )60(The acute ar)-41(thr)-25(itis-der)-25(matitis)]TJ
0 -1.328 TD
0.06 Tc
0.137 Tw
[(syndrome.)50( )59(The changing impor)-52(tance of )]TJ
7.5 0 1.594 7.5 252.65 446.39 Tm
0.062 Tc
[(Neisser)-18(i)8(a)]TJ
2.217 32.928 TD
0.028 Tc
(gonorrhoeae)Tj
7.5 0 0 7.5 366.77 693.35 Tm
0.136 Tw
[( and )]TJ
7.5 0 1.594 7.5 386.45 693.35 Tm
0.137 Tw
[(Neisser)-20(ia meningitidis)12(.)50( )]TJ
7.5 0 0 7.5 470.33 693.35 Tm
0.027 Tc
0.14 Tw
[(Archiv)27(es of)]TJ
-19.808 -1.344 TD
0.008 Tc
0.04 Tw
(Internal Medicine 147:281-283, 1987.)Tj
-1.888 -1.712 TD
0.009 Tc
0.137 Tw
[(49.)-471(Rothenherg RB)9(, Simon R, Chipperfield F)137(,Catter)9(all RD)57(.)]TJ
1.888 -1.328 TD
0.066 Tc
[(Efficacy of selected diagnostic tests f)18(or se)34(xually)]TJ
0 -1.344 TD
0.044 Tc
[(transmitted diseases)12(.)50( Jour)-36(nal of American Medical)]TJ
0 -1.328 TD
0.007 Tc
0.053 Tw
(Association 235:49-51, 1976.)Tj
-1.888 -1.712 TD
0.066 Tc
0.137 Tw
[(5)57(0)57(.)-414(Schoolnik GK, F)18(e)-5(r)-30(nandez R, )34(T)133(ai JY)130(, Rothbard J)18(,)]TJ
1.888 -1.328 TD
0.01 Tc
(Gotschlich EC. Gonococcal pili: Primary structure and)Tj
0 -1.344 TD
0.057 Tc
(receptor binding domain. Journal of Experimental)Tj
0 -1.328 TD
0.008 Tc
0.046 Tw
(Medicine 159:1351-1370, 1984.)Tj
-1.888 -1.712 TD
0.007 Tc
0.048 Tw
[(51.)-473(Segal E, Billy)23(ard E, So M, Storzbach S)23(,)5( Me)7(y)11(er )38(T)13(F)151(.)61( Role)]TJ
1.888 -1.328 TD
-0.056 Tw
(of chromossomal rearrangement in )Tj
7.5 0 1.594 7.5 440.33 574.79 Tm
0.009 Tc
-0.057 Tw
(N. gonorrhoeae )Tj
7.5 0 0 7.5 494.69 574.79 Tm
0.006 Tc
(pilus)Tj
-23.056 -1.344 TD
0.008 Tc
0.031 Tw
(phase variation. Cell 40:293-300, 1985.)Tj
-1.888 -1.712 TD
0.097 Tw
[(52.)-472(Sherrard J, Barlow D. Gonorrhoea in men: clinical and)]TJ
1.888 -1.328 TD
0.01 Tc
0.137 Tw
(diagnostic aspects. Genitourinal Medicine 72:422-426,)Tj
T*
0.011 Tc
(1996.)Tj
-1.888 -1.728 TD
0.006 Tc
-0.009 Tw
[(53.)-474(Stamm )39(WE, Guinan ME, Johnson C)6(,)-2( Starcher )55(T)121(,)-1( Holmes)]TJ
1.888 -1.328 TD
0.01 Tc
0.136 Tw
[(KK, McCor)-38(mac)26(k)13( )25(WM.)58( Eff)42(ect of treatment regimens f)10(o)3(r)]TJ
7.5 0 1.594 7.5 321.77 499.07 Tm
0.014 Tc
0.137 Tw
(Neisseria gonorrhoeae )Tj
7.5 0 0 7.5 404.09 499.07 Tm
0.138 Tw
(on simultaneous infection with)Tj
7.5 0 1.594 7.5 321.77 488.99 Tm
-0.001 Tc
-0.067 Tw
(Chlamydia trachomatis. )Tj
7.5 0 0 7.5 400.97 488.99 Tm
-0.002 Tc
-0.068 Tw
(New England Journal of Medicine)Tj
-10.56 -1.328 TD
0.008 Tc
0.053 Tw
(310:545-549, 1984.)Tj
-1.888 -1.712 TD
0.007 Tc
0.011 Tw
[(54.)-473(Thayer JD, Martin Jr JE. Improved medium selective for)]TJ
1.888 -1.328 TD
0.011 Tc
0.138 Tw
(the cultivation of )Tj
7.5 0 1.594 7.5 382.85 456.23 Tm
0.013 Tc
0.137 Tw
(N. gonorrhoeae )Tj
7.5 0 0 7.5 440.57 456.23 Tm
0.014 Tc
(and )Tj
7.5 0 1.594 7.5 456.65 456.23 Tm
0.012 Tc
0.14 Tw
(N. meningitidis.)Tj
7.5 0 0 7.5 321.77 446.15 Tm
0.007 Tc
0.034 Tw
(Public Health 81:559-562, 1966)Tj
7.5 0 1.594 7.5 429.29 446.15 Tm
(.)Tj
7 0 0 7 85.01 759.71 Tm
0.01 Tc
0.012 Tw
[(Penna GO  et al)]TJ
ET
endstreamendobj54 0 obj<< /ProcSet [ /PDF /Text ] /Font << /F4 5 0 R >> /ExtGState << /GS1 9 0 R /GS2 10 0 R >> >> endobj56 0 obj<< /Type /FontDescriptor /Ascent 706 /CapHeight 623 /Descent -225 /Flags 262178 /FontBBox [ -124 -250 1247 845 ] /FontName /Garamond-Bold /ItalicAngle 0 /StemV 148 /XHeight 457 >> endobj57 0 obj<< /Type /FontDescriptor /Ascent 706 /CapHeight 623 /Descent -229 /Flags 34 /FontBBox [ -156 -250 1066 842 ] /FontName /Garamond-Light /ItalicAngle 0 /StemV 69 /XHeight 439 >> endobj58 0 obj<< /Type /Encoding /Differences [ 0 /grave /acute /circumflex /tilde /macron /breve /dotaccent /dieresis /ring /cedilla /hungarumlaut /ogonek /caron /dotlessi 39 /quotesingle 96 /grave 127 /bullet /bullet /bullet /quotesinglbase /florin /quotedblbase /ellipsis /dagger /daggerdbl /circumflex /perthousand /Scaron /guilsinglleft /OE /bullet /bullet /bullet /bullet /quoteleft /quoteright /quotedblleft /quotedblright /bullet /endash /emdash /tilde /trademark /scaron /guilsinglright /oe /bullet /bullet /Ydieresis /space 164 /currency 166 /brokenbar 168 /dieresis /copyright /ordfeminine 172 /logicalnot /hyphen /registered /macron /degree /plusminus /twosuperior /threesuperior /acute /mu 183 /periodcentered /cedilla /onesuperior /ordmasculine 188 /onequarter /onehalf /threequarters 192 /Agrave /Aacute /Acircumflex /Atilde /Adieresis /Aring /AE /Ccedilla /Egrave /Eacute /Ecircumflex /Edieresis /Igrave /Iacute /Icircumflex /Idieresis /Eth /Ntilde /Ograve /Oacute /Ocircumflex /Otilde /Odieresis /multiply /Oslash /Ugrave /Uacute /Ucircumflex /Udieresis /Yacute /Thorn /germandbls /agrave /aacute /acircumflex /atilde /adieresis /aring /ae /ccedilla /egrave /eacute /ecircumflex /edieresis /igrave /iacute /icircumflex /idieresis /eth /ntilde /ograve /oacute /ocircumflex /otilde /odieresis /divide /oslash /ugrave /uacute /ucircumflex /udieresis /yacute /thorn /ydieresis ] >> endobj59 0 obj<< /Type /Catalog /Pages 44 0 R /Outlines 60 0 R >> endobj60 0 obj<< /Count 0 /Type /Outlines >> endobjxref0 61 0000000055 65535 f 0000000016 00000 n 0000000240 00000 n 0000000368 00000 n 0000008151 00000 n 0000008294 00000 n 0000008398 00000 n 0000008507 00000 n 0000009724 00000 n 0000010943 00000 n 0000011020 00000 n 0000011097 00000 n 0000011243 00000 n 0000011374 00000 n 0000021810 00000 n 0000021923 00000 n 0000022054 00000 n 0000033721 00000 n 0000033834 00000 n 0000033965 00000 n 0000044770 00000 n 0000044893 00000 n 0000064470 00000 n 0000095031 00000 n 0000095162 00000 n 0000103465 00000 n 0000103636 00000 n 0000103767 00000 n 0000115055 00000 n 0000115178 00000 n 0000115309 00000 n 0000125784 00000 n 0000125907 00000 n 0000126038 00000 n 0000136602 00000 n 0000136715 00000 n 0000136846 00000 n 0000146539 00000 n 0000146662 00000 n 0000146793 00000 n 0000154067 00000 n 0000154190 00000 n 0000154321 00000 n 0000162501 00000 n 0000162624 00000 n 0000162725 00000 n 0000162828 00000 n 0000162959 00000 n 0000172977 00000 n 0000173100 00000 n 0000173231 00000 n 0000185684 00000 n 0000185797 00000 n 0000185928 00000 n 0000191902 00000 n 0000000000 00001 f 0000192015 00000 n 0000192223 00000 n 0000192427 00000 n 0000193847 00000 n 0000193920 00000 n trailer<</Size 61/Info 1 0 R /Root 59 0 R /ID[<92dcb0bdf2ef4096ce366844332c1f4a><66759b315b4af9f308ca044e311f5af4>]>>startxref193971%%EOF